1,112,446 results on '"To D"'
Search Results
2. International Core Outcome Set for Acute Simple Appendicitis in Children
- Author
-
Max Knaapen, Ernst W E Van Heurn, Martin Offringa, Shireen Anne Nah, Dayang Anita Abdul Aziz, Ramon R. Gorter, Nigel J. Hall, Roel Bakx, Sherif Emil, Johanna H. van der Lee, Erik D. Skarsgard, Shawn D. St. Peter, Jan F. Svensson, Janne S. Suominen, Darcy Moulin, Augusto Zani, Peter C. Minneci, Susan Adams, Nancy J. Butcher, Rambha Rai, Surgery, Amsterdam Gastroenterology Endocrinology Metabolism, Pediatric surgery, Amsterdam Reproduction & Development (AR&D), Other Research, Paediatric Surgery, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, ARD - Amsterdam Reproduction and Development, General Paediatrics, APH - Methodology, and APH - Quality of Care
- Subjects
medicine.medical_specialty ,appendicitis ,appendicitis research ,Consensus ,Adolescent ,Delphi Technique ,MEDLINE ,Delphi method ,core outcome set ,03 medical and health sciences ,0302 clinical medicine ,nonoperative treatment ,Outcome Assessment, Health Care ,medicine ,Humans ,simple appendicitis ,Child ,Adverse effect ,business.industry ,medicine.disease ,Focus group ,Appendicitis ,Bowel obstruction ,Clinical trial ,Treatment Outcome ,Systematic review ,Research Design ,030220 oncology & carcinogenesis ,Family medicine ,Acute Disease ,030211 gastroenterology & hepatology ,Surgery ,business - Abstract
Objective: : To develop an international Core Outcome Set (COS), a minimal collection of outcomes that should be measured and reported in all future clinical trials evaluating treatments of acute simple appendicitis in children.Summary Background Data: A previous systematic review identified 115 outcomes in 60 trials and systematic reviews evaluating treatments for children with appendicitis, suggesting the need for a COS.Methods: The development process consisted of four phases: (1) an updated systematic review identifying all previously reported outcomes, (2) a two-stage international Delphi study in which parents with their children and surgeons rated these outcomes for inclusion in the COS, (3) focus groups with young people to identify missing outcomes, and (4) international expert meetings to ratify the final COS.Results: The systematic review identified 129 outcomes which were mapped to 43 unique outcome terms for the Delphi survey. The first-round included 137 parents (eight countries) and 245 surgeons (10 countries), the second-round response rates were 61% and 85% respectively, with ten outcomes emerging with consensus. After two young peoples’ focus groups, two additional outcomes were added to the final COS (12): mortality, bowel obstruction, intra-abdominal abscess, recurrent appendicitis, complicated appendicitis, return to baseline health, readmission, reoperation, unplanned appendectomy, adverse events related to treatment, major and minor complications.Conclusion: An evidence-informed COS based on international consensus, including patients and parents has been developed. This COS is recommended for all future studies evaluating treatment of simple appendicitis in children, to reduce heterogeneity between studies and facilitate data synthesis and evidence-based decision-making.
- Published
- 2022
3. Refinement of saliva microRNA biomarkers for sports-related concussion
- Author
-
Timothy Lee, Gregory R. Fedorchak, Cayce Onks, Christopher Neville, Raymond Y. Kim, Zofia E. Gagnon, Samantha DeVita, Elise Fengler, Callan D. McLoughlin, Chuck Monteith, Thomas R. Campbell, Matthew Heller, Miguel Madeira, Steven D. Hicks, Kevin J. Zhen, Michael N. Dretsch, Robert P. Olympia, Scott L. Zuckerman, Andrea C. Loeffert, and Jayson Loeffert
- Subjects
Oncology ,Saliva ,medicine.medical_specialty ,biology ,business.industry ,Traumatic brain injury ,Athletes ,Confounding ,Physical Therapy, Sports Therapy and Rehabilitation ,medicine.disease ,biology.organism_classification ,Logistic regression ,Internal medicine ,microRNA ,Concussion ,Medicine ,Biomarker (medicine) ,Orthopedics and Sports Medicine ,business - Abstract
Recognizing sport-related concussion (SRC) is challenging and relies heavily on subjective symptom reports. An objective, biological marker could improve recognition and understanding of SRC. There is emerging evidence that salivary micro-ribonucleic acids (miRNAs) may serve as biomarkers of concussion; however, it remains unclear whether concussion-related miRNAs are impacted by exercise. We sought to determine whether 40 miRNAs previously implicated in concussion pathophysiology were affected by participation in a variety of contact and non-contact sports. Our goal was to refine a miRNA-based tool capable of identifying athletes with SRC without the confounding effects of exercise.This case-control study harmonized data from concussed and non-concussed athletes recruited across 10 sites. Levels of salivary miRNAs within 455 samples from 314 individuals were measured with RNA sequencing. Within-subjects testing was used to identify and exclude miRNAs that changed with either: (a) a single episode of exercise (166 samples from 83 individuals) or (b) season-long participation in contact sports (212 samples from 106 individuals). The miRNAs that were not impacted by exercise were interrogated for SRC diagnostic utility using logistic regression (172 samples from 75 concussed and 97 non-concussed individuals).Two miRNAs (miR-532-5p, miR-182-5p) decreased (adjusted p0.05) after a single episode of exercise, and 1 miRNA (miR-4510) increased only after contact sports participation. Twenty-three miRNAs changed at the end of a contact sports season. Two of these miRNAs (miR-26b-3p, miR-29c-3p) were associated (R0.50; adjusted p0.05) with the number of head impacts sustained in a single football practice. Among the 15 miRNAs not confounded by exercise or season-long contact sports participation, 11 demonstrated a significant difference (adjusted p0.05) between concussed and non-concussed participants, and 6 displayed moderate ability (AUC0.70) to identify concussion. A single ratio (miR-27a-5p/miR-30a-3p) displayed the highest accuracy (AUC = 0.810, sensitivity = 82.4%, specificity = 73.3%) for differentiating concussed and non-concussed participants. Accuracy did not differ between participants with SRC and non-SRC (z = 0.5, p = 0.60).Salivary miRNA levels may accurately identify SRC when not confounded by exercise. Refinement of this approach in a large cohort of athletes could eventually lead to a non-invasive, sideline adjunct for SRC assessment.
- Published
- 2023
4. Trends in Distal Esophageal and Gastroesophageal Junction Cancer Care
- Author
-
Misha D. P. Luyer, Guusje Vugts, Renu R. Bahadoer, Marc J. van Det, Willem J. Koemans, Meindert N. Sosef, B. Görgec, Fatih Polat, Rene Scheer, Baukje Brattinga, Philip P. van der Linden, Cettela A. M. Slootmans, Richard van Hillegersberg, Marianne C Kalff, Erwin van der Harst, Marinus J. Wiezer, Frederik Lecot, Camiel Rosman, Jean-Pierre E. N. Pierie, Jan Willem Haveman, Pim B. Olthof, Peter C. Baas, Suzanne S. Gisbertz, Wendy Kelder, Víola B. Weeda, Annette D. van Dalsen, E. G. J. M. Robert Pierik, Marcia P. Gaspersz, Joos Heisterkamp, Eric J. T. Belt, Sjoerd M. Lagarde, Daan M. Voeten, Jelle P. Ruurda, Fanny J. Stoop, Peter van Duijvendijk, Linda Claassen, Victor D. Plat, Mark I. van Berge Henegouwen, Grard A. P. Nieuwenhuijzen, Jan Willem T. Dekker, Admira Ćosović, David Crull, Hein B. A. C. Stockmann, Richard P. R. Groenendijk, Guy H. E. J. Vijgen, Odin V. Sosef, Wietse J. Eshuis, Manon Drost, Martijn G. H. van Oijen, Ewout A. Kouwenhoven, Freek Daams, Wobbe O. de Steur, Johanna W. van Sandick, Henk H. Hartgrink, Donald L. van der Peet, Stijn van Esser, B. Feike Kingma, and Surgery
- Subjects
medicine.medical_specialty ,complications ,business.industry ,General surgery ,neo-adjuvant treatment ,Cancer ,medicine.disease ,Gastroesophageal Junction ,survival ,Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14] ,All institutes and research themes of the Radboud University Medical Center ,SDG 3 - Good Health and Well-being ,medicine ,esophagectomy ,Surgery ,esophageal cancer ,business ,minimally invasive surgery - Abstract
Objective: This study evaluated the nationwide trends in care and accompanied postoperative outcomes for patients with distal esophageal and gastro-esophageal junction cancer.Summary of Background Data: The introduction of transthoracic esophagectomy, minimally invasive surgery, and neo-adjuvant chemo(radio)therapy changed care for patients with esophageal cancer.Methods: Patients after elective transthoracic and transhiatal esophagectomy for distal esophageal or gastroesophageal junction carcinoma in the Netherlands between 2007-2016 were included. The primary aim was to evaluate trends in both care and postoperative outcomes for the included patients. Additionally, postoperative outcomes after transthoracic and tran-shiatal esophagectomy were compared, stratified by time periods.Results: Among 4712 patients included, 74% had distal esophageal tumors and 87% had adenocarcinomas. Between 2007 and 2016, the proportion of transthoracic esophagectomy increased from 41% to 81%, and neo-adjuvant treatment and minimally invasive esophagectomy increased from 31% to 96%, and from 7% to 80%, respectively. Over this 10-year period, postoperative outcomes improved: postoperative morbidity decreased from 66.6% to 61.8% (P = 0.001), R0 resection rate increased from 90.0% to 96.5% (P Conclusion: In this nationwide cohort, a transition towards more neo-adju-vant treatment, transthoracic esophagectomy and minimally invasive surgery was observed over a 10-year period, accompanied by decreased postoperative morbidity, improved surgical radicality and lymph node harvest, and improved survival.
- Published
- 2023
5. Heart Rate and Mortality in Patients With Acute Symptomatic Pulmonary Embolism
- Author
-
G. Pellejero, Jose Gutierrez, R. Malý, M. Basaglia, L. Chasco, P. Suchon, R. Le Mao, Laurent Bertoletti, F. Martins, J. Caprini, A. Braester, F. Galeano-Valle, Hanh My Bui, J. Alonso, Y. Sato, G. Vidal, Y. Nishimoto, C. Tolosa, E. Nofuentes-Pérez, A.M. Díaz-Brasero, N. Ait Abdallah, M.D. Adarraga, R. Sánchez-Martínez, L. Font, Raquel López-Reyes, Inna Tzoran, Karine Lacut, J. del Toro, Andris Skride, Ana Jaureguizar, Joseph A. Caprini, C. Amado, R. García de la Garza, A.M. Camon, S. Merla, Luciano López-Jiménez, G. Salgueiro, Sebastian Schellong, Alfonso Muriel, F. Bilora, S. Lainez-Justo, B. Suárez-Rodríguez, Carme Font, F. Beddar Chaib, I. Francisco, C. Jiménez-Alfaro, P. Azcarate-Agüero, Maurizio Ciammaichella, J.A. Porras, N. Vo Hong, F. Martín-Martos, Dominique Farge-Bancel, D. Farge-Bancel, José Luis Lobo, M. Giménez-Suau, E. Grau, F. García-Bragado, Ángeles Blanco-Molina, Carmen Fernández-Capitán, María del Carmen Díaz-Pedroche, C. Grange, Adriana Visonà, L. Guirado, P. Villares, P. López-Miguel, José María Pedrajas, S. Accassat, Beatriz Valero, B. Crichi, Juan J. López-Núñez, Luis Jara-Palomares, G. Sarlon-Bartoli, J. Lima, C. Bortoluzzi, Alicia Lorenzo, C. de Ancos, M.A. Fidalgo, Philippe Debourdeau, Pablo Javier Marchena, C. Rodríguez-Matute, A.I. Farfán-Sedano, José Luis Fernández-Reyes, J.C. Escribano, Juan I. Arcelus, M. Barrón, I. Quere, Remedios Otero, A. De Angelis, P. Morange, Peter Verhamme, G. Kenet, P. Prandoni, Pedro Ruiz-Artacho, C. Siniscalchi, A. Zaicenko, M. Olid-Velilla, C. García-Díaz, B. Barrón-Andrés, T. Sancho, Fernando Uresandi, Javier Trujillo-Santos, A. Muñoz-Blanco, A. Villalobos, A. Dubois-Silva, J. Moisés, J. Osorio, M.I. Mercado, J.M. Suriñach, M.A. Aibar, M.D. Joya, Cihan Ay, J.A. Díaz-Peromingo, H. Bounameaux, Diego Martínez-Urbistondo, Thomas Vanassche, L. Bertoletti, Marijan Bosevski, Farès Moustafa, M. Martín del Pozo, J.F. Sánchez-Muñoz-Torrero, H.M. Bui, Ingrid Pabinger, M.C. Olivares, M. García de Herreros, M.J. Núñez-Fernández, B. Zalunardo, J.F. Varona, Stephan Nopp, Behnood Bikdeli, B. Brandolin, B. Bikdeli, Olga Madridano, Manuel Monreal, M.J. Jaras, Alessandra Bura-Rivière, Abílio Reis, J. Portillo, O. Espitia, J. Catella, Aitor Ballaz, F. Esposito, R. Barba, R. Valle, H. Helfer, I. Tzoran, J.B. López-Sáez, P. Ruiz-Artacho, M.A. García, J. Aibar, C. Gómez-Cuervo, C. Gabara, A. Latorre, J. Ruiz-Ruiz, Benjamin Brenner, S. Fonseca, S. Schellong, Raffaele Pesavento, Barry M. Brenner, Silvia Soler, Paolo Prandoni, Victor F. Tapson, Ana Maestre, Pierpaolo Di Micco, M. Muñoz, J. Criado, D. Jiménez, Antonella Tufano, G. Krstevski, B. Valero, Henri Bounameaux, M.I. Torres, G. Poenou, Isabelle Mahé, Aída Gil-Díaz, A. Asuero, S. Otalora, V. Rosa, L. Vela, E. Imbalzano, C. Vandenbriele, C. Barbagelata, Jana Hirmerova, J. Meireles, David Jiménez, Lucia Mazzolai, L. Hernández-Blasco, M. Bosevski, Gili Kenet, C. Mella, M. Monreal, J.R. Vela, P. Di Micco, Carlos Zamora, K. Flores, P. Demelo-Rodríguez, Radovan Malý, J. Birzulis, J.A. Nieto, J. Castro, M.V. Di Campli, Francis Couturaud, Raquel Barba, Jaureguizar, A., Jimenez, D., Bikdeli, B., Ruiz-Artacho, P., Muriel, A., Tapson, V., Lopez-Reyes, R., Valero, B., Kenet, G., Monreal, M., Prandoni, P., Brenner, B., Farge-Bancel, D., Barba, R., Di Micco, P., Bertoletti, L., Schellong, S., Tzoran, I., Reis, A., Bosevski, M., Bounameaux, H., Maly, R., Verhamme, P., Caprini, J. A., Bui, H. M., Adarraga, M. D., Aibar, J., Aibar, M. A., Alonso, J., Amado, C., Arcelus, J. I., Asuero, A., Azcarate-Aguero, P., Ballaz, A., Barbagelata, C., Barron, M., Barron-Andres, B., Blanco-Molina, A., Beddar Chaib, F., Camon, A. M., Castro, J., Chasco, L., Criado, J., de Ancos, C., del Toro, J., Demelo-Rodriguez, P., Diaz-Brasero, A. M., Diaz-Pedroche, M. C., Diaz-Peromingo, J. A., Di Campli, M. V., Dubois-Silva, A., Escribano, J. C., Esposito, F., Farfan-Sedano, A. I., Fernandez-Capitan, C., Fernandez-Reyes, J. L., Fidalgo, M. A., Flores, K., Font, C., Font, L., Francisco, I., Gabara, C., Galeano-Valle, F., Garcia, M. A., Garcia-Bragado, F., Garcia de Herreros, M., Garcia de la Garza, R., Garcia-Diaz, C., Gil-Diaz, A., Gomez-Cuervo, C., Gimenez-Suau, M., Grau, E., Guirado, L., Gutierrez, J., Hernandez-Blasco, L., Jara-Palomares, L., Jaras, M. J., Jimenez-Alfaro, C., Joya, M. D., Lainez-Justo, S., Latorre, A., Lima, J., Lobo, J. L., Lopez-Jimenez, L., Lopez-Miguel, P., Lopez-Nunez, J. J., Lopez-Saez, J. B., Lorenzo, A., Madridano, O., Maestre, A., Marchena, P. J., Martin del Pozo, M., Martin-Martos, F., Martinez-Urbistondo, D., Mella, C., Mercado, M. I., Moises, J., Munoz, M., Munoz-Blanco, A., Nieto, J. A., Nofuentes-Perez, E., Nunez-Fernandez, M. J., Olid-Velilla, M., Olivares, M. C., Osorio, J., Otalora, S., Otero, R., Pedrajas, J. M., Pellejero, G., Porras, J. A., Portillo, J., Rodriguez-Matute, C., Rosa, V., Ruiz-Ruiz, J., Salgueiro, G., Sanchez-Martinez, R., Sanchez-Munoz-Torrero, J. F., Sancho, T., Soler, S., Suarez-Rodriguez, B., Surinach, J. M., Torres, M. I., Tolosa, C., Trujillo-Santos, J., Uresandi, F., Valle, R., Varona, J. F., Vela, L., Vela, J. R., Vidal, G., Villalobos, A., Villares, P., Zamora, C., Ay, C., Nopp, S., Pabinger, I., Vanassche, T., Vandenbriele, C., Hirmerova, J., Accassat, S., Ait Abdallah, N., Bura-Riviere, A., Catella, J., Couturaud, F., Crichi, B., Debourdeau, P., Espitia, O., Grange, C., Helfer, H., Lacut, K., Le Mao, R., Mahe, I., Morange, P., Moustafa, F., Poenou, G., Sarlon-Bartoli, G., Suchon, P., Quere, I., Braester, A., Basaglia, M., Bilora, F., Bortoluzzi, C., Brandolin, B., Ciammaichella, M., De Angelis, A., Imbalzano, E., Merla, S., Pesavento, R., Siniscalchi, C., Tufano, A., Visona, A., Vo Hong, N., Zalunardo, B., Nishimoto, Y., Sato, Y., Birzulis, J., Skride, A., Zaicenko, A., Fonseca, S., Martins, F., Meireles, J., Krstevski, G., and Mazzolai, L.
- Subjects
Male ,Registrie ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,pulmonary embolism ,Critical Care and Intensive Care Medicine ,Logistic regression ,Heart Rate ,Internal medicine ,Heart rate ,medicine ,In patient ,Aged ,Aged, 80 and over ,business.industry ,medicine.disease ,mortality ,Pulmonary embolism ,Prospective Studie ,Increased risk ,Spain ,Cardiology ,Positive relationship ,Female ,Cardiology and Cardiovascular Medicine ,business ,Human - Abstract
Background: The association between heart rate (HR) and pulmonary embolism (PE) outcomes has not been well studied. Furthermore, optimal cutoffs to identify low-risk and intermediate- to high-risk patients are not well known. Research Question: Does an association exist between baseline HR and PE outcome across the continuum of HR values? Study Design and Methods: The current study included 44,331 consecutive nonhypotensive patients with symptomatic PE from the Registro Informatizado de la Enfermedad TromboEmbólica registry between 2001 and 2021. Outcomes included 30-day all-cause and PE-specific mortality. We used hierarchical logistic regression to assess the association between admission HR and outcomes. Results: A positive relationship was found between admission HR and 30-day all-cause and PE-related mortality. Considering an HR of 80 to 99 beats/min as a reference, patients in the higher HR strata showed higher rates of all-cause death (adjusted OR, 1.5 for HR of 100-109 beats/min; adjusted OR, 1.7 for HR of 110-119 beats/min; adjusted OR, 1.9 for HR of 120-139 beats/min; and adjusted OR, 2.4 for HR of ≥ 140 beats/min). Patients in the lower strata of HR showed significantly lower rates of 30-day all-cause mortality compared with the same reference group (adjusted OR, 0.6 for HR of 60-79 beats/min; and adjusted OR, 0.5 for HR of < 60 beats/min). The findings for 30-day PE-related mortality were similar. For identification of low-risk patients, a cutoff value of 80 beats/min (vs 110 beats/min) increased the sensitivity of the simplified Pulmonary Embolism Severity Index (sPESI) from 93.4% to 98.8%. For identification of intermediate- to high-risk patients, a cutoff value of 140 beats/min (vs 110 beats/min) increased the specificity of the Bova score from 93.2% to 98.0%. Interpretation: In nonhypotensive patients with acute symptomatic PE, a high HR portends an increased risk of all-cause and PE-related mortality. Modifying the HR cutoff in the sPESI and the Bova score improves prognostication of patients with PE.
- Published
- 2022
6. Work Ability in Patients With Stage I to IV Colon Cancer
- Author
-
Mira D, Franken, Geraldine, Vink, Wilhelmina M U, van Grevenstein, Helena M, Verkooijen, Cornelis J A, Punt, Miriam, Koopman, Anne M, May, David D E, Zimmerman, Interne Geneeskunde, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, and MUMC+: MA Medische Oncologie (9)
- Subjects
medicine.medical_specialty ,Colorectal cancer ,Population ,Work Capacity Evaluation ,Disease ,Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14] ,All institutes and research themes of the Radboud University Medical Center ,Internal medicine ,medicine ,Humans ,Prospective Studies ,Stage (cooking) ,Prospective cohort study ,education ,Neoplasm Staging ,Retrospective Studies ,education.field_of_study ,business.industry ,Colonic Neoplasms/surgery ,Gastroenterology ,Cancer ,General Medicine ,medicine.disease ,Comorbidity ,Cohort ,business - Abstract
BACKGROUND: Colon cancer affects a patient's ability to work. Many patients who have colon cancer are employed at the time of diagnosis.OBJECTIVE: We evaluated work ability during the first 2 years after colon cancer diagnosis.DESIGN: This study is a national prospective study, the Prospective Dutch ColoRectal Cancer cohort, including clinical data and patient-reported outcomes.SETTINGS: Data were collected in 59 medical centers in the Netherlands.PATIENTS: Patients MAIN OUTCOME MEASURES: Work ability was assessed at baseline, 3, 6, 12, 18, and 24 months. The Work Ability Index (range, 0 to 49) was evaluated using linear mixed models. Outcomes were matched to population controls without cancer.RESULTS: Of 390 patients, 84% had paid employment. Work ability of patients with stage I to IV colon cancer was significantly lower at the time of diagnosis than in matched population controls (31 ± 8.2 and 41 ± 5.6). Patients with stage I to III disease receiving surgery only regained Work Ability Index scores comparable to matched population controls at 18 months. Patients receiving adjuvant systemic treatment initially demonstrated a decrease in work ability with improvements from 6 months onward and normalization at 24 months. Patients with stage IV disease did not demonstrate improvements in work ability outcomes over time. Work ability scores were negatively influenced by the administration of systemic treatment and ≥1 comorbidities.LIMITATIONS: Only patients with patient-reported outcomes and work at baseline were included in this analysis. Also, questionnaire response rates decreased over time.CONCLUSIONS: Work ability in patients with colon cancer is decreased for a prolonged time. Recovery depends on disease stage, type of treatment, and comorbidities. Patients with stage I to III disease treated with curative surgery alone were the first to regain work ability, followed by patients who receive adjuvant chemotherapy. Patients with stage IV disease did not regain work ability. See Video Abstract at http://links.lww.com/DCR/B759 .CAPACIDAD LABORAL EN PACIENTES CON CNCER DE COLON EN ESTADIO IIV RESULTADOS PROSPECTIVOS DE CNCER COLORECTAL EN UNA COHORTE HOLANDESA: ANTECEDENTES:El cáncer de colon afecta la capacidad de trabajo en un paciente. Muchos pacientes con cáncer de colon están empleados en el momento del diagnóstico.OBJETIVO:Evaluamos la capacidad laboral durante los dos primeros años posteriores al diagnóstico de cáncer de colon.DISEÑO:Es un estudio prospectivo nacional, la cohorte de cáncer colorrectal holandés, incluye datos clínicos y resultados informados por los pacientes.ENTORNO CLINICO:Se recopilaron datos de 59 centros médicos en los Países Bajos.PACIENTES:Se seleccionaron pacientes < 67 años, con cáncer de colon en estadio I-IV, que completaron los cuestionarios de índice de capacidad para el trabajo.PRINCIPALES MEDIDAS DE VALORACIÓN:La capacidad para el trabajo se evaluó al inicio, a los 3, 6, 12, 18 y 24 meses. El índice de capacidad para el trabajo (que va de 0 a 49) se evaluó mediante modelos lineales mixtos. Los resultados fueron comparados con el grupo control sin cáncer.RESULTADOS:De 390 pacientes, el 84% tenía un empleo remunerado. La capacidad de trabajo de los pacientes en estadio I-IV fue significativamente menor en el momento del diagnóstico en comparación con el grupo control (31 ± 8,2 y 41 ± 5,6, respectivamente). Los pacientes con enfermedad en estadio I-III que recibieron cirugía lograron recuperar puntajes del índice de capacidad laboral comparables a los controles a los 18 meses. Los pacientes que recibieron tratamiento sistémico adyuvante inicialmente demostraron una disminución en la capacidad de trabajo con mejoras a partir de los 6 meses en adelante y una normalización a los 24 meses. Los pacientes en estadio IV no demostraron mejoras en los resultados de la capacidad laboral a lo largo del tiempo. Las puntuaciones de capacidad para el trabajo se vieron influidas negativamente por la administración del tratamiento sistémico y la existencia de ≥1 comorbilidades.LIMITACIONES:En este análisis solo se incluyeron los pacientes con resultados y trabajo desde el inicio del estudio. Además, las tasas de respuesta al cuestionario disminuyeron con el tiempo.CONCLUSIONES:La capacidad de trabajo en pacientes con cáncer de colon se reduce durante un tiempo prolongado. La recuperación depende del estadio de la enfermedad, el tipo de tratamiento y la comorbilidad. Los pacientes con enfermedad en estadio I-III tratados con cirugía curativa exclusivamente, son los primeros en recuperar la capacidad para trabajar, seguidos de los pacientes que reciben quimioterapia adyuvante. Los pacientes con enfermedad en estadio IV no recuperan la capacidad para trabajar. Consulte Video Resumen en http://links.lww.com/DCR/B759 . (Traducción- Dr. Ingrid Melo ).
- Published
- 2023
7. Accuracy of the International Classification of Diseases, 9th Revision for Identifying Infantile Eye Disease
- Author
-
Launia J. White, Tina M. Hendricks, Sasha A. Mansukhani, Timothy T. Xu, Cole E. Bothun, Brian G. Mohney, and Erick D. Bothun
- Subjects
Pediatrics ,medicine.medical_specialty ,Eye Diseases ,Epidemiology ,Eye disease ,Population ,International Classification of Diseases ,Predictive Value of Tests ,Lacrimal Duct Obstruction ,Medicine ,Pseudostrabismus ,Humans ,education ,Child ,Retrospective Studies ,education.field_of_study ,business.industry ,Medical record ,Retrospective cohort study ,medicine.disease ,Conjunctivitis ,Anisocoria ,Ophthalmology ,Nasolacrimal duct obstruction ,Pediatrics, Perinatology and Child Health ,Cohort ,Pediatric ophthalmology ,business ,Nasolacrimal Duct - Abstract
PURPOSE To determine the predictive value of International Classification of Diseases, 9th Revision (ICD-9) codes for identifying infantile eye diagnoses. METHODS Population-based retrospective cohort study of all residents of Olmsted County, Minnesota diagnosed at ≤1 year of age with an ocular disorder. The medical records of all infants diagnosed with any ocular disorder from January 1, 2005, through December 31, 2014, were identified. To assess ICD-9 code accuracy, the medical records of all diagnoses with ≥20 cases were individually reviewed and compared to their corresponding ICD-9 codes. Main outcome measures included positive predictive value (PPV), negative predictive value (NPV), sensitivity, and specificity of ICD-9 codes. RESULTS In a cohort of 5,109 infants with ≥1 eye-related ICD-9 code, 10 ocular diagnoses met study criteria. The most frequent diagnoses were conjunctivitis (N = 1,695) and congenital nasolacrimal duct obstruction (N = 1,250), while the least common was physiologic anisocoria (N = 23). The PPVs ranged from 8.3% to 88.0%, NPVs from 96.3% to 100%, sensitivity from 3.0% to 98.7%, and specificity from 72.6% to 99.9%. ICD-9 codes were most accurate at identifying physiologic anisocoria (PPV: 88.0%) and least accurate at identifying preseptal cellulitis (PPV: 8.3%). In eye specialists versus non-eye specialists, there was a significant difference in PPV of ICD-9 codes for conjunctivitis (26.8% vs. 63.9%, p
- Published
- 2023
8. Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project
- Author
-
Trifiro, G., Isgro, V., Ingrasciotta, Y., Ientile, V., L'Abbate, L., Foti, S. S., Belleudi, V., Poggi, F., Fontana, A., Moretti, U., Lora, R., Sabaini, A., Senesi, I., Sorrentino, C., Puzo, M. R., Padula, A., Fusco, M., Giordana, R., Solfrini, V., Puccini, A., Rossi, P., Del Zotto, S., Leoni, O., Zanforlini, M., Ancona, D., Bavaro, V., Garau, D., Ledda, S., Scondotto, S., Allotta, A., Tuccori, M., Gini, R., Bucaneve, G., Franchini, D., Cavazzana, A., Biasi, V., Spila Alegiani, S., Massari, M., Andretta, I., Tanaglia, M., Carriero, A., Sassano, S., De Sarro, G., Mirarchi, S., Palleria, C., Sarro, C., Balestrieri, M., Rostan, S., Capuano, A., Bernardi, F. F., Trama, U., Russo, A., Fumo, M. G., Addis, A., Musicco, F., Sapigni, E., Mazzetti, I., Podetti, D., Potenza, A. M., Nikitina, V., Ricciardelli, R., Mogheiseh, N., Croce, S., Pettinelli, A., Ejlli, L., Fortino, I., Ercolanoni, M., Mazzone, A., Nisic, A., Schiatti, S., Ludergnani, M., Mancini, M., Patregnani, L., Fabbietti, P., Antonicelli, E., Mangano, A., Campomori, A., Urru, S. A., Costa, G., Guarrera, G. M., Stella, P., Serra, E., Carta, P., Vannacci, A., Lucenteforte, E., Parrilli, M., Convertino, I., De Giorgi, M., Rocchi, R. E., Rossi, M., Scroccaro, G., Deambrosis, P., Grindelli, G., Ferroni, E., Trifiro, G., Isgro, V., Ingrasciotta, Y., Ientile, V., L'Abbate, L., Foti, S. S., Belleudi, V., Poggi, F., Fontana, A., Moretti, U., Lora, R., Sabaini, A., Senesi, I., Sorrentino, C., Puzo, M. R., Padula, A., Fusco, M., Giordana, R., Solfrini, V., Puccini, A., Rossi, P., Del Zotto, S., Leoni, O., Zanforlini, M., Ancona, D., Bavaro, V., Garau, D., Ledda, S., Scondotto, S., Allotta, A., Tuccori, M., Gini, R., Bucaneve, G., Franchini, D., Cavazzana, A., Biasi, V., Spila Alegiani, S., Massari, M., Andretta, I., Tanaglia, M., Carriero, A., Sassano, S., De Sarro, G., Mirarchi, S., Palleria, C., Sarro, C., Balestrieri, M., Rostan, S., Capuano, A., Bernardi, F. F., Trama, U., Russo, A., Fumo, M. G., Addis, A., Musicco, F., Sapigni, E., Mazzetti, I., Podetti, D., Potenza, A. M., Nikitina, V., Ricciardelli, R., Mogheiseh, N., Croce, S., Pettinelli, A., Ejlli, L., Fortino, I., Ercolanoni, M., Mazzone, A., Nisic, A., Schiatti, S., Ludergnani, M., Mancini, M., Patregnani, L., Fabbietti, P., Antonicelli, E., Mangano, A., Campomori, A., Urru, S. A., Costa, G., Guarrera, G. M., Stella, P., Serra, E., Carta, P., Vannacci, A., Lucenteforte, E., Parrilli, M., Convertino, I., De Giorgi, M., Rocchi, R. E., Rossi, M., Scroccaro, G., Deambrosis, P., Grindelli, G., and Ferroni, E.
- Subjects
Male ,medicine.medical_specialty ,Population ,Postmarketing surveillance ,Rate ratio ,REGISTRIES ,Retrospective Studie ,Internal medicine ,BIOSIMILARS ,medicine ,Adalimumab ,Humans ,Pharmacology (medical) ,Original Research Article ,education ,Adverse effect ,ANTI-TNF THERAPY, RHEUMATOID-ARTHRITIS, RISK, PHARMACOVIGILANCE, BIOSIMILARS, EXPERIENCE, REGISTRIES, PSORIASIS, MEDICINES, ACCESS ,Biosimilar Pharmaceuticals ,Retrospective Studies ,RISK ,Delivery of Health Care ,Female ,Infliximab ,Italy ,SARS-CoV-2 ,COVID-19 ,Pharmacology ,education.field_of_study ,PSORIASIS ,business.industry ,Biosimilar ,ANTI-TNF THERAPY ,General Medicine ,medicine.disease ,RHEUMATOID-ARTHRITIS ,PHARMACOVIGILANCE ,MEDICINES ,EXPERIENCE ,Immune-mediated inflammatory diseases ,ACCESS ,business ,Human ,Biosimilar Pharmaceutical ,Biotechnology ,medicine.drug - Abstract
Background Biological drugs have improved the management of immune-mediated inflammatory diseases (IMIDs) despite being associated with important safety issues such as immunogenicity, infections, and malignancies in real-world settings. Objective The aim of this study was to explore the potential of a large Italian multi-database distributed network for use in the postmarketing surveillance of biological drugs, including biosimilars, in patients with IMID. Methods A retrospective cohort study was conducted using 13 Italian regional claims databases during 2010–2019. A tailor-made R-based tool developed for distributed analysis of claims data using a study-specific common data model was customized for this study. We measured the yearly prevalence of biological drug users and the frequency of switches between originator and biosimilars for infliximab, etanercept, and adalimumab separately and stratified them by calendar year and region. We then calculated the cumulative number of users and person-years (PYs) of exposure to individual biological drugs approved for IMIDs. For a number of safety outcomes (e.g., severe acute respiratory syndrome coronavirus 2 [SARS-COV-2] infection), we conducted a sample power calculation to estimate the PYs of exposure required to investigate their association with individual biological drugs approved for IMIDs, considering different strengths of association. Results From a total underlying population of almost 50 million inhabitants from 13 Italian regions, we identified 143,602 (0.3%) biological drug users, with a cumulative exposure of 507,745 PYs during the entire follow-up. The mean age ± standard deviation of biological drug users was 49.3 ± 16.3, with a female-to-male ratio of 1.2. The age-adjusted yearly prevalence of biological drug users increased threefold from 0.7 per 1000 in 2010 to 2.1 per 1000 in 2019. Overall, we identified 40,996 users of biosimilars of tumor necrosis factor (TNF)-α inhibitors (i.e., etanercept, adalimumab, and infliximab) in the years 2015–2019. Of these, 46% (N = 18,845) switched at any time between originator and biosimilars or vice versa. To investigate a moderate association (incidence rate ratio 2) between biological drugs approved for IMIDs and safety events of interest, such as optic neuritis (lowest background incidence rate 10.4/100,000 PYs) or severe infection (highest background incidence rate 4312/100,000 PYs), a total of 43,311 PYs and 104 PYs of exposure to individual biological drugs, respectively, would be required. As such, using this network, of 15 individual biological drugs approved for IMIDs, the association with those adverse events could be investigated for four (27%) and 14 (93%), respectively. Conclusion The VALORE project multi-database network has access to data on more than 140,000 biological drug users (and > 0.5 million PYs) from 13 Italian regions during the years 2010–2019, which will be further expanded with the inclusion of data from other regions and more recent calendar years. Overall, the cumulated amount of person-time of exposure to biological drugs approved for IMIDs provides enough statistical power to investigate weak/moderate associations of almost all individual compounds and the most relevant safety outcomes. Moreover, this network may offer the opportunity to investigate the interchangeability of originator and biosimilars of several TNFα inhibitors in different therapeutic areas in real-world settings. Supplementary Information The online version contains supplementary material available at 10.1007/s40259-021-00498-3.
- Published
- 2021
9. Risk of autoimmune diseases in patients with RASopathies: systematic study of humoral and cellular immunity
- Author
-
Maria Siano, Pietro Strisciuglio, Valentina Pinna, Serena Cabaro, F. Di Candia, S. Sestito, D. Melis, D. De Brasi, Maria Alessio, Vittoria D'Esposito, Stefano Pagano, Pietro Formisano, Marco Tartaglia, Daniela Concolino, V. Marchetti, Giuseppe Perruolo, A. De Luca, Siano, M A, Marchetti, V, Pagano, S, Di Candia, F, Alessio, M, De Brasi, D, De Luca, A, Pinna, V, Sestito, S, Concolino, D, Tartaglia, M, Strisciuglio, P, D'Esposito, V, Cabaro, S, Perruolo, G, Formisano, P, and Melis, D
- Subjects
medicine.medical_specialty ,Cellular immunity ,Inflammatory cytokine ,Antigens, CD19 ,Autoimmunity ,CD8 T cells ,RASopathy ,medicine.disease_cause ,Autoimmune Disease ,Gastroenterology ,Autoimmune Diseases ,Immune system ,Psoriasis ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,Genetics (clinical) ,Autoimmune disease ,Immunity, Cellular ,biology ,business.industry ,Research ,Autoantibody ,General Medicine ,medicine.disease ,Inflammatory cytokines ,CD8 T cell ,biology.protein ,Medicine ,Antibody ,business ,Human - Abstract
Background Abnormalities of the immune system are rarely reported in patients affected by RASopathies. Aim of the current study was to investigate the prevalence of immune system dysfunction in a cohort of patients affected by RASopathies. Study design A group of 69 patients was enrolled: 60 at the Federico II University, Naples, 7 at University Magna Graecia of Catanzaro, 2 at “Scuola Medica Salernitana”, Salerno. An age- and sex-matched control group was also enrolled. Autoimmune disorders were investigated according to international consensus criteria. Immune framework was also evaluated by immunoglobulin levels, CD3, CD4, CD8, CD19, CD56 lymphocyte subpopulations, autoantibodies levels and panel of inflammatory molecules, in both patients and controls. Results Frequent upper respiratory tract infections were recorded in 2 patients; pneumonia, psoriasis and alopecia in single patients. Low IgA levels were detected in 8/44 patients (18.18%), low CD8 T cells in 13/35 patients (37.14%). Anti-tg and anti-TPO antibodies were detected in 3/24 patients (12.5%), anti r-TSH in 2 cases (8.33%), all in euthyroidism. Serum IgA and CD8 levels were significantly lower in patients than in controls (p 0.00685; p 0.000656 respectively). All tested patients showed increased inflammatory molecules compared to controls. These findings may anticipate the detection of overt autoimmune disease. Conclusions Patients affected by RASopathies are at risk to develop autoimmune disorders. Routine screening for autoimmunity is recommended in patients with RASopathy.
- Published
- 2021
10. An international assessment of the adoption of enhanced recovery after surgery (ERAS®) principles across colorectal units in 2019–2020
- Author
-
Pinkney T., Taylor H., Tong C., Schmitz N. -D., Morton D. G., Pinkney T. D., Bhangu A., Blackwell S., Dardanov D., Dulskas A., Gallo G., Glasbey J., Keatley J., Knowles C., Li Y. E., McCourt V., Minaya-Bravo A., Neary P., Nepogodiev D., Pata F., Pellino G., Sivrikoz E., van Ramshorst G., Zmora O., Perry R., Magill E. L., Abdalkoddus M., Abelevich A., Abraham S., Abraham-Nordling M., Adamina M., Agalar C., Agresta F., Ahallat M., Ahmad N., Aiupov R., Akca O., Aleksic A., Aleotti F., Alias D., Alonso J., Alonso Goncalves S., Alonso Martin J., Alonso Poza A., Alonso-Hernandez N., Alos Company R., Al-Saeedi M., Alvarez-Laso C., Alvarez-Gallego M., Amanatidis T., Americano M., Amorim E., Anandan L., Anania G., Ancans G., Andreev P., Andrejevic P., Antonacci N., Anwer M., Aonzo P., Arencibia B., Argeny S., Arieli H., Arnold S., Ashraf M., Aslam M., Atanasov B., Atif M., Atladottir J., Avital S., Awny S., Aytac B., Azahr N., Aznar-Puig S., Bailey S., Balalis D., Baldi C., Baldonedo R., Balducci G., Balestra F., Balestri R., Balfour A., Baloyiannis I., Banky B., Baral J., Baranyai Z., Barbashinov N., Bargallo J., Barisic G., Barugola G., Batashki I., Battersby N., Belev N., Belli A., Beltran de Heredia J., Bemelman W., Benavides Buleje J., Benckert A., Bernal-Sprekelsen J., Bertocchi E., Beuran M., Bhan C., Bianco F., Bilali S., Bilali V., Bintintan V., Birindelli A., Birsan T., Blanco Antona F., Blas J., Blasco-Segura T., Blom R., Bocchetti T., Boerma E., Bogdan M., Boland M., Bomans B., Borda N., Bowen M., Bradulskis S., Branagan G., Brankovic B., Brenna M., Brewer H., Broadhurst J., Bronder C., Brouwer R., Buccianti P., Buchs N., Buchwald P., Bugatti A., Bui A., Burcos T., Buskens C., Bustamante C., Caceres N., Cagigas Fernandez C., Calero-Lillo A., Camps I., Canda A., Caravaca-Garcia I., Carballo F., Carcoforo P., Carlander J., Carlos S., Caro A., Carpelan A., Carrasco Prats M., Carrillo Lopez M., Carvello M., Casal E., Casoni Pattacini G., Castellvi Valls J., Castillo Diego J., Cavallesco G., Cavenaile V., Cayetano L., Ceccotti A., Cervera-Aldama J., Chabok A., Chafai N., Chandrasinghe P., Chandratreya N., Chaudhri S., Chaudhry Z., Cherdancev D., Chernov A., Chevallay M., Chirletti P., Chouillard E., Chouliaras C., Chowdri N., Cillo M., Cini C., Ciubotaru C., Ciuce C., Claeys D., Cocorullo G., Codina-Cazador A., Colak E., Coletta D., Colombo F., Copaescu C., Corte Real J., Corver M., Cosic J., Costa S., Costa Pereira J., Costa Pereira C., Costa-Navarro D., Cotte E., Cracco N., Cristian D., Cuadrado M., Cuk V., Cunha M., Cunha J., Curinga R., Curletti G., Curtis N., Dabic D., Dainius E., d'Alessandro A., Daniels I., Darvin V., Dauser B., David G., Davidova O., Davies E., de Andres Asenjo B., De franciscis S., de Graaf E., De la Portilla F., De Luca E., De Nisco C., De Toma G., Defoort B., Den Boer F., Di Candido F., Di Saverio S., Diaz Pavon J., Dieguez Fernandez B., Diez-Alonso M., Dimitrijevic I., Dindelegan G., Djuric M., Domingos H., Doornebosch P., Dos Santos M., Drami I., Dudarovaska H., Dusek T., Dzhumabaev H., Eden Y., Egenvall M., Eismiontas V., El Sorogy M., Elgeidie A., Elhemaly M., El-Hussuna A., Ellul S., Elmore U., ElNakeeb A., Elrefai M., Emile S., Enrriquez-Navascues J., Epstein J., Escartin J., Escola D., Escuder J., Espin E., Espina B., Estefania D., Etienne J., Fabbri S., Falato A., Fares R., Farina P., Farkasova M., Farres R., Fasolini F., Fatayer T., Febles G., Feliu F., Feo C., Feoktistov D., Fernandez F., Fernandez Isart M., Fernando J., Ferreira G., Ferrer R., Ferreras Garcia C., Ferri M., Figueiredo N., Finotti E., Fitzgerald J., Flateh Backe I., Flor-Lorente B., Forero-Torres A., Foschi D., Francart D., Francois Y., Frasson M., Freil-Lanter C., Frois Borges M., Fuzun M., Gala T., Galleano R., Galvez P., Galvez Saldana A., Gamundi Cuesta M., Garcia Cabrera A., Garcia Egea J., Garcia Olmo D., Garcia-Gonzalez J., Garcia-Granero A., Garcia-Granero E., Garcia-Septiem J., Gardea A., Garipov M., Gefen R., Geraghty A., Gerkis S., Germanos S., Ghaffari S., Ghilles E., Gianotti L., Gil Santos M., Gilsanz Martin C., Gingert C., Gklavas A., Glehen O., Golda T., Gomez N., Gomez R., Gomez Ruiz M., Gonzalez Santin V., Graham B., Grainger J., Grama F., Gregoir T., Gregori M., Grolich T., Grosek J., Guadalajara H., Guckenheimer S., Guevara J., Gulotta G., Gupta S., Gurevich N., Gurjar S., Haapaniemi S., Hahnloser D., Hamad Y., Hamid M., Hanly A., Harris G., Harsanyi L., Hartig N., Hawkin P., Henriques P., Herbst F., Hermann N., Hernandez Garcia M., Hoch J., Hrora A., Huhtinen H., Iarumov N., Ilkanich A., Insua C., Ioannidis P., Iqbal M., Iqbal A., Isik A., Ismaiel M., Ivlev D., Jadhav V., Jareno S., Jehaes C., Jimenez V., Jimenez-Toscano M., Jimenez-Miramon J., Jimenez-Rodriguez R., Jonsson T., Jotautas V., Julia D., Juloski J., Jung B., Kala Z., Kalayci M., Kara Y., Karachun A., Karagul S., Karvonen J., Katorkin S., Katsoulis I., Katsounis D., Kaubrys M., Kaul N., Kefalou E., Keijzers M., Kelly M., Kenic M., Kennelly R., Khan J., Khan M., Kho H., Kinas V., Knight J., Kocian P., Koeter T., Kokobelyan A., Konsten J., Koolen L., Kosir J., Kostic I., Krdzic I., Kreisler Moreno E., Krivokapic Z., Krstev P., Krsul D., Kumarasinghe N., La Torre F., Labarga F., Ladra M., Lage Laredo A., Lahodzich N., Lai C., Lakkis Z., Lal R., Lamas S., Lang T., Latkauskas T., Lawes D., Lazar G., Lebedev K., Lebedeva M., Lefevre J., Lekic Vitlov V., Lemma M., Leo C., Leon C., Leventoglu S., Levy B., Li L., Licari L., Lizdenis P., Loftas P., Longhi M., Longstaff L., Lopez Dominguez J., Lopez-Lara M., Lora P., Lorenzon L., Lorusso D., Lozev I., Lozoya Trujillo R., Lukic D., Lunins R., Luzan R., Luzzi A., Maderuelo V., Madsboll T., Mahotin D., Majbar M., Makhmudov A., Malik K., Maly O., Mamaloudis I., Mamedli Z., Manatakis D., Mandi D., Mangell P., Marharint T., Mariani N., Maric B., Marimuthu K., Marinello F., Marino F., Markiewicz S., Markovic V., Marom G., Maroni N., Maroulis I., Marsanic P., Marsman H., Martens M., Marti M., Martinek L., Martinez S., Martinez D., Martinez Manzano A., Martins R., Maslyankov S., McArdle K., McDermott F., Mege D., Mehraj A., Mehta A., Mendrila D., Menendez P., Mercantini P., Metwally I., Mikalauskas S., Millan M., Mingoli A., Mirshekar-Syahkal B., Moggia E., Mohan S., Moller P., Mompart Garcia S., Monami B., Moniz Pereira P., Montroni I., Morel P., Moshev B., Mostovoy E., Mothe S., Mukhtar H., Muller P., Munch S., Munoz Camarena J., Munoz-Collado S., Muratore A., Muscara F., Muysoms F., Myrelid P., N. Lah N., Nail S., Narayanan A., Nastos K., Negoi I., Nesbakken A., Nestler G., Nestorovic M., Nesytykh A., Newton K., Ng Y., Ngu J., Nguyen B., Nijs Y., Nikberg M., Nimmersgern T., Nogues E., Norcic G., Nutautiene V., Nygren J., O'Brien J., Ochogavia Segui A., O'Kelly J., Oliveira-Cunha M., Omar W., Omar G., Onishchenko S., Onody P., Opocher E., Orhalmi J., Oshowo A., Otero J., Ozgen U., Pace K., Padin H., Papaconstantinou I., Papadopoulos A., Papadopoulos G., Papandrea M., Paral J., Parc Y., Paredes J., Parmar M., Parra Banos P., Parray F., Pascual Damieta M., Pascual Miguelanez I., Passot G., Pastor C., Paszt A., Patel P., Paterson H., Patron Uriburu J., Paulos A., Pavlov V., Pcolkins A., Pecic V., Pena Ros E., Penkov R., Pera Roman M., Perunicic V., Pery R., Petrovic D., Pezzolla F., Photi E., Pikarsky A., Piramanayagam B., Pisani Ceretti A., Planellas P., Platt E., Pletinckx P., Podda M., Poskus T., Poskus E., Pozdnyakov A., Pravosudov I., Previsic A., Prieto D., Prochazka V., Prodan A., Proud D., Psaila J., Psaras G., Pulighe F., Pullig F., Qureshi M., Rachadell J., Radovanovic Z., Radovanovic D., Raguan B., Rahman M., Raiss M., Ramirez Faraco M., Ramos J., Ramos-Prada J., Rantala A., Rao M., Rasulov A., Ratnatunga K., Raymond T., Refky B., Reggiani L., Regusci L., Reyes Diaz M., Richardson J., Richiteanu G., Rios A., Ris F., Rodriguez Garcia P., Roffi N., Romairone E., Romano G., Romero I., Romero de Diego A., Romero-Simo M., Roque C., Rosati R., Rossi B., Rossi E., Rossini R., Ruano A., Rubbini M., Rubio-Perez I., Ruffo G., Ruiz H., Ruiz Carmona M., Ryska O., Sabia D., Sacchi M., Sacco R., Sakr A., Saladzinskas Z., Salamone G., Salomon M., Salvans Ruiz S., Sammarco G., Sampietro G., Samsonov D., Samsonyuk V., Sanchez J., Sanchez Romero A., Sanchez-Guillen L., Santak G., Santamaria-Olabarrieta M., Santos J., Saraceno F., Saralegui Y., Sarici I., Savino G., Scabini S., Schafli J., Schiltz B., Schofield A., Schon M., Scurtu R., Segalini E., Segelman J., Segura-Sampedro J., Seicean R., Sekulic A., Selniahina L., Seretis F., Serrano Paz P., Shaikh I., Shalaby M., Shams N., Sharma A., Sharma G., Shukla A., Shussman N., Shweejawee Z., Sielezneff I., Sigurdsson H., Sileri P., Silva M., Simcikas D., Simoes J., Simonka Z., Singh B., Sivins A., Skroubis G., Skull A., Slavchev M., Slavin M., Smart N., Smart C., Smart P., Smedh K., Smolarek S., Sokmen S., Sokolov M., Solana Bueno A., Solar L., Sorrentino L., Sotona O., Spacca D., Spinelli A., Stanojevic G., Stearns A., Stefan S., Stift A., Stijns J., Stoyanov V., Straarup D., Strupas K., Stubbs B., Subocius A., Sudlow A., Suero C., Sungurtekin U., Svagzdys S., Syk I., Tamelis A., Tamhane R., Tamini N., Tamosiunas A., Tanis P., Tarasov N., Tate S., Tennakoon A., Teo N., Terzi C., Tezas S., Thabet W., Tham J., Thavanesan N., Theodosopoulos T., Thomas W., Tiret E., Tiselius C., Todorov G., Tomazic A., Tomulescu V., Torkington J., Totis M., Trostchansky I., Truan N., Tulchinsky H., Tutino R., Tzivanakis A., Tzovaras G., Ugolini G., Unger L., Upanishad I., Urbani L., Uth Ovesen A., Vaizey C., Vallribera F., Valsdottir E., Valverde I., Valverde-Sintas J., Van Belle K., Van Cleven S., van Hagen P., van Loon Y., van Ruler O., Van Wijck K., Varabei A., Varcada M., Varpe P., Vartic M., Velchuru V., Vencius J., Venskutonis D., Vercher D., Vermaas M., Vertruyen M., Verza L., Vescio G., Vezakis A., Vieira P., Vignali A., Vigorita V., Vila Tura M., Vinson-Bonnet B., Viso Pons L., Voloshin S., Voronin Y., Vukusic L., Wang X., Wang J., Wani R., Warusavitarne J., Wasserberg N., Weerts J., Weiss D., Weizman A., Westerduin E., Wheat J., White I., Wik T., Wilson J., Winter D., Wolthuis A., Wong M., Yahia S., Yamamoto T., Yanishev A., Yao C., Yildiz A., Yuksel O., Zain Z., Zakaria A., Zakaria Z., Zampitis N., Zarand A., Zarco-Pleguezuelos A., Zattoni D., Zelic M., Zeromskas P., Zhuravlev A., Zimmerman D., Zuhdy M., Zukanovic G., Surgery, CCA - Cancer Treatment and Quality of Life, Amsterdam Gastroenterology Endocrinology Metabolism, Graduate School, Amsterdam Neuroscience - Cellular & Molecular Mechanisms, Amsterdam Neuroscience - Neuroinfection & -inflammation, APH - Methodology, APH - Personalized Medicine, Pinkney, T, Taylor, H, Tong, C, Schmitz, N, Morton, D, Bhangu, A, Blackwell, S, Dardanov, D, Dulskas, A, Gallo, G, Glasbey, J, Keatley, J, Knowles, C, Li, Y, Mccourt, V, Minaya-Bravo, A, Neary, P, Nepogodiev, D, Pata, F, Pellino, G, Sivrikoz, E, van Ramshorst, G, Zmora, O, Perry, R, Magill, E, Abdalkoddus, M, Abelevich, A, Abraham, S, Abraham-Nordling, M, Adamina, M, Agalar, C, Agresta, F, Ahallat, M, Ahmad, N, Aiupov, R, Akca, O, Aleksic, A, Aleotti, F, Alias, D, Alonso, J, Alonso Goncalves, S, Alonso Martin, J, Alonso Poza, A, Alonso-Hernandez, N, Alos Company, R, Al-Saeedi, M, Alvarez-Laso, C, Alvarez-Gallego, M, Amanatidis, T, Americano, M, Amorim, E, Anandan, L, Anania, G, Ancans, G, Andreev, P, Andrejevic, P, Antonacci, N, Anwer, M, Aonzo, P, Arencibia, B, Argeny, S, Arieli, H, Arnold, S, Ashraf, M, Aslam, M, Atanasov, B, Atif, M, Atladottir, J, Avital, S, Awny, S, Aytac, B, Azahr, N, Aznar-Puig, S, Bailey, S, Balalis, D, Baldi, C, Baldonedo, R, Balducci, G, Balestra, F, Balestri, R, Balfour, A, Baloyiannis, I, Banky, B, Baral, J, Baranyai, Z, Barbashinov, N, Bargallo, J, Barisic, G, Barugola, G, Batashki, I, Battersby, N, Belev, N, Belli, A, Beltran de Heredia, J, Bemelman, W, Benavides Buleje, J, Benckert, A, Bernal-Sprekelsen, J, Bertocchi, E, Beuran, M, Bhan, C, Bianco, F, Bilali, S, Bilali, V, Bintintan, V, Birindelli, A, Birsan, T, Blanco Antona, F, Blas, J, Blasco-Segura, T, Blom, R, Bocchetti, T, Boerma, E, Bogdan, M, Boland, M, Bomans, B, Borda, N, Bowen, M, Bradulskis, S, Branagan, G, Brankovic, B, Brenna, M, Brewer, H, Broadhurst, J, Bronder, C, Brouwer, R, Buccianti, P, Buchs, N, Buchwald, P, Bugatti, A, Bui, A, Burcos, T, Buskens, C, Bustamante, C, Caceres, N, Cagigas Fernandez, C, Calero-Lillo, A, Camps, I, Canda, A, Caravaca-Garcia, I, Carballo, F, Carcoforo, P, Carlander, J, Carlos, S, Caro, A, Carpelan, A, Carrasco Prats, M, Carrillo Lopez, M, Carvello, M, Casal, E, Casoni Pattacini, G, Castellvi Valls, J, Castillo Diego, J, Cavallesco, G, Cavenaile, V, Cayetano, L, Ceccotti, A, Cervera-Aldama, J, Chabok, A, Chafai, N, Chandrasinghe, P, Chandratreya, N, Chaudhri, S, Chaudhry, Z, Cherdancev, D, Chernov, A, Chevallay, M, Chirletti, P, Chouillard, E, Chouliaras, C, Chowdri, N, Cillo, M, Cini, C, Ciubotaru, C, Ciuce, C, Claeys, D, Cocorullo, G, Codina-Cazador, A, Colak, E, Coletta, D, Colombo, F, Copaescu, C, Corte Real, J, Corver, M, Cosic, J, Costa, S, Costa Pereira, J, Costa Pereira, C, Costa-Navarro, D, Cotte, E, Cracco, N, Cristian, D, Cuadrado, M, Cuk, V, Cunha, M, Cunha, J, Curinga, R, Curletti, G, Curtis, N, Dabic, D, Dainius, E, D'Alessandro, A, Daniels, I, Darvin, V, Dauser, B, David, G, Davidova, O, Davies, E, de Andres Asenjo, B, De franciscis, S, de Graaf, E, De la Portilla, F, De Luca, E, De Nisco, C, De Toma, G, Defoort, B, Den Boer, F, Di Candido, F, Di Saverio, S, Diaz Pavon, J, Dieguez Fernandez, B, Diez-Alonso, M, Dimitrijevic, I, Dindelegan, G, Djuric, M, Domingos, H, Doornebosch, P, Dos Santos, M, Drami, I, Dudarovaska, H, Dusek, T, Dzhumabaev, H, Eden, Y, Egenvall, M, Eismiontas, V, El Sorogy, M, Elgeidie, A, Elhemaly, M, El-Hussuna, A, Ellul, S, Elmore, U, Elnakeeb, A, Elrefai, M, Emile, S, Enrriquez-Navascues, J, Epstein, J, Escartin, J, Escola, D, Escuder, J, Espin, E, Espina, B, Estefania, D, Etienne, J, Fabbri, S, Falato, A, Fares, R, Farina, P, Farkasova, M, Farres, R, Fasolini, F, Fatayer, T, Febles, G, Feliu, F, Feo, C, Feoktistov, D, Fernandez, F, Fernandez Isart, M, Fernando, J, Ferreira, G, Ferrer, R, Ferreras Garcia, C, Ferri, M, Figueiredo, N, Finotti, E, Fitzgerald, J, Flateh Backe, I, Flor-Lorente, B, Forero-Torres, A, Foschi, D, Francart, D, Francois, Y, Frasson, M, Freil-Lanter, C, Frois Borges, M, Fuzun, M, Gala, T, Galleano, R, Galvez, P, Galvez Saldana, A, Gamundi Cuesta, M, Garcia Cabrera, A, Garcia Egea, J, Garcia Olmo, D, Garcia-Gonzalez, J, Garcia-Granero, A, Garcia-Granero, E, Garcia-Septiem, J, Gardea, A, Garipov, M, Gefen, R, Geraghty, A, Gerkis, S, Germanos, S, Ghaffari, S, Ghilles, E, Gianotti, L, Gil Santos, M, Gilsanz Martin, C, Gingert, C, Gklavas, A, Glehen, O, Golda, T, Gomez, N, Gomez, R, Gomez Ruiz, M, Gonzalez Santin, V, Graham, B, Grainger, J, Grama, F, Gregoir, T, Gregori, M, Grolich, T, Grosek, J, Guadalajara, H, Guckenheimer, S, Guevara, J, Gulotta, G, Gupta, S, Gurevich, N, Gurjar, S, Haapaniemi, S, Hahnloser, D, Hamad, Y, Hamid, M, Hanly, A, Harris, G, Harsanyi, L, Hartig, N, Hawkin, P, Henriques, P, Herbst, F, Hermann, N, Hernandez Garcia, M, Hoch, J, Hrora, A, Huhtinen, H, Iarumov, N, Ilkanich, A, Insua, C, Ioannidis, P, Iqbal, M, Iqbal, A, Isik, A, Ismaiel, M, Ivlev, D, Jadhav, V, Jareno, S, Jehaes, C, Jimenez, V, Jimenez-Toscano, M, Jimenez-Miramon, J, Jimenez-Rodriguez, R, Jonsson, T, Jotautas, V, Julia, D, Juloski, J, Jung, B, Kala, Z, Kalayci, M, Kara, Y, Karachun, A, Karagul, S, Karvonen, J, Katorkin, S, Katsoulis, I, Katsounis, D, Kaubrys, M, Kaul, N, Kefalou, E, Keijzers, M, Kelly, M, Kenic, M, Kennelly, R, Khan, J, Khan, M, Kho, H, Kinas, V, Knight, J, Kocian, P, Koeter, T, Kokobelyan, A, Konsten, J, Koolen, L, Kosir, J, Kostic, I, Krdzic, I, Kreisler Moreno, E, Krivokapic, Z, Krstev, P, Krsul, D, Kumarasinghe, N, La Torre, F, Labarga, F, Ladra, M, Lage Laredo, A, Lahodzich, N, Lai, C, Lakkis, Z, Lal, R, Lamas, S, Lang, T, Latkauskas, T, Lawes, D, Lazar, G, Lebedev, K, Lebedeva, M, Lefevre, J, Lekic Vitlov, V, Lemma, M, Leo, C, Leon, C, Leventoglu, S, Levy, B, Li, L, Licari, L, Lizdenis, P, Loftas, P, Longhi, M, Longstaff, L, Lopez Dominguez, J, Lopez-Lara, M, Lora, P, Lorenzon, L, Lorusso, D, Lozev, I, Lozoya Trujillo, R, Lukic, D, Lunins, R, Luzan, R, Luzzi, A, Maderuelo, V, Madsboll, T, Mahotin, D, Majbar, M, Makhmudov, A, Malik, K, Maly, O, Mamaloudis, I, Mamedli, Z, Manatakis, D, Mandi, D, Mangell, P, Marharint, T, Mariani, N, Maric, B, Marimuthu, K, Marinello, F, Marino, F, Markiewicz, S, Markovic, V, Marom, G, Maroni, N, Maroulis, I, Marsanic, P, Marsman, H, Martens, M, Marti, M, Martinek, L, Martinez, S, Martinez, D, Martinez Manzano, A, Martins, R, Maslyankov, S, Mcardle, K, Mcdermott, F, Mege, D, Mehraj, A, Mehta, A, Mendrila, D, Menendez, P, Mercantini, P, Metwally, I, Mikalauskas, S, Millan, M, Mingoli, A, Mirshekar-Syahkal, B, Moggia, E, Mohan, S, Moller, P, Mompart Garcia, S, Monami, B, Moniz Pereira, P, Montroni, I, Morel, P, Moshev, B, Mostovoy, E, Mothe, S, Mukhtar, H, Muller, P, Munch, S, Munoz Camarena, J, Munoz-Collado, S, Muratore, A, Muscara, F, Muysoms, F, Myrelid, P, N. Lah, N, Nail, S, Narayanan, A, Nastos, K, Negoi, I, Nesbakken, A, Nestler, G, Nestorovic, M, Nesytykh, A, Newton, K, Ng, Y, Ngu, J, Nguyen, B, Nijs, Y, Nikberg, M, Nimmersgern, T, Nogues, E, Norcic, G, Nutautiene, V, Nygren, J, O'Brien, J, Ochogavia Segui, A, O'Kelly, J, Oliveira-Cunha, M, Omar, W, Omar, G, Onishchenko, S, Onody, P, Opocher, E, Orhalmi, J, Oshowo, A, Otero, J, Ozgen, U, Pace, K, Padin, H, Papaconstantinou, I, Papadopoulos, A, Papadopoulos, G, Papandrea, M, Paral, J, Parc, Y, Paredes, J, Parmar, M, Parra Banos, P, Parray, F, Pascual Damieta, M, Pascual Miguelanez, I, Passot, G, Pastor, C, Paszt, A, Patel, P, Paterson, H, Patron Uriburu, J, Paulos, A, Pavlov, V, Pcolkins, A, Pecic, V, Pena Ros, E, Penkov, R, Pera Roman, M, Perunicic, V, Pery, R, Petrovic, D, Pezzolla, F, Photi, E, Pikarsky, A, Piramanayagam, B, Pisani Ceretti, A, Planellas, P, Platt, E, Pletinckx, P, Podda, M, Poskus, T, Poskus, E, Pozdnyakov, A, Pravosudov, I, Previsic, A, Prieto, D, Prochazka, V, Prodan, A, Proud, D, Psaila, J, Psaras, G, Pulighe, F, Pullig, F, Qureshi, M, Rachadell, J, Radovanovic, Z, Radovanovic, D, Raguan, B, Rahman, M, Raiss, M, Ramirez Faraco, M, Ramos, J, Ramos-Prada, J, Rantala, A, Rao, M, Rasulov, A, Ratnatunga, K, Raymond, T, Refky, B, Reggiani, L, Regusci, L, Reyes Diaz, M, Richardson, J, Richiteanu, G, Rios, A, Ris, F, Rodriguez Garcia, P, Roffi, N, Romairone, E, Romano, G, Romero, I, Romero de Diego, A, Romero-Simo, M, Roque, C, Rosati, R, Rossi, B, Rossi, E, Rossini, R, Ruano, A, Rubbini, M, Rubio-Perez, I, Ruffo, G, Ruiz, H, Ruiz Carmona, M, Ryska, O, Sabia, D, Sacchi, M, Sacco, R, Sakr, A, Saladzinskas, Z, Salamone, G, Salomon, M, Salvans Ruiz, S, Sammarco, G, Sampietro, G, Samsonov, D, Samsonyuk, V, Sanchez, J, Sanchez Romero, A, Sanchez-Guillen, L, Santak, G, Santamaria-Olabarrieta, M, Santos, J, Saraceno, F, Saralegui, Y, Sarici, I, Savino, G, Scabini, S, Schafli, J, Schiltz, B, Schofield, A, Schon, M, Scurtu, R, Segalini, E, Segelman, J, Segura-Sampedro, J, Seicean, R, Sekulic, A, Selniahina, L, Seretis, F, Serrano Paz, P, Shaikh, I, Shalaby, M, Shams, N, Sharma, A, Sharma, G, Shukla, A, Shussman, N, Shweejawee, Z, Sielezneff, I, Sigurdsson, H, Sileri, P, Silva, M, Simcikas, D, Simoes, J, Simonka, Z, Singh, B, Sivins, A, Skroubis, G, Skull, A, Slavchev, M, Slavin, M, Smart, N, Smart, C, Smart, P, Smedh, K, Smolarek, S, Sokmen, S, Sokolov, M, Solana Bueno, A, Solar, L, Sorrentino, L, Sotona, O, Spacca, D, Spinelli, A, Stanojevic, G, Stearns, A, Stefan, S, Stift, A, Stijns, J, Stoyanov, V, Straarup, D, Strupas, K, Stubbs, B, Subocius, A, Sudlow, A, Suero, C, Sungurtekin, U, Svagzdys, S, Syk, I, Tamelis, A, Tamhane, R, Tamini, N, Tamosiunas, A, Tanis, P, Tarasov, N, Tate, S, Tennakoon, A, Teo, N, Terzi, C, Tezas, S, Thabet, W, Tham, J, Thavanesan, N, Theodosopoulos, T, Thomas, W, Tiret, E, Tiselius, C, Todorov, G, Tomazic, A, Tomulescu, V, Torkington, J, Totis, M, Trostchansky, I, Truan, N, Tulchinsky, H, Tutino, R, Tzivanakis, A, Tzovaras, G, Ugolini, G, Unger, L, Upanishad, I, Urbani, L, Uth Ovesen, A, Vaizey, C, Vallribera, F, Valsdottir, E, Valverde, I, Valverde-Sintas, J, Van Belle, K, Van Cleven, S, van Hagen, P, van Loon, Y, van Ruler, O, Van Wijck, K, Varabei, A, Varcada, M, Varpe, P, Vartic, M, Velchuru, V, Vencius, J, Venskutonis, D, Vercher, D, Vermaas, M, Vertruyen, M, Verza, L, Vescio, G, Vezakis, A, Vieira, P, Vignali, A, Vigorita, V, Vila Tura, M, Vinson-Bonnet, B, Viso Pons, L, Voloshin, S, Voronin, Y, Vukusic, L, Wang, X, Wang, J, Wani, R, Warusavitarne, J, Wasserberg, N, Weerts, J, Weiss, D, Weizman, A, Westerduin, E, Wheat, J, White, I, Wik, T, Wilson, J, Winter, D, Wolthuis, A, Wong, M, Yahia, S, Yamamoto, T, Yanishev, A, Yao, C, Yildiz, A, Yuksel, O, Zain, Z, Zakaria, A, Zakaria, Z, Zampitis, N, Zarand, A, Zarco-Pleguezuelos, A, Zattoni, D, Zelic, M, Zeromskas, P, Zhuravlev, A, Zimmerman, D, Zuhdy, M, Zukanovic, G, Pinkney T.D., Taylor H., Tong C., Schmitz N.-D., Morton D.G., Bhangu A., Blackwell S., Dardanov D., Dulskas A., Gallo G., Glasbey J., Keatley J., Knowles C., Li Y.E., McCourt V., Minaya-Bravo A., Neary P., Nepogodiev D., Pata F., Pellino G., Sivrikoz E., van Ramshorst G., Zmora O., Perry R., Magill E.L., Abdalkoddus M., Abelevich A., Abraham S., Abraham-Nordling M., Adamina M., Agalar C., Agresta F., Ahallat M., Ahmad N., Aiupov R., Akca O., Aleksic A., Aleotti F., Alias D., Alonso J., Alonso Goncalves S., Alonso Martin J., Alonso Poza A., Alonso-Hernandez N., Alos Company R., Al-Saeedi M., Alvarez-Laso C., Alvarez-Gallego M., Amanatidis T., Americano M., Amorim E., Anandan L., Anania G., Ancans G., Andreev P., Andrejevic P., Antonacci N., Anwer M., Aonzo P., Arencibia B., Argeny S., Arieli H., Arnold S., Ashraf M., Aslam M., Atanasov B., Atif M., Atladottir J., Avital S., Awny S., Aytac B., Azahr N., Aznar-Puig S., Bailey S., Balalis D., Baldi C., Baldonedo R., Balducci G., Balestra F., Balestri R., Balfour A., Baloyiannis I., Banky B., Baral J., Baranyai Z., Barbashinov N., Bargallo J., Barisic G., Barugola G., Batashki I., Battersby N., Belev N., Belli A., Beltran de Heredia J., Bemelman W., Benavides Buleje J., Benckert A., Bernal-Sprekelsen J., Bertocchi E., Beuran M., Bhan C., Bianco F., Bilali S., Bilali V., Bintintan V., Birindelli A., Birsan T., Blanco Antona F., Blas J., Blasco-Segura T., Blom R., Bocchetti T., Boerma E., Bogdan M., Boland M., Bomans B., Borda N., Bowen M., Bradulskis S., Branagan G., Brankovic B., Brenna M., Brewer H., Broadhurst J., Bronder C., Brouwer R., Buccianti P., Buchs N., Buchwald P., Bugatti A., Bui A., Burcos T., Buskens C., Bustamante C., Caceres N., Cagigas Fernandez C., Calero-Lillo A., Camps I., Canda A., Caravaca-Garcia I., Carballo F., Carcoforo P., Carlander J., Carlos S., Caro A., Carpelan A., Carrasco Prats M., Carrillo Lopez M., Carvello M., Casal E., Casoni Pattacini G., Castellvi Valls J., Castillo Diego J., Cavallesco G., Cavenaile V., Cayetano L., Ceccotti A., Cervera-Aldama J., Chabok A., Chafai N., Chandrasinghe P., Chandratreya N., Chaudhri S., Chaudhry Z., Cherdancev D., Chernov A., Chevallay M., Chirletti P., Chouillard E., Chouliaras C., Chowdri N., Cillo M., Cini C., Ciubotaru C., Ciuce C., Claeys D., Cocorullo G., Codina-Cazador A., Colak E., Coletta D., Colombo F., Copaescu C., Corte Real J., Corver M., Cosic J., Costa S., Costa Pereira J., Costa Pereira C., Costa-Navarro D., Cotte E., Cracco N., Cristian D., Cuadrado M., Cuk V., Cunha M., Cunha J., Curinga R., Curletti G., Curtis N., Dabic D., Dainius E., d'Alessandro A., Daniels I., Darvin V., Dauser B., David G., Davidova O., Davies E., de Andres Asenjo B., De franciscis S., de Graaf E., De la Portilla F., De Luca E., De Nisco C., De Toma G., Defoort B., Den Boer F., Di Candido F., Di Saverio S., Diaz Pavon J., Dieguez Fernandez B., Diez-Alonso M., Dimitrijevic I., Dindelegan G., Djuric M., Domingos H., Doornebosch P., Dos Santos M., Drami I., Dudarovaska H., Dusek T., Dzhumabaev H., Eden Y., Egenvall M., Eismiontas V., El Sorogy M., Elgeidie A., Elhemaly M., El-Hussuna A., Ellul S., Elmore U., ElNakeeb A., Elrefai M., Emile S., Enrriquez-Navascues J., Epstein J., Escartin J., Escola D., Escuder J., Espin E., Espina B., Estefania D., Etienne J., Fabbri S., Falato A., Fares R., Farina P., Farkasova M., Farres R., Fasolini F., Fatayer T., Febles G., Feliu F., Feo C., Feoktistov D., Fernandez F., Fernandez Isart M., Fernando J., Ferreira G., Ferrer R., Ferreras Garcia C., Ferri M., Figueiredo N., Finotti E., Fitzgerald J., Flateh Backe I., Flor-Lorente B., Forero-Torres A., Foschi D., Francart D., Francois Y., Frasson M., Freil-Lanter C., Frois Borges M., Fuzun M., Gala T., Galleano R., Galvez P., Galvez Saldana A., Gamundi Cuesta M., Garcia Cabrera A., Garcia Egea J., Garcia Olmo D., Garcia-Gonzalez J., Garcia-Granero A., Garcia-Granero E., Garcia-Septiem J., Gardea A., Garipov M., Gefen R., Geraghty A., Gerkis S., Germanos S., Ghaffari S., Ghilles E., Gianotti L., Gil Santos M., Gilsanz Martin C., Gingert C., Gklavas A., Glehen O., Golda T., Gomez N., Gomez R., Gomez Ruiz M., Gonzalez Santin V., Graham B., Grainger J., Grama F., Gregoir T., Gregori M., Grolich T., Grosek J., Guadalajara H., Guckenheimer S., Guevara J., Gulotta G., Gupta S., Gurevich N., Gurjar S., Haapaniemi S., Hahnloser D., Hamad Y., Hamid M., Hanly A., Harris G., Harsanyi L., Hartig N., Hawkin P., Henriques P., Herbst F., Hermann N., Hernandez Garcia M., Hoch J., Hrora A., Huhtinen H., Iarumov N., Ilkanich A., Insua C., Ioannidis P., Iqbal M., Iqbal A., Isik A., Ismaiel M., Ivlev D., Jadhav V., Jareno S., Jehaes C., Jimenez V., Jimenez-Toscano M., Jimenez-Miramon J., Jimenez-Rodriguez R., Jonsson T., Jotautas V., Julia D., Juloski J., Jung B., Kala Z., Kalayci M., Kara Y., Karachun A., Karagul S., Karvonen J., Katorkin S., Katsoulis I., Katsounis D., Kaubrys M., Kaul N., Kefalou E., Keijzers M., Kelly M., Kenic M., Kennelly R., Khan J., Khan M., Kho H., Kinas V., Knight J., Kocian P., Koeter T., Kokobelyan A., Konsten J., Koolen L., Kosir J., Kostic I., Krdzic I., Kreisler Moreno E., Krivokapic Z., Krstev P., Krsul D., Kumarasinghe N., La Torre F., Labarga F., Ladra M., Lage Laredo A., Lahodzich N., Lai C., Lakkis Z., Lal R., Lamas S., Lang T., Latkauskas T., Lawes D., Lazar G., Lebedev K., Lebedeva M., Lefevre J., Lekic Vitlov V., Lemma M., Leo C., Leon C., Leventoglu S., Levy B., Li L., Licari L., Lizdenis P., Loftas P., Longhi M., Longstaff L., Lopez Dominguez J., Lopez-Lara M., Lora P., Lorenzon L., Lorusso D., Lozev I., Lozoya Trujillo R., Lukic D., Lunins R., Luzan R., Luzzi A., Maderuelo V., Madsboll T., Mahotin D., Majbar M., Makhmudov A., Malik K., Maly O., Mamaloudis I., Mamedli Z., Manatakis D., Mandi D., Mangell P., Marharint T., Mariani N., Maric B., Marimuthu K., Marinello F., Marino F., Markiewicz S., Markovic V., Marom G., Maroni N., Maroulis I., Marsanic P., Marsman H., Martens M., Marti M., Martinek L., Martinez S., Martinez D., Martinez Manzano A., Martins R., Maslyankov S., McArdle K., McDermott F., Mege D., Mehraj A., Mehta A., Mendrila D., Menendez P., Mercantini P., Metwally I., Mikalauskas S., Millan M., Mingoli A., Mirshekar-Syahkal B., Moggia E., Mohan S., Moller P., Mompart Garcia S., Monami B., Moniz Pereira P., Montroni I., Morel P., Moshev B., Mostovoy E., Mothe S., Mukhtar H., Muller P., Munch S., Munoz Camarena J., Munoz-Collado S., Muratore A., Muscara F., Muysoms F., Myrelid P., N.Lah N., Nail S., Narayanan A., Nastos K., Negoi I., Nesbakken A., Nestler G., Nestorovic M., Nesytykh A., Newton K., Ng Y., Ngu J., Nguyen B., Nijs Y., Nikberg M., Nimmersgern T., Nogues E., Norcic G., Nutautiene V., Nygren J., O'Brien J., Ochogavia Segui A., O'Kelly J., Oliveira-Cunha M., Omar W., Omar G., Onishchenko S., Onody P., Opocher E., Orhalmi J., Oshowo A., Otero J., Ozgen U., Pace K., Padin H., Papaconstantinou I., Papadopoulos A., Papadopoulos G., Papandrea M., Paral J., Parc Y., Paredes J., Parmar M., Parra Banos P., Parray F., Pascual Damieta M., Pascual Miguelanez I., Passot G., Pastor C., Paszt A., Patel P., Paterson H., Patron Uriburu J., Paulos A., Pavlov V., Pcolkins A., Pecic V., Pena Ros E., Penkov R., Pera Roman M., Perunicic V., Pery R., Petrovic D., Pezzolla F., Photi E., Pikarsky A., Piramanayagam B., Pisani Ceretti A., Planellas P., Platt E., Pletinckx P., Podda M., Poskus T., Poskus E., Pozdnyakov A., Pravosudov I., Previsic A., Prieto D., Prochazka V., Prodan A., Proud D., Psaila J., Psaras G., Pulighe F., Pullig F., Qureshi M., Rachadell J., Radovanovic Z., Radovanovic D., Raguan B., Rahman M., Raiss M., Ramirez Faraco M., Ramos J., Ramos-Prada J., Rantala A., Rao M., Rasulov A., Ratnatunga K., Raymond T., Refky B., Reggiani L., Regusci L., Reyes Diaz M., Richardson J., Richiteanu G., Rios A., Ris F., Rodriguez Garcia P., Roffi N., Romairone E., Romano G., Romero I., Romero de Diego A., Romero-Simo M., Roque C., Rosati R., Rossi B., Rossi E., Rossini R., Ruano A., Rubbini M., Rubio-Perez I., Ruffo G., Ruiz H., Ruiz Carmona M., Ryska O., Sabia D., Sacchi M., Sacco R., Sakr A., Saladzinskas Z., Salamone G., Salomon M., Salvans Ruiz S., Sammarco G., Sampietro G., Samsonov D., Samsonyuk V., Sanchez J., Sanchez Romero A., Sanchez-Guillen L., Santak G., Santamaria-Olabarrieta M., Santos J., Saraceno F., Saralegui Y., Sarici I., Savino G., Scabini S., Schafli J., Schiltz B., Schofield A., Schon M., Scurtu R., Segalini E., Segelman J., Segura-Sampedro J., Seicean R., Sekulic A., Selniahina L., Seretis F., Serrano Paz P., Shaikh I., Shalaby M., Shams N., Sharma A., Sharma G., Shukla A., Shussman N., Shweejawee Z., Sielezneff I., Sigurdsson H., Sileri P., Silva M., Simcikas D., Simoes J., Simonka Z., Singh B., Sivins A., Skroubis G., Skull A., Slavchev M., Slavin M., Smart N., Smart C., Smart P., Smedh K., Smolarek S., Sokmen S., Sokolov M., Solana Bueno A., Solar L., Sorrentino L., Sotona O., Spacca D., Spinelli A., Stanojevic G., Stearns A., Stefan S., Stift A., Stijns J., Stoyanov V., Straarup D., Strupas K., Stubbs B., Subocius A., Sudlow A., Suero C., Sungurtekin U., Svagzdys S., Syk I., Tamelis A., Tamhane R., Tamini N., Tamosiunas A., Tanis P., Tarasov N., Tate S., Tennakoon A., Teo N., Terzi C., Tezas S., Thabet W., Tham J., Thavanesan N., Theodosopoulos T., Thomas W., Tiret E., Tiselius C., Todorov G., Tomazic A., Tomulescu V., Torkington J., Totis M., Trostchansky I., Truan N., Tulchinsky H., Tutino R., Tzivanakis A., Tzovaras G., Ugolini G., Unger L., Upanishad I., Urbani L., Uth Ovesen A., Vaizey C., Vallribera F., Valsdottir E., Valverde I., Valverde-Sintas J., Van Belle K., Van Cleven S., van Hagen P., van Loon Y., van Ruler O., Van Wijck K., Varabei A., Varcada M., Varpe P., Vartic M., Velchuru V., Vencius J., Venskutonis D., Vercher D., Vermaas M., Vertruyen M., Verza L., Vescio G., Vezakis A., Vieira P., Vignali A., Vigorita V., Vila Tura M., Vinson-Bonnet B., Viso Pons L., Voloshin S., Voronin Y., Vukusic L., Wang X., Wang J., Wani R., Warusavitarne J., Wasserberg N., Weerts J., Weiss D., Weizman A., Westerduin E., Wheat J., White I., Wik T., Wilson J., Winter D., Wolthuis A., Wong M., Yahia S., Yamamoto T., Yanishev A., Yao C., Yildiz A., Yuksel O., Zain Z., Zakaria A., Zakaria Z., Zampitis N., Zarand A., Zarco-Pleguezuelos A., Zattoni D., Zelic M., Zeromskas P., Zhuravlev A., Zimmerman D., Zuhdy M., Zukanovic G., Pinkney, T. D., Taylor, H., Tong, C., Schmitz, N. -D., Morton, D. G., Bhangu, A., Blackwell, S., Dardanov, D., Dulskas, A., Gallo, G., Glasbey, J., Keatley, J., Knowles, C., Li, Y. E., Mccourt, V., Minaya-Bravo, A., Neary, P., Nepogodiev, D., Pata, F., Pellino, G., Sivrikoz, E., van Ramshorst, G., Zmora, O., Perry, R., Magill, E. L., Abdalkoddus, M., Abelevich, A., Abraham, S., Abraham-Nordling, M., Adamina, M., Agalar, C., Agresta, F., Ahallat, M., Ahmad, N., Aiupov, R., Akca, O., Aleksic, A., Aleotti, F., Alias, D., Alonso, J., Alonso Goncalves, S., Alonso Martin, J., Alonso Poza, A., Alonso-Hernandez, N., Alos Company, R., Al-Saeedi, M., Alvarez-Laso, C., Alvarez-Gallego, M., Amanatidis, T., Americano, M., Amorim, E., Anandan, L., Anania, G., Ancans, G., Andreev, P., Andrejevic, P., Antonacci, N., Anwer, M., Aonzo, P., Arencibia, B., Argeny, S., Arieli, H., Arnold, S., Ashraf, M., Aslam, M., Atanasov, B., Atif, M., Atladottir, J., Avital, S., Awny, S., Aytac, B., Azahr, N., Aznar-Puig, S., Bailey, S., Balalis, D., Baldi, C., Baldonedo, R., Balducci, G., Balestra, F., Balestri, R., Balfour, A., Baloyiannis, I., Banky, B., Baral, J., Baranyai, Z., Barbashinov, N., Bargallo, J., Barisic, G., Barugola, G., Batashki, I., Battersby, N., Belev, N., Belli, A., Beltran de Heredia, J., Bemelman, W., Benavides Buleje, J., Benckert, A., Bernal-Sprekelsen, J., Bertocchi, E., Beuran, M., Bhan, C., Bianco, F., Bilali, S., Bilali, V., Bintintan, V., Birindelli, A., Birsan, T., Blanco Antona, F., Blas, J., Blasco-Segura, T., Blom, R., Bocchetti, T., Boerma, E., Bogdan, M., Boland, M., Bomans, B., Borda, N., Bowen, M., Bradulskis, S., Branagan, G., Brankovic, B., Brenna, M., Brewer, H., Broadhurst, J., Bronder, C., Brouwer, R., Buccianti, P., Buchs, N., Buchwald, P., Bugatti, A., Bui, A., Burcos, T., Buskens, C., Bustamante, C., Caceres, N., Cagigas Fernandez, C., Calero-Lillo, A., Camps, I., Canda, A., Caravaca-Garcia, I., Carballo, F., Carcoforo, P., Carlander, J., Carlos, S., Caro, A., Carpelan, A., Carrasco Prats, M., Carrillo Lopez, M., Carvello, M., Casal, E., Casoni Pattacini, G., Castellvi Valls, J., Castillo Diego, J., Cavallesco, G., Cavenaile, V., Cayetano, L., Ceccotti, A., Cervera-Aldama, J., Chabok, A., Chafai, N., Chandrasinghe, P., Chandratreya, N., Chaudhri, S., Chaudhry, Z., Cherdancev, D., Chernov, A., Chevallay, M., Chirletti, P., Chouillard, E., Chouliaras, C., Chowdri, N., Cillo, M., Cini, C., Ciubotaru, C., Ciuce, C., Claeys, D., Cocorullo, G., Codina-Cazador, A., Colak, E., Coletta, D., Colombo, F., Copaescu, C., Corte Real, J., Corver, M., Cosic, J., Costa, S., Costa Pereira, J., Costa Pereira, C., Costa-Navarro, D., Cotte, E., Cracco, N., Cristian, D., Cuadrado, M., Cuk, V., Cunha, M., Cunha, J., Curinga, R., Curletti, G., Curtis, N., Dabic, D., Dainius, E., D'Alessandro, A., Daniels, I., Darvin, V., Dauser, B., David, G., Davidova, O., Davies, E., de Andres Asenjo, B., De franciscis, S., de Graaf, E., De la Portilla, F., De Luca, E., De Nisco, C., De Toma, G., Defoort, B., Den Boer, F., Di Candido, F., Di Saverio, S., Diaz Pavon, J., Dieguez Fernandez, B., Diez-Alonso, M., Dimitrijevic, I., Dindelegan, G., Djuric, M., Domingos, H., Doornebosch, P., Dos Santos, M., Drami, I., Dudarovaska, H., Dusek, T., Dzhumabaev, H., Eden, Y., Egenvall, M., Eismiontas, V., El Sorogy, M., Elgeidie, A., Elhemaly, M., El-Hussuna, A., Ellul, S., Elmore, U., Elnakeeb, A., Elrefai, M., Emile, S., Enrriquez-Navascues, J., Epstein, J., Escartin, J., Escola, D., Escuder, J., Espin, E., Espina, B., Estefania, D., Etienne, J., Fabbri, S., Falato, A., Fares, R., Farina, P., Farkasova, M., Farres, R., Fasolini, F., Fatayer, T., Febles, G., Feliu, F., Feo, C., Feoktistov, D., Fernandez, F., Fernandez Isart, M., Fernando, J., Ferreira, G., Ferrer, R., Ferreras Garcia, C., Ferri, M., Figueiredo, N., Finotti, E., Fitzgerald, J., Flateh Backe, I., Flor-Lorente, B., Forero-Torres, A., Foschi, D., Francart, D., Francois, Y., Frasson, M., Freil-Lanter, C., Frois Borges, M., Fuzun, M., Gala, T., Galleano, R., Galvez, P., Galvez Saldana, A., Gamundi Cuesta, M., Garcia Cabrera, A., Garcia Egea, J., Garcia Olmo, D., Garcia-Gonzalez, J., Garcia-Granero, A., Garcia-Granero, E., Garcia-Septiem, J., Gardea, A., Garipov, M., Gefen, R., Geraghty, A., Gerkis, S., Germanos, S., Ghaffari, S., Ghilles, E., Gianotti, L., Gil Santos, M., Gilsanz Martin, C., Gingert, C., Gklavas, A., Glehen, O., Golda, T., Gomez, N., Gomez, R., Gomez Ruiz, M., Gonzalez Santin, V., Graham, B., Grainger, J., Grama, F., Gregoir, T., Gregori, M., Grolich, T., Grosek, J., Guadalajara, H., Guckenheimer, S., Guevara, J., Gulotta, G., Gupta, S., Gurevich, N., Gurjar, S., Haapaniemi, S., Hahnloser, D., Hamad, Y., Hamid, M., Hanly, A., Harris, G., Harsanyi, L., Hartig, N., Hawkin, P., Henriques, P., Herbst, F., Hermann, N., Hernandez Garcia, M., Hoch, J., Hrora, A., Huhtinen, H., Iarumov, N., Ilkanich, A., Insua, C., Ioannidis, P., Iqbal, M., Iqbal, A., Isik, A., Ismaiel, M., Ivlev, D., Jadhav, V., Jareno, S., Jehaes, C., Jimenez, V., Jimenez-Toscano, M., Jimenez-Miramon, J., Jimenez-Rodriguez, R., Jonsson, T., Jotautas, V., Julia, D., Juloski, J., Jung, B., Kala, Z., Kalayci, M., Kara, Y., Karachun, A., Karagul, S., Karvonen, J., Katorkin, S., Katsoulis, I., Katsounis, D., Kaubrys, M., Kaul, N., Kefalou, E., Keijzers, M., Kelly, M., Kenic, M., Kennelly, R., Khan, J., Khan, M., Kho, H., Kinas, V., Knight, J., Kocian, P., Koeter, T., Kokobelyan, A., Konsten, J., Koolen, L., Kosir, J., Kostic, I., Krdzic, I., Kreisler Moreno, E., Krivokapic, Z., Krstev, P., Krsul, D., Kumarasinghe, N., La Torre, F., Labarga, F., Ladra, M., Lage Laredo, A., Lahodzich, N., Lai, C., Lakkis, Z., Lal, R., Lamas, S., Lang, T., Latkauskas, T., Lawes, D., Lazar, G., Lebedev, K., Lebedeva, M., Lefevre, J., Lekic Vitlov, V., Lemma, M., Leo, C., Leon, C., Leventoglu, S., Levy, B., Li, L., Licari, L., Lizdenis, P., Loftas, P., Longhi, M., Longstaff, L., Lopez Dominguez, J., Lopez-Lara, M., Lora, P., Lorenzon, L., Lorusso, D., Lozev, I., Lozoya Trujillo, R., Lukic, D., Lunins, R., Luzan, R., Luzzi, A., Maderuelo, V., Madsboll, T., Mahotin, D., Majbar, M., Makhmudov, A., Malik, K., Maly, O., Mamaloudis, I., Mamedli, Z., Manatakis, D., Mandi, D., Mangell, P., Marharint, T., Mariani, N., Maric, B., Marimuthu, K., Marinello, F., Marino, F., Markiewicz, S., Markovic, V., Marom, G., Maroni, N., Maroulis, I., Marsanic, P., Marsman, H., Martens, M., Marti, M., Martinek, L., Martinez, S., Martinez, D., Martinez Manzano, A., Martins, R., Maslyankov, S., Mcardle, K., Mcdermott, F., Mege, D., Mehraj, A., Mehta, A., Mendrila, D., Menendez, P., Mercantini, P., Metwally, I., Mikalauskas, S., Millan, M., Mingoli, A., Mirshekar-Syahkal, B., Moggia, E., Mohan, S., Moller, P., Mompart Garcia, S., Monami, B., Moniz Pereira, P., Montroni, I., Morel, P., Moshev, B., Mostovoy, E., Mothe, S., Mukhtar, H., Muller, P., Munch, S., Munoz Camarena, J., Munoz-Collado, S., Muratore, A., Muscara, F., Muysoms, F., Myrelid, P., N. Lah, N., Nail, S., Narayanan, A., Nastos, K., Negoi, I., Nesbakken, A., Nestler, G., Nestorovic, M., Nesytykh, A., Newton, K., Ng, Y., Ngu, J., Nguyen, B., Nijs, Y., Nikberg, M., Nimmersgern, T., Nogues, E., Norcic, G., Nutautiene, V., Nygren, J., O'Brien, J., Ochogavia Segui, A., O'Kelly, J., Oliveira-Cunha, M., Omar, W., Omar, G., Onishchenko, S., Onody, P., Opocher, E., Orhalmi, J., Oshowo, A., Otero, J., Ozgen, U., Pace, K., Padin, H., Papaconstantinou, I., Papadopoulos, A., Papadopoulos, G., Papandrea, M., Paral, J., Parc, Y., Paredes, J., Parmar, M., Parra Banos, P., Parray, F., Pascual Damieta, M., Pascual Miguelanez, I., Passot, G., Pastor, C., Paszt, A., Patel, P., Paterson, H., Patron Uriburu, J., Paulos, A., Pavlov, V., Pcolkins, A., Pecic, V., Pena Ros, E., Penkov, R., Pera Roman, M., Perunicic, V., Pery, R., Petrovic, D., Pezzolla, F., Photi, E., Pikarsky, A., Piramanayagam, B., Pisani Ceretti, A., Planellas, P., Platt, E., Pletinckx, P., Podda, M., Poskus, T., Poskus, E., Pozdnyakov, A., Pravosudov, I., Previsic, A., Prieto, D., Prochazka, V., Prodan, A., Proud, D., Psaila, J., Psaras, G., Pulighe, F., Pullig, F., Qureshi, M., Rachadell, J., Radovanovic, Z., Radovanovic, D., Raguan, B., Rahman, M., Raiss, M., Ramirez Faraco, M., Ramos, J., Ramos-Prada, J., Rantala, A., Rao, M., Rasulov, A., Ratnatunga, K., Raymond, T., Refky, B., Reggiani, L., Regusci, L., Reyes Diaz, M., Richardson, J., Richiteanu, G., Rios, A., Ris, F., Rodriguez Garcia, P., Roffi, N., Romairone, E., Romano, G., Romero, I., Romero de Diego, A., Romero-Simo, M., Roque, C., Rosati, R., Rossi, B., Rossi, E., Rossini, R., Ruano, A., Rubbini, M., Rubio-Perez, I., Ruffo, G., Ruiz, H., Ruiz Carmona, M., Ryska, O., Sabia, D., Sacchi, M., Sacco, R., Sakr, A., Saladzinskas, Z., Salamone, G., Salomon, M., Salvans Ruiz, S., Sammarco, G., Sampietro, G., Samsonov, D., Samsonyuk, V., Sanchez, J., Sanchez Romero, A., Sanchez-Guillen, L., Santak, G., Santamaria-Olabarrieta, M., Santos, J., Saraceno, F., Saralegui, Y., Sarici, I., Savino, G., Scabini, S., Schafli, J., Schiltz, B., Schofield, A., Schon, M., Scurtu, R., Segalini, E., Segelman, J., Segura-Sampedro, J., Seicean, R., Sekulic, A., Selniahina, L., Seretis, F., Serrano Paz, P., Shaikh, I., Shalaby, M., Shams, N., Sharma, A., Sharma, G., Shukla, A., Shussman, N., Shweejawee, Z., Sielezneff, I., Sigurdsson, H., Sileri, P., Silva, M., Simcikas, D., Simoes, J., Simonka, Z., Singh, B., Sivins, A., Skroubis, G., Skull, A., Slavchev, M., Slavin, M., Smart, N., Smart, C., Smart, P., Smedh, K., Smolarek, S., Sokmen, S., Sokolov, M., Solana Bueno, A., Solar, L., Sorrentino, L., Sotona, O., Spacca, D., Spinelli, A., Stanojevic, G., Stearns, A., Stefan, S., Stift, A., Stijns, J., Stoyanov, V., Straarup, D., Strupas, K., Stubbs, B., Subocius, A., Sudlow, A., Suero, C., Sungurtekin, U., Svagzdys, S., Syk, I., Tamelis, A., Tamhane, R., Tamini, N., Tamosiunas, A., Tanis, P., Tarasov, N., Tate, S., Tennakoon, A., Teo, N., Terzi, C., Tezas, S., Thabet, W., Tham, J., Thavanesan, N., Theodosopoulos, T., Thomas, W., Tiret, E., Tiselius, C., Todorov, G., Tomazic, A., Tomulescu, V., Torkington, J., Totis, M., Trostchansky, I., Truan, N., Tulchinsky, H., Tutino, R., Tzivanakis, A., Tzovaras, G., Ugolini, G., Unger, L., Upanishad, I., Urbani, L., Uth Ovesen, A., Vaizey, C., Vallribera, F., Valsdottir, E., Valverde, I., Valverde-Sintas, J., Van Belle, K., Van Cleven, S., van Hagen, P., van Loon, Y., van Ruler, O., Van Wijck, K., Varabei, A., Varcada, M., Varpe, P., Vartic, M., Velchuru, V., Vencius, J., Venskutonis, D., Vercher, D., Vermaas, M., Vertruyen, M., Verza, L., Vescio, G., Vezakis, A., Vieira, P., Vignali, A., Vigorita, V., Vila Tura, M., Vinson-Bonnet, B., Viso Pons, L., Voloshin, S., Voronin, Y., Vukusic, L., Wang, X., Wang, J., Wani, R., Warusavitarne, J., Wasserberg, N., Weerts, J., Weiss, D., Weizman, A., Westerduin, E., Wheat, J., White, I., Wik, T., Wilson, J., Winter, D., Wolthuis, A., Wong, M., Yahia, S., Yamamoto, T., Yanishev, A., Yao, C., Yildiz, A., Yuksel, O., Zain, Z., Zakaria, A., Zakaria, Z., Zampitis, N., Zarand, A., Zarco-Pleguezuelos, A., Zattoni, D., Zelic, M., Zeromskas, P., Zhuravlev, A., Zimmerman, D., Zuhdy, M., and Zukanovic, G.
- Subjects
medicine.medical_specialty ,Prehabilitation ,medicine.medical_treatment ,MEDLINE ,Colorectal Neoplasm ,Perioperative Care ,NO ,medicine ,Humans ,03.02. Klinikai orvostan ,Perioperative Optimisation ,Enhanced recovery after surgery ,Digestive System Surgical Procedures ,LS7_4 ,Enhanced Recovery After Surgery (ERAS) ,business.industry ,Gastroenterology ,Digestive System Surgical Procedure ,Guideline ,Colorectal surgery ,Surgery ,Family medicine ,Perioperative care ,Nasogastric intubation ,Preoperative fasting ,Colorectal Neoplasms ,Enhanced Recovery After Surgery ,business ,Colorectal Surgery ,Human - Abstract
Aim The Enhanced Recovery After Surgery (ERAS® ) Society guidelines aim to standardise perioperative care in colorectal surgery via 25 principles. We aimed to assess the variation in uptake of these principles across an international network of colorectal units. Method An online survey was circulated amongst European Society of Coloproctology members in 2019/20. For each ERAS® principle, respondents were asked to score how frequently the principle was implemented in their hospital, from 1 ('rarely') to 4 ('always'). Respondents were also asked to recall whether practice had changed since 2017. Subgroup analyses based on hospital characteristics were conducted. Results Of hospitals approached, 58% responded to the survey (195/335), with 296 individual responses (multiple responses were received from some hospitals). The majority were European (163/195 [83.6%]). Overall, respondents indicated they 'most often' or 'always' adhered to most individual ERAS® principles (18/25 [72%]). Variability in uptake of principles was reported, with universal uptake of some principles (e.g., prophylactic antibiotics; early mobilisation) and inconsistency from 'rarely' to 'always' in others (e.g., no nasogastric intubation; no preoperative fasting and carbohydrate drinks). In alignment with 2018 ERAS® guideline updates, adherence to principles for prehabilitation, managing anaemia, and postoperative nutrition appears to have increased since 2017. Conclusions Uptake of ERAS® principles varied across hospitals, and not all 25 principles were equally adhered to. Whilst some principles exhibited a high level of acceptance, others had a wide variability in uptake indicative of controversy or barriers to uptake. Further research into specific principles is required to improve ERAS® implementation.
- Published
- 2021
11. The Effect of Resistance Training in Healthy Adults on Body Fat Percentage, Fat Mass and Visceral Fat: A Systematic Review and Meta-Analysis
- Author
-
Amanda D. Hagstrom, Briana Clifford, Brandon Coorie, Cameron Honey, Hayley B. Leake, Imtiaz Desai, Matthew D. Jones, Michael A. Wewege, Wewege, Michael A, Desai, Imtiaz, Honey, Cameron, Coorie, Brandon, Jones, Matthew D, Clifford, Briana K, Leake, Hayley B, and Hagstrom, Amanda D
- Subjects
body composition ,medicine.medical_specialty ,exercise ,Sports medicine ,business.industry ,adult ,Resistance training ,Physical Therapy, Sports Therapy and Rehabilitation ,Subgroup analysis ,Body fat percentage ,Confidence interval ,Fat mass ,female ,male ,intra-abdominal fat ,Internal medicine ,Meta-analysis ,physiology ,medicine ,Orthopedics and Sports Medicine ,human ,resistance training ,business ,Visceral fat ,meta analysis - Abstract
Refereed/Peer-reviewed Background: Resistance training is the gold standard exercise mode for accrual of lean muscle mass, but the isolated effect of resistance training on body fat is unknown. Objectives: This systematic review and meta-analysis evaluated resistance training for body composition outcomes in healthy adults. Our primary outcome was body fat percentage; secondary outcomes were body fat mass and visceral fat. Design: Systematic review with meta-analysis. Data Sources: We searched five electronic databases up to January 2021. Eligibility Criteria: We included randomised trials that compared full-body resistance training for at least 4 weeks to no-exercise control in healthy adults. Analysis: We assessed study quality with the TESTEX tool and conducted a rand.om-effects meta-analysis, with a subgroup analysis based on measurement type (scan or non-scan) and sex (male or female), and a meta-regression for volume of resistance training and training components Results: From 11,981 records, we included 58 studies in the review, with 54 providing data for a meta-analysis. Mean study quality was 9/15 (range 6–15). Compared to the control, resistance training reduced body fat percentage by − 1.46% (95% confidence interval − 1.78 to − 1.14, p < 0.0001), body fat mass by − 0.55 kg (95% confidence interval − 0.75 to − 0.34, p < 0.0001) and visceral fat by a standardised mean difference of − 0.49 (95% confidence interval − 0.87 to − 0.11, p = 0.0114). Measurement type was a significant moderator in body fat percentage and body fat mass, but sex was not. Training volume and training components were not associated with effect size. Summary/Conclusions: Resistance training reduces body fat percentage, body fat mass and visceral fat in healthy adults. Study Registration: osf.io/hsk32.
- Published
- 2021
12. The frequency of rare and monogenic diseases in pediatric organ transplant recipients in Italy
- Author
-
Vaisitti T., Peritore D., Magistroni P., Ricci A., Lombardini L., Gringeri E., Catalano S., Spada M., Sciveres M., Di Giorgio A., Limongelli G., Varrenti M., Gerosa G., Terzi A., Napoleone C. P., Amodeo A., Ragni L., Strologo L., Benetti E., Fontana I., Testa S., Peruzzi L., Mitrotti A., Abbate S., Comai G., Gotti E., Schiavon M., Boffini M., De Angelis D., Bertani A., Pinelli D., Torre M., Poggi C., Deaglio S., Cardillo M., Amoroso A., Serena A., Giorgia C., Vaisitti, T., Peritore, D., Magistroni, P., Ricci, A., Lombardini, L., Gringeri, E., Catalano, S., Spada, M., Sciveres, M., Di Giorgio, A., Limongelli, G., Varrenti, M., Gerosa, G., Terzi, A., Napoleone, C. P., Amodeo, A., Ragni, L., Strologo, L., Benetti, E., Fontana, I., Testa, S., Peruzzi, L., Mitrotti, A., Abbate, S., Comai, G., Gotti, E., Schiavon, M., Boffini, M., De Angelis, D., Bertani, A., Pinelli, D., Torre, M., Poggi, C., Deaglio, S., Cardillo, M., Amoroso, A., Serena, A., and Giorgia, C.
- Subjects
Registrie ,Pediatrics ,medicine.medical_specialty ,Transplant outcome ,Transplant Recipient ,Monogenic diseases ,Organ transplantation ,Rare diseases ,Child ,Humans ,Italy ,Quality of Life ,Registries ,Transplant Recipients ,Kidney Transplantation ,Organ Transplantation ,Disease ,Quality of life ,medicine ,Pharmacology (medical) ,Monogenic disease ,Genetics (clinical) ,Lung ,business.industry ,Research ,Liver and kidney ,General Medicine ,Transplantation ,medicine.anatomical_structure ,Cohort ,Medicine ,business ,Rare disease ,Human - Abstract
Background Rare diseases are chronic and life-threatening disorders affecting Results To the purpose of our analysis, we considered heart, lung, liver and kidney transplants included in the Transplant Registry (TR) of the Italian National Transplantation Center in the 2002–2019 timeframe. Overall, 49,404 recipients were enrolled in the cohort, 5.1% of whom in the pediatric age. For 40,909 (82.8%) transplant recipients, a disease diagnosis was available, of which 38,615 in the adult cohort, while 8,495 patients (17.2%) were undiagnosed. There were 128 disease categories, and of these, 117 were listed in the main rare disease databases. In the pediatric cohort, 2,294 (5.6%) patients had a disease diagnosis: of the 2,126 (92.7%) patients affected by a rare disease, 1,402 (61.1%) presented with a monogenic condition. As expected, the frequencies of pathologies leading to organ failure were different between the pediatric and the adult cohort. Moreover, the pediatric group was characterized, compared to the adult one, by an overall better survival of the graft at ten years after transplant, with the only exception of lung transplants. When comparing survival considering rare vs non-rare diseases or rare and monogenic vs rare non-monogenic conditions, no differences were highlighted for kidney and lung transplants, while rare diseases had a better survival in liver as opposed to heart transplants. Conclusions This work represents the first national survey analyzing the main genetic causes and frequencies of rare and/or monogenic diseases leading to organ failure and requiring transplantation both in adults and children.
- Published
- 2021
13. Esophageal and gastric malignancies after bariatric surgery: a retrospective global study
- Author
-
Chetan Parmar, Roxanna Zakeri, Mohamed Abouelazayem, Thomas H. Shin, Ali Aminian, Tala Mahmoud, Barham K. Abu Dayyeh, Melissa Y. Wee, Laura Fischer, Freek Daams, Kamal Mahawar, Carlos Sosa Gallardo, Cataldo Agustin, Fernando Wright, Ignacio Fuente, Miguel Carbajo, Patricio Cal, Jacob Chisholm, Lilian Kow, Michael H.L. Tan, Philip Gan, Sivakumar Gananadha, Daniel M. Felsenreich, Gerhard Prager, Chris Matthys, Jacques M. Himpens, Marc A.M.R.M. Focquet, Almino Ramos, Manoel Galvano Nato, Thiago Vidal, Amin Andalib, Aya Siblini, Lorenzo Ferri, Lina Abdarabo, Yehonatan Nevo, Radu Pescarus, Wah Yang, Hosam Hamed, Arnaud Liagre, Damien Bergeat, De Montrichard Marie, Francesco Martini, François Regis, Laurent Genser, Mehdi Skalli, Marius Nedelcu, Milan Smejkal, Radwan Kassir, Regenet Nicolas, Christine Stier, Dan-Sebastian Nedelcut, Grigorios Christodoulidis, Amar Vennapusa, Mohammad Kermansaravi, Asnat Raziel, Nasser Sakran, Alberto Oldani, Cristian Eugeniu Boru, Fouzia Mécheri, Francesca Ciccarese, Giovanni Carlo Cesana, Mario Musella, Matteo Uccelli, Mirto Foletto, Pasquale Auricchio, Stefano Olmi, Yosuke Seki, Anne Kasteleijn, Gerhard Van 'T Hof, Jan A. Apers, Judith W.H. Hart, Justin S.L. Van De Sande, Marijn Takkenberg, Pierre B.G.M. Feskens, Rob Snoekx, Victor D. Plat, Jorunn Sandvik, Piotr Kalinowski, Celso Nabais, Ahmed Z. Al-Bahrani, Mohammad Al Zoubi, Carla Bettonica, Javier Osorio, Javier Tejedor-Tejada, Lourdes M. Sanz, Marta Cuadrado, Rajesh Gianchandani Moorjani, Fringeli Yannick, Michel Suter, Yves Borbély, Zehetner Joerg, Juan S. Barajas-Gamboa, Matthew Kroh, Aaron P. Kisiel, Anna Kamocka, Arul Immanuel, Bruno Sgromo, Bussa Gopinath, David Khoo, Samrat Mukherjee, Dimitrios Pournaras, Tim Underwood, Ewen A. Griffiths, Glenn V. Miller, Helen Jaretzke, Jan Dmitrewski, Martin S. Wadley, Ragad Al-Housni, Richard S. Gillies, Rishi Singhal, Shaun R. Preston, Steven John Robinson, William J. Hawkins, Marco Adamo, Mohamed El Kalaawy, James Gossage, Christopher B. Crawford, Veeravich Jaruvongvanich, Parmar, C., Zakeri, R., Abouelazayem, M., Shin, T. H., Aminian, A., Mahmoud, T., Abu Dayyeh, B. K., Wee, M. Y., Fischer, L., Daams, F., Mahawar, K., Gallardo, C. S., Agustin, C., Wright, F., Fuente, I., Carbajo, M., Cal, P., Chisholm, J., Kow, L., Tan, M. H. L., Gan, P., Gananadha, S., Felsenreich, D. M., Prager, G., Matthys, C., Himpens, J. M., Focquet, M. A. M. R. M., Ramos, A., Nato, M. G., Vidal, T., Andalib, A., Siblini, A., Ferri, L., Abdarabo, L., Nevo, Y., Pescarus, R., Yang, W., Hamed, H., Liagre, A., Bergeat, D., Marie, D. M., Martini, F., Regis, F., Genser, L., Skalli, M., Nedelcu, M., Smejkal, M., Kassir, R., Nicolas, R., Stier, C., Nedelcut, D. -S., Christodoulidis, G., Vennapusa, A., Kermansaravi, M., Raziel, A., Sakran, N., Oldani, A., Boru, C. E., Mecheri, F., Ciccarese, F., Cesana, G. C., Musella, M., Uccelli, M., Foletto, M., Auricchio, P., Olmi, S., Seki, Y., Kasteleijn, A., Van 'T Hof, G., Apers, J. A., Hart, J. W. H., Van De Sande, J. S. L., Takkenberg, M., Feskens, P. B. G. M., Snoekx, R., Plat, V. D., Sandvik, J., Kalinowski, P., Nabais, C., Al-Bahrani, A. Z., Al Zoubi, M., Bettonica, C., Osorio, J., Tejedor-Tejada, J., Sanz, L. M., Cuadrado, M., Moorjani, R. G., Yannick, F., Suter, M., Borbely, Y., Joerg, Z., Barajas-Gamboa, J. S., Kroh, M., Kisiel, A. P., Kamocka, A., Immanuel, A., Sgromo, B., Gopinath, B., Khoo, D., Mukherjee, S., Pournaras, D., Underwood, T., Griffiths, E. A., Miller, G. V., Jaretzke, H., Dmitrewski, J., Wadley, M. S., Al-Housni, R., Gillies, R. S., Singhal, R., Preston, S. R., Robinson, S. J., Hawkins, W. J., Adamo, M., El Kalaawy, M., Gossage, J., Crawford, C. B., Jaruvongvanich, V., Surgery, CCA - Cancer Treatment and quality of life, Amsterdam Gastroenterology Endocrinology Metabolism, and Plastic, Reconstructive and Hand Surgery
- Subjects
Adult ,obesity ,Sleeve gastrectomy ,medicine.medical_specialty ,Palliative treatment ,bariatric surgery ,esophageal cancer ,esophagogastric cancer ,gtastric cancer ,metabolic surgery ,adult ,female ,gastrectomy ,humans ,middle aged ,retrospective studies ,treatment outcome ,gastric bypass ,morbid ,stomach neoplasms ,medicine.medical_treatment ,Esophageal cancer ,Esophagogastric cancer ,Population ,Gastric Bypass ,Bariatric Surgery ,Gastrectomy ,Stomach Neoplasms ,medicine ,Humans ,In patient ,Adjustable gastric band ,education ,Retrospective Studies ,Bariatric surgery ,education.field_of_study ,business.industry ,Cancer ,Middle Aged ,medicine.disease ,Obesity ,Obesity, Morbid ,Surgery ,Treatment Outcome ,Adenocarcinoma ,Female ,Metabolic surgery ,Gastric cancer ,business - Abstract
Background Bariatric surgery can influence the presentation, diagnosis, and management of gastrointestinal cancers. Oesophago-Gastric (OG) malignancies in patients who have had a prior bariatric procedure have not been fully characterised. Objective To characterise OG malignancies after bariatric procedures. Setting University Hospital, United Kingdom. Methods We performed a retrospective, multi-centre observational study of patients with OG malignancies after bariatric surgery to characterise this condition. Results This study includes 170 patients from 75 centres in 25 countries who underwent bariatric procedures between 1985 and 2020. At the time of the bariatric procedure, the mean age was 50.2 ± 10 years and the mean weight 128.8 ± 28.9 kg. Females comprised 57.3% (n=98) of the population. Most (n=64) patients underwent a Roux-en-Y Gastric Bypass (RYGB) followed by Adjustable Gastric Band (AGB) (n = 46) and Sleeve Gastrectomy (SG) (n = 43). Time to cancer diagnosis after bariatric surgery was 9.5 ± 7.4 years and mean weight at diagnosis was 87.4 ± 21.9 kg. The time lag was 5.9 ± 4.1 years after SG compared to 9.4 ± 7.1 years after RYGB and 10.5 ± 5.7 years after AGB. One-third of patients presented with metastatic disease. The majority of tumours were adenocarcinoma (82.9%). Approximately 1 in 5 patients underwent palliative treatment from the outset. Time from diagnosis to mortality was under one year for most patients who died over the intervening period. Conclusions The OGMOS (Oesophago-Gastric Malignancies after Obesity/ Bariatric Surgery) study presents the largest series to date of patients developing OG malignancies after bariatric surgery and attempts to characterise this condition.
- Published
- 2022
14. NOVEL MFRP MUTATION WITH NANOPHTHALMOS, OPTIC DISK DRUSEN, AND PERIPHERAL RETINOSCHISIS IMAGED WITH ULTRA-WIDEFIELD OPTICAL COHERENCE TOMOGRAPHY
- Author
-
Kyle D. Kovacs, Sarah H. Van Tassel, and Mrinali P. Gupta
- Subjects
Retina ,medicine.medical_specialty ,genetic structures ,medicine.diagnostic_test ,business.industry ,Retinoschisis ,Glaucoma ,General Medicine ,medicine.disease ,Optic disc drusen ,eye diseases ,Hypoplasia ,Foveoschisis ,Ophthalmology ,medicine.anatomical_structure ,Optical coherence tomography ,Retinitis pigmentosa ,medicine ,sense organs ,business - Abstract
Purpose To describe with multimodal imaging including the use of ultra-widefield optical coherence tomography (OCT) imaging a distinct phenotype of autosomal recessive nanophthalmos associated with a novel mutation of the MFRP gene (membrane-type frizzled-related protein). Methods Case report and review of the relevant literature. Patients Single patient followed by the Weill Cornell Medicine Department of Ophthalmology Retina and Glaucoma Services. Results A patient with a novel homozygous mutation in the MFRP gene (c.472C>T) presented with nanophthalmos, optic disc drusen, foveal hypoplasia, and extensive peripheral retinoschisis, which was revealed to be multilevel retinoschisis on ultra-wide field OCT. Unlike other reported cases, the findings associated with this novel mutation did not include foveoschisis nor clinically obvious retinitis pigmentosa. The patient underwent prophylactic peripheral laser iridotomy in both eyes. Conclusion Here we present a patient with nanophthalmos, optic disc drusen, and foveal hypoplasia associated with extensive peripheral retinoschisis imaged by ultra-widefield OCT, but not foveal retinoschisis or prominent retinitis pigmentosa. The findings may expand the clinical spectrum of MFRP-associated nanophthalmos.
- Published
- 2023
15. Phonation Resistance Training Exercises (PhoRTE) With and Without Expiratory Muscle Strength Training (EMST) For Patients With Presbyphonia: A Noninferiority Randomized Clinical Trial
- Author
-
Edie R. Hapner, Michael A. Belsky, Scott D. Rothenberger, Sandeep Shelly, Aaron Ziegler, Amanda I. Gillespie, Jackie Gartner-Schmidt, and Bari Hoffman
- Subjects
medicine.medical_specialty ,business.industry ,Voice therapy ,Resistance training ,Repeated measures design ,Expiratory Muscle Strength Training ,LPN and LVN ,law.invention ,030507 speech-language pathology & audiology ,03 medical and health sciences ,Speech and Hearing ,0302 clinical medicine ,Otorhinolaryngology ,Quality of life ,Randomized controlled trial ,law ,Statistical significance ,Physical therapy ,Medicine ,Phonation ,030223 otorhinolaryngology ,0305 other medical science ,business - Abstract
Presbyphonia negatively impacts quality of life in patients with age-related voice changes. A proof-of-concept study showed promise for high vocal intensity exercise to treat presbyphonia, which became the basis for a novel intervention for age-related voice changes known as Phonation Resistance Training Exercises (PhoRTE). Expiratory Muscle Strength Training (EMST) has also been proposed as an additional intervention to target and strengthen the aging respiratory system; however, EMST has undergone limited evaluation as an adjunct treatment for elderly patients undergoing voice therapy for presbyphonia. This study determined if the addition of EMST to PhoRTE voice therapy (PhoRTE + EMST) is at least as effective at voice improvement as PhoRTE alone.Prospective, randomized, controlled, single-blinded, non-inferiority.Participants aged 55 years or older with a diagnosis of vocal fold atrophy were randomized to complete PhoRTE therapy or PhoRTE + EMST. The primary outcome was change in Voice Handicap Index-10 (VHI-10). Secondary outcomes included the Aging Voice Index, maximum expiratory pressure, and acoustic and aerodynamic measures of voice. Repeated measures linear mixed models were constructed to analyze outcomes at a significance level of α = 0.10.Twenty-six participants were recruited for the study, and 24 participants were randomized to either treatment arm. Sixteen participants completed the entire study. Both treatment arms showed statistically significant and clinically meaningful improvements in VHI-10 (PhoRTE mean [M] = -8.20, P0.001; PhoRTE + EMST M = -9.58, P0.001), and PhoRTE + EMST was noninferior to PhoRTE alone (P = 0.069). Both groups experienced a statistically significant pre-post treatment decrease (improvement) in AVI scores (PhoRTE M = -18.40, P = 0.004; PhoRTE + EMST M = -16.28, P = 0.005). PhoRTE+EMST had statistically significantly greater changes in maximum expiratory pressure compared to PhoRTE alone (PhoRTE M = 8.24 cm HThis study demonstrates that voice therapy targeting high vocal intensity exercise (eg, PhoRTE) and EMST can play a role in improving voice outcomes for patients with presbyphonia.
- Published
- 2023
16. Stratifying risk outcomes among adult COVID-19 inpatients with high flow oxygen: The R4 score
- Author
-
Reynaldo Lara-Medrano, J.F. Moreno-Hoyos, E.S. Velázquez-Ávila, G.M. Rhoades, C.A. Diaz-Garza, Victor M Sánchez-Nava, G.M. Aguirre-García, Guillermo Torre-Amione, M.T. Ramírez-Elizondo, Michel F. Martinez-Resendez, D. Ramonfaur, and Fernando Castilleja-Leal
- Subjects
Risk ,HFO, High flow oxygen therapy ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Respiratory distress syndrome ,medicine.medical_treatment ,Disease ,CVD, cardiovascular disease ,RT-PCR, reverse transcriptase polymerase chain reaction ,AUC, area under the curve ,FiO2, fraction of inspired oxygen ,Internal medicine ,Diabetes mellitus ,medicine ,Clinical endpoint ,IL-6, interleukin-6 ,IQR, interquartile range ,COT, conventional oxygen therapy ,SOFA, Sequential Organ Failure Assessment ,Asthma ,Mechanical ventilation ,SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 ,BNP, brain natriuretic peptide ,COPD ,COVID-19, Coronavirus infectious disease 2019 ,LDH, lactate dehydrogenase ,Oxygen inhalation therapy ,Proportional hazards model ,business.industry ,NIV, non-invasive ventilation ,medicine.disease ,HR, hazard ratio ,Comorbidity ,ROC, receiver operating characteristic ,Coronavirus ,PSI, Pneumonia Severity Index ,IMV, invasive mechanical ventilation ,COPD, chronic obstructive pulmonary disease ,HS, highly sensitive ,CRP, C-reactive protein ,Original Article ,business ,IV, intravenous ,NEWS 2, National Early Warning Score 2 - Abstract
Background High flow oxygen therapy (HFO) is a widely used intervention for pulmonary complications. Amid the coronavirus infectious disease 2019 (COVID-19) pandemic, HFO became a popular alternative to conventional oxygen supplementation therapies. Risk stratification tools have been repurposed –and new ones developed– to estimate outcome risks among COVID-19 patients. This study aims to provide a simple risk stratification system to predict invasive mechanical ventilation (IMV) or death among COVID-19 inpatients on HFO. Methods Among 529 adult inpatients with COVID-19 pneumonia, we selected unadjusted clinical risk factors for developing the composite endpoint of IMV or death. The risk for the primary outcome by each category was estimated using a Cox proportional hazards model. Bootstrapping was used to validate the results. Results Age above 62, eGFR under 60 ml/min, room air SpO2 ≤89 % upon admission, history of hypertension, history of diabetes, and any comorbidity (cancer, cardiovascular disease, COPD/ asthma, hypothyroidism, or autoimmune disease) were considered for the score. Each of the six criteria scored 1 point. The score was further simplified into 4 categories: 1) 0 criteria, 2) 1 criterion, 3) 2-3 criteria, and 4) ≥4 criteria. Taking the first category as the reference, risk estimates for the primary endpoint were HR; 2.94 [1.67 – 5.26], 4.08 [2.63 – 7.05], and 6.63 [3.74 – 11.77], respectively. In ROC analysis, the AUC for the model was 0.72. Conclusions Our score uses simple criteria to estimate the risk for IMV or death among COVID-19 inpatients with HFO. Higher category reflects consistent increases in risk for the endpoint.
- Published
- 2023
17. Psoriasis and hidradenitis suppurativa: A large-scale population-based study
- Author
-
Khalaf Kridin, Michal Shani, Arnon D. Cohen, Yochai Schonmann, Guy Shalom, Shani Fisher, Doron Comaneshter, and Erez Batat
- Subjects
0301 basic medicine ,Computerized databases ,medicine.medical_specialty ,business.industry ,Dermatology ,medicine.disease ,Control subjects ,Retrospective data ,Population based study ,030207 dermatology & venereal diseases ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Psoriasis ,medicine ,Hidradenitis suppurativa ,In patient ,Observational study ,business - Abstract
The coexistence of psoriasis and hidradenitis suppurativa (HS) has been described, but the association between these conditions is yet to be firmly established.To study the association between psoriasis and HS using a large-scale real-life computerized database.A cross-sectional study was conducted comparing the prevalence of HS among patients with psoriasis and among age-, sex- and ethnicity-matched control subjects.A total of 68,836 patients with psoriasis and 68,836 controls were included in the study. The prevalence of HS was increased in patients with psoriasis as compared to the control group (0.3% vs. 0.2%, respectively; OR, 1.8; 95% CI, 1.5-2.3; P0.001). In a multivariate analysis adjusting for smoking, obesity, and other comorbidities, psoriasis was still associated with HS (OR, 1.8; 95% CI, 1.4-2.2; P0.001). Patients with coexistent psoriasis and HS were significantly younger (39.0±15.7 vs. 42.6±21.2 years; P=0.015) and had a higher prevalence of obesity (35.1% vs. 25.3%; P=0.001) and smoking (58.5% vs. 37.3%; P0.001) as compared to patients with psoriasis alone.Retrospective data collection.A positive association was observed between HS and psoriasis. Further longitudinal observational studies are necessary to establish these findings in other study populations.
- Published
- 2023
18. Early-onset peri-partum cardiomyopathy in a twin gestation: A rare presentation
- Author
-
Payel Kundu, G. D. Maiti, Tony Jose, and Shilpa Gupta
- Subjects
medicine.medical_specialty ,Pregnancy ,In vitro fertilisation ,Peripartum cardiomyopathy ,Obstetrics ,business.industry ,medicine.medical_treatment ,Cardiomyopathy ,Dilated cardiomyopathy ,General Medicine ,medicine.disease ,medicine ,Gestation ,Presentation (obstetrics) ,business ,Twin Pregnancy - Abstract
Peripartum cardiomyopathy (PPCM) is a rare pregnancy-associated dilated cardiomyopathy occurring in the last month of pregnancy and five months postdelivery, which presents with features of cardiac failure. Diagnosis is based on characteristic echocardiographic findings and elevated cardiac biomarkers and has significant mortality and morbidity when undiagnosed and untreated. Atypical presentations in earlier gestations are rare and associated with risk factors. Here we present a case of PPCM diagnosed in the second trimester in a post in vitro fertilization (IVF) twin pregnancy to emphasize the importance of considering the diagnosis of PPCM in all cases of unexplained cardiac failures during pregnancy in previously healthy patients, especially in the presence of risk factors.
- Published
- 2023
19. El rol de la 18F-FDG PET/TC para el diagnóstico de la enfermedad ósea de Paget con compromiso craneal y espinal: reporte de caso y revisión de la literatura
- Author
-
María Alejandra Valero, Andrés David Ramírez-Sanabria, Edgar Gerardo Ordóñez-Rubiano, and Rubén D. Mantilla-Hernández
- Subjects
Gynecology ,medicine.medical_specialty ,Rheumatology ,business.industry ,Medicine ,business - Abstract
Resumen La enfermedad osea de Paget (EOP) es un trastorno benigno, caracterizado por areas focales de recambio oseo. Hasta el momento solo se han descrito 17 casos en Colombia. Se presenta el caso de un paciente masculino de 68 anos que consulto por otorrea e hipoacusia. Los hallazgos en la radiografia y la tomografia computarizada fueron sugestivos de malignidad craneana, se realizo una 18F-FDG PET/TC que mostro hipercaptacion en el craneo y en la columna lumbar. Se encontraron niveles altos de fosfatasa alcalina consistente con EOP. La biopsia descarto otros diagnosticos diferenciales. El paciente recibio alendronato y experimento una mejoria sintomatica y disminucion en la fosfatasa alcalina.
- Published
- 2023
20. Has the Increase of Women in Surgical Training Programs Led to a Concomitant Increase in Female Leadership Positions? A 10-Year Analysis
- Author
-
Christine Yin, Christopher D. Liao, Phoebe McAuliffe, Sami U. Khan, Kaitlin Monroig, A. Laurie Shroyer, Tara L. Huston, Olivia L. Hanson, and Jocellie Marquez
- Subjects
medicine.medical_specialty ,business.industry ,Concomitant ,Physical therapy ,Medicine ,Surgery ,business ,Surgical training - Published
- 2023
21. Late recurrence in birdshot chorioretinopathy
- Author
-
C. Stephen Foster, Stephen D Anesi, Arash Maleki, Andrew M. Philip, Soheila Asgari, Ambika Manhapra, Peter Y. Chang, and Sydney Look-Why
- Subjects
Ideal point ,Multimodal imaging ,medicine.medical_specialty ,Receiver operating characteristic ,business.industry ,General Medicine ,medicine.disease ,Birdshot chorioretinopathy ,Ophthalmology ,Internal medicine ,Late Recurrence ,Medicine ,Observational study ,business ,Survival analysis - Abstract
Objective To compare the demographic, clinical, ancillary testing, and multimodal imaging characteristics of birdshot chorioretinopathy (BSCR) patients with late recurrence and birdshot patients with durable remission. Patients and Methods This was a retrospective observational case series. The above-mentioned parameters were studied in BSCR patients with late recurrence (group 1) and BSCR patients with durable remission (group 2). Results Fifty-five patients were included in this study. The average age of patients was 62.1 ± 11.1 years (range, 35–88 years). Groups 1 and 2 included 20 (36.4%) and 35 (63.6%) patients, respectively. In group 1, the average age of patients was 60.5 ± 10.39 years (range, 35–79 years). The female-to-male ratio was 16:4. In group 2, the average age of patients was 63.1 ± 11.6 years (range, 37–88 years). The female-to-male ratio was 22:13. None of the demographic, clinical, ancillary testing, and multimodal imaging parameters were statistically significantly different between the two groups. Using a receiver operating characteristics (ROC) curve, we found that the ideal duration of successful therapy to induce durable remission was 30 months with 70% sensitivity and 40% specificity (ideal point on the curve). A Kaplan–Meier survival curve demonstrated that late recurrence was seen within 30 months after stopping successful treatment of patients with BSCR. Conclusion There are no demographic, clinical, ancillary testing, or multimodal imaging characteristics that can predict late recurrence in BSCR patients. However, we found that 30 months of successful treatment may be ideal and recommended.
- Published
- 2023
22. Trends in Feminizing Hormone Therapy for Transgender Patients, 2006–2017
- Author
-
Joshua D. Safer, Julie Thompson, Jillian C. Shipherd, Michael Stephen Dunbar, Asa Radix, Jaclyn M. White Hughto, Jamie L Feldman, Madeline B. Deutsch, Adam J. Rose, Emily Quinn, and Guneet K. Jasuja
- Subjects
Gender Studies ,Pediatrics ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Transgender ,medicine ,Medicine (miscellaneous) ,Hormone therapy ,business - Published
- 2023
23. Application of deep hypothermic circulatory arrest in open left chest aortic aneurysm repair
- Author
-
George J. Arnaoutakis, Eric I. Jeng, Amber Fillion, Dan Neal, Matheus P. Falasa, Mahmoud Alhussaini, Thomas M. Beaver, Tomas D. Martin, and Torben K. Becker
- Subjects
Pulmonary and Respiratory Medicine ,Aortic arch ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,030204 cardiovascular system & hematology ,medicine.disease ,Thoracic aortic aneurysm ,law.invention ,Surgery ,03 medical and health sciences ,Aortic aneurysm ,0302 clinical medicine ,Aneurysm ,030228 respiratory system ,law ,medicine.artery ,Cardiopulmonary bypass ,medicine ,Deep hypothermic circulatory arrest ,Thoracotomy ,Cardiology and Cardiovascular Medicine ,business ,Stroke - Abstract
Objectives Deep hypothermic circulatory arrest (DHCA) is often required for patients undergoing repair of descending thoracic aortic aneurysm (DTAA) or thoracoabdominal aortic aneurysm via left thoracotomy when proximal crossclamping is not feasible or when aneurysmal disease extends into the transverse aortic arch. Historical literature suggests higher complications rates due to the technical complexity of this approach; we examined outcomes with this approach at our center. Methods Between January 2008 and May 2018, 84 patients with DTAA or Crawford extent I thoracoabdominal aortic aneurysm underwent open repair. DHCA was employed in 46 of 84 (55%) patients, of which 33 (72%) required repair of distal arch and DTAA, and 13 (28%) required repair of the distal arch and extent I thoracoabdominal aortic aneurysm. Patients who underwent DHCA had more chronic dissections than those in the non-DHCA group (70% vs 34%; P ≤ .05). Results Major adverse outcomes for the DHCA group versus non-DHCA group were as follows: early mortality 3 out of 46 (7%) versus 4 out of 38 (11%) (P = .70), stroke 3 out of 46 (7%) versus 1 out of 38 (3%) (P = .62), permanent spinal cord deficit 2 out of 46 (4%) versus 3 out of 38 (8%) (P = .65), permanent renal failure necessitating dialysis 1 out of 46 (2%) versus 2 out of 38 (5%) (P = .59). Freedom from major adverse outcomes was 38 out of 46 (83%) versus 31 out of 38 (82%) for DHCA versus non-DHCA (P = 1). Conclusions DHCA can be employed via left thoracotomy for combined arch and DTAA or extent I thoracoabdominal aortic aneurysm open repair.
- Published
- 2023
24. Extrahepatic Biliary Tract Obstruction
- Author
-
Steve J. Mehler and Philipp D. Mayhew
- Subjects
medicine.medical_specialty ,business.industry ,Radiography ,General surgery ,Internal medicine ,medicine ,Cholecystitis ,Extrahepatic biliary tract ,Pancreatitis ,business ,medicine.disease ,Gastroenterology ,Gallbladder mucocele - Published
- 2023
25. Epidemiología de la miastenia gravis en la provincia de Ourense (Galicia, noroeste de España)
- Author
-
D. Rodríguez Gómez, N.A. Sabbagh Casado, G. Pérez Lorenzo, G. Ozaita Arteche, D.A. García Estévez, L.M. López Díaz, and M. Pardo Parrado
- Subjects
Gynecology ,03 medical and health sciences ,medicine.medical_specialty ,0302 clinical medicine ,business.industry ,medicine ,Vitamina d ,Neurology (clinical) ,business ,030217 neurology & neurosurgery - Abstract
Resumen Introduccion La miastenia gravis (MG) es un enfermedad autoinmune que afecta a la transmision nerviosa a nivel de la union neuromuscular causando debilidad muscular tipicamente fluctuante. Los estudios epidemiologicos constatan un aumento de las tasas de prevalencia de la MG y es especialmente evidente en la poblacion anciana. Objetivo Realizar un estudio epidemiologico retrospectivo para conocer las tasas de incidencia y prevalencia en la provincia de Ourense (Galicia) caracterizada por el envejecimiento poblacional. Material y metodos Los pacientes fueron reclutados de nuestra base de datos clinica de enfermedades neuromusculares y a traves de la busqueda de pacientes con prescripcion activa de bromuro de piridostigmina. La tasa de incidencia se estimo entre los anos 2009-2018. Se establecio la fecha de prevalencia al 31/12/2018. El censo de la provincia de Ourense al 1/1/2019 era de 307.651 habitantes, de los que 96.544 (31,4%) tenian una edad ≥ de 65 anos. Resultados Se identificaron 80 casos de MG. La prevalencia fue de 260 casos/1.000.000 habitantes (IC95%: 202,7-316,4), y en la poblacion ≥ 65 anos de 517,9/1.000.000 habitantes (IC95%: 363,2-672,9). La incidencia acumulada en el periodo de estudio fue de 15,4 casos/1.000.000 habitantes-ano. El inicio precoz (≤ 50 anos) ocurrio en el 29,1% de los casos. Conclusion La prevalencia de la MG en nuestra area sanitaria es de las mas altas entre las cifras previamente reportadas, y es una enfermedad muy prevalente en la poblacion anciana.
- Published
- 2023
26. Trauma, mental health, and health care experiences of lesbian and bisexual women in Rwanda
- Author
-
Darius Gishoma, Ellen D. B. Riggle, Patricia J. Moreland, Rebecca White, and Tonda L. Hughes
- Subjects
Gender Studies ,medicine.medical_specialty ,business.industry ,Birth weight ,Health care ,medicine ,Lesbian ,Psychology ,Psychiatry ,business ,Minority stress ,Mental health ,General Psychology - Published
- 2023
27. Intersections of gendered racial trauma and childbirth trauma: Clinical interventions for Black women
- Author
-
Rayna D. Markin and M. Nicole Coleman
- Subjects
medicine.medical_specialty ,business.industry ,media_common.quotation_subject ,Traumatic stress ,Psychological intervention ,Racism ,Neglect ,Therapeutic relationship ,Psychiatry and Mental health ,Clinical Psychology ,Intervention (counseling) ,Health care ,medicine ,Childbirth ,Psychology ,business ,Psychiatry ,media_common - Abstract
Studies suggest that racism affects the type and quality of health care that patients who are Black receive, perhaps in part because poorer patient-provider communication and less provider encouragement of patient involvement have been consistently reported for patients of color. In particular, Black women are 3-4 times more likely to experience dangerous and even life-threatening complications, and more likely to report mistreatment and neglect from medical providers and staff, during childbirth. Experiences with gendered racism during childbirth, which in itself is a vulnerable, intense, and potentially traumatic experience when proper support is absent, may lead to posttraumatic stress reactions. Psychotherapy can help affected clients to process gendered racial and childbirth traumas through: (a) the establishment of a safe, trusting, and collaborative therapeutic relationship, in which careful attention is paid to repairing alliance ruptures caused by cultural misunderstandings or gendered racial microaggressions, and (b) framing experiences and "symptoms" as understandable reactions to gendered race-based traumatic stress during childbirth. In addition to direct therapeutic intervention, therapists should collaborate with doulas and/or medical providers on patient care, and, separately, advocate for systemic-level change, supporting clients' lived experiences outside of the therapy room. (PsycInfo Database Record (c) 2021 APA, all rights reserved).
- Published
- 2023
28. Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer
- Author
-
Jennet Harvey, D. Craig Allred, Gary M. Clark, and C. Kent Osborne
- Subjects
Oncology ,Adult ,medicine.medical_specialty ,Pathology ,Cancer Research ,medicine.drug_class ,medicine.medical_treatment ,Mammary gland ,Statistics as Topic ,Estrogen receptor ,Breast Neoplasms ,Ligands ,Breast cancer ,Predictive Value of Tests ,Internal medicine ,Biomarkers, Tumor ,Medicine ,Humans ,Estrogen Receptor Status ,Aged ,biology ,business.industry ,Middle Aged ,medicine.disease ,Prognosis ,Immunohistochemistry ,medicine.anatomical_structure ,Receptors, Estrogen ,Estrogen ,Chemotherapy, Adjuvant ,biology.protein ,Female ,Reagent Kits, Diagnostic ,Antibody ,business ,Adjuvant - Abstract
PURPOSE Immunohistochemistry (IHC) is a newer technique for assessing the estrogen receptor (ER) status of breast cancers, with the potential to overcome many of the shortcomings associated with the traditional ligand-binding assay (LBA). The purpose of this study was to evaluate the ability of ER status determination by IHC, compared with LBA, to predict clinical outcome—especially response to adjuvant endocrine therapy—in a large number of patients with long-term clinical follow-up. PATIENTS AND METHODS ER status was evaluated in 1,982 primary breast cancers by IHC on formalin-fixed paraffin-embedded tissue sections, using antibody 6F11 and standard methodology. Slides were scored on a scale representing the estimated proportion and intensity of positive-staining tumor cells (range, 0 to 8). Results were compared with ER values obtained by the LBA in the same tumors and to clinical outcome. RESULTS An IHC score of greater than 2 (corresponding to as few as 1% to 10% weakly positive cells) was used to define ER positivity on the basis of a univariate cut-point analysis of all possible scores and disease-free survival (DFS) in patients receiving any adjuvant endocrine therapy. Using this definition, 71% of all tumors were determined to be ER-positive by IHC, and the level of agreement with the LBA was 86%. In multivariate analyses of patients receiving adjuvant endocrine therapy alone, ER status determined by IHC was better than that determined by the LBA at predicting improved DFS (hazard ratios/ P = 0.474/.0008 and 0.707/.3214, respectively) and equivalent at predicting overall survival (0.379/.0001 and 0.381/.0003, respectively). CONCLUSION IHC is superior to the LBA for assessing ER status in primary breast cancer because it is easier, safer, and less expensive, and has an equivalent or better ability to predict response to adjuvant endocrine therapy.
- Published
- 2023
29. Pattern and distribution of neovascularization in proliferative diabetic retinopathy on fundus fluorescein angiography: A growing paradigm
- Author
-
Sumedha Vats, Poninder Kumar, D. Srujana, Jaya Kaushik, Aanchal Singhal, Mohini Agrawal, and Arun Kumar Yadav
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Leak ,genetic structures ,business.industry ,030106 microbiology ,Posterior pole ,General Medicine ,Diabetic retinopathy ,Fundus (eye) ,medicine.disease ,eye diseases ,Neovascularization ,03 medical and health sciences ,Quadrant (abdomen) ,0302 clinical medicine ,medicine.anatomical_structure ,Ophthalmology ,medicine ,sense organs ,030212 general & internal medicine ,medicine.symptom ,business ,Optic disc ,Fundus fluorescein angiography - Abstract
Background The objective of this study was to evaluate pattern and distribution of neovascularization of optic disc (NVD) and elsewhere (NVE) in proliferative diabetic retinopathy (PDR). Methods A cross-sectional study was conducted among freshly detected cases of PDR. Fundus fluorescein angiographic images of 61 eyes were assessed. Parameters studied for NVD were their number and location and for NVE were their number, location, type of leak, and distance from center of optic disc. Results Of 61 eyes, 29 eyes (47.5%) had NVD with a total of 49 leaks. Of these 49 NVD leaks, the maximum was concentrated in the superotemporal quadrant with 21 leaks (42.9%; 95%CI 28.8–57.8%). Of 61 eyes, 50 eyes (82%) had NVE with 97 leaks. Of 97 NVE leaks, 41 were found in the superotemporal quadrant (42.3%; 95%CI 32.3–52.7%). Maximum NVE was found within the circle of radius 3–6 mm centered on optic disc (p value = 0.001) with no leaks in central macula. Of 29 eyes with NVD, only 7 eyes had >1/3 area of disc involvement. Also, of 18 eyes with concurrent NVD and NVE, only 2 eyes had >1/3 area of disc involvement which is a high-risk characteristic of PDR. Conclusion Neovascular lesions have a predilection for superotemporal part for both NVD and NVE. NVE leaks were almost double the number of NVD leaks. Maximum NVE leaks were found at posterior pole with no central macular involvement. This study provides comprehensive data and further adds to knowledge of neovascularization for early diagnosis and management of PDR.
- Published
- 2023
30. Blue dye single labelling for colorimetric sentinel lymph node mapping in early endometrial cancer: A feasibility study
- Author
-
Monica Saraswat, Amarinder Singh, G. D. Maiti, Raju Agarwal, and Tony Jose
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Blue dye ,business.industry ,medicine.medical_treatment ,Endometrial cancer ,030106 microbiology ,Sentinel lymph node ,Systematic lymphadenectomy ,General Medicine ,medicine.disease ,Sentinel lymph node mapping ,03 medical and health sciences ,0302 clinical medicine ,Labelling ,medicine ,Sampling (medicine) ,Lymphadenectomy ,030212 general & internal medicine ,Radiology ,business - Abstract
Background Surgical staging in endometrial cancer includes a systematic lymphadenectomy with significant morbidity, although its therapeutic role is unclear. Sentinel lymph node (SLN) study is a less morbid alternative to identify nodes most likely to be metastatic, permitting selective removal and thus reducing morbidity without compromising oncological safety. This study was done using blue dye single labelling to study the feasibility and utility in identifying SLN in early disease. Methods Twenty-two patients of early-stage low-risk disease during surgical staging underwent cervical injection of methylene blue, SLN mapping, and sampling as per the standard algorithm, followed by a systematic lymphadenectomy in all cases. SLN were submitted separately for ultrastaging (US). Results Twenty patients underwent the procedure, and SLN could be identified in 18 patients with an overall mapping rate of 90% with a bilateral mapping rate of 70%, and a negative mapping rate of 10%. 57 SLN were identified along with two suspicious non-sentinel nodes and 11 were metastatic on US with a sensitivity of 66.7% and NPV of 87.5%. All patients with metastatic nodes, however, could be identified by applying the standard SLN algorithm for sampling. Conclusion SLN mapping algorithm with blue dye single labelling in early endometrial cancer, by identifying LN most likely to be metastatic enabling their selective removal may help avoid routine lymphadenectomies without compromising oncological safety. The procedure is simple and can be practiced at all centres and can also aid pathologists by pinpointing the likely metastatic nodes after a selective or complete lymphadenectomy.
- Published
- 2023
31. Spatiotemporal assessment of immunogenomic heterogeneity in multiple myeloma
- Author
-
Paul K. Wallace, Lei Wei, Philip L. McCarthy, Theresa Hahn, Almuth Maria Anni Merz, Jesse Luce, Qiang Hu, Prashant Singh, Maximilian Merz, Megan M. Herr, Song Liu, Ahmed Belal, Ronald A. Alberico, Joseph D. Tario, AnneMarie W. Block, Cherie Rondeau, Kelvin P. Lee, Hemn Mohammadpour, Sean T. Glenn, Jens Hillengass, Kimberly Celotto, and Jie Wang
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Immunology ,Cell Biology ,Newly diagnosed ,Hematology ,medicine.disease ,Biochemistry ,Prospective trial ,Internal medicine ,medicine ,Spatial evolution ,Current employment ,In patient ,business ,Multiple myeloma - Abstract
Introduction: Therapy and immune mediated processes are associated with clonal evolution in multiple myeloma (MM). In this study, we performed whole-exome sequencing (WES) and single cell RNA sequencing (scRNA-seq) on plasma cells (PC) from bone marrow aspirates of the iliac crest (BM) and corresponding osteolytic lesions (OL) to investigate spatial heterogeneity in patients with newly diagnosed (NDMM) and relapsed/refractory MM (RRMM). Next generation flow (NGF) and T-cell receptor sequencing (TCRseq) were performed to investigate the immunogenomic landscape surrounding malignant PC. Methods: In a prospective trial, 18 patients (NDMM: n=10; RRMM: n=8) consented to an imaging-guided biopsy of an OL in addition to the regular BM sampling. At inclusion, 37 different locations were biopsied. Follow-up samples were obtained from 5 patients in remission after therapy. After CD138+ selection, PC were subjected to WES and scRNA-seq (Chromium, 10x genomics). TCRseq was performed using multiplex PCR (ImmunoSEQ, Adaptive biotechnologies) on the CD138- fraction. For scRNA-seq data analyses, Cell Ranger (v3.1.0) and the Seurat R toolkit (v3.1) were used. TCRseq data were analyzed with immunoSEQ ANALYZER (v3.0) and the immunarch R toolkit (v0.6.6.). NGF was performed to study subsets of T-, B-, NK- and dendritic cells (DC). Results: Median PC infiltration was higher in OL compared to random BM (50.0% vs 12.5%, p=0.041). WES revealed more mutations in RRMM compared to NDMM (median; range: 189;120-523 vs 71;23-136, p Conclusion: We report the first prospective clinical trial to investigate spatiotemporal immunogenomic heterogeneity in multiple myeloma as assessed by WES and scRNA-seq of PC and NGF and TCRseq of the non-PC compartment. We demonstrate spatial evolution and reduced TCR diversity especially in patients with RRMM and/or EMD. ScRNA-seq adds another layer of complexity compared to WES and helps identifying how PC create an immune suppressive BM niche. Disclosures Merz: Amgen, BMS, Celgene, Takeda: Honoraria. Block:GlaxoSmithKline LLC: Current Employment. McCarthy:Karyopharm: Consultancy, Honoraria; Magenta: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Advisory Board; Juno Therapeutics, a Bristol-Myers Squibb Company: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Advisory Board , Research Funding is to Roswell Park, Research Funding; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Advisory Board; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Advisory Board; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Advisory Board; Starton: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Advisory Board; Genentech: Consultancy, Honoraria. Hillengass:Adaptive, Amgen, BMS, Celgene, GSK, Janssen, Oncotracker, Takeda: Honoraria.
- Published
- 2023
32. Screening for palliative care needs in the community using SPICT
- Author
-
Akhilesh Pandey, Pankaj Singhai, Naveen Salins, Deepak Sudhakaran, Ashwini Shivakumar Bidnurmath, Sneha D. Mallya, Ranjitha S Shetty, and Pawan Kumar
- Subjects
medicine.medical_specialty ,Univariate analysis ,Palliative care ,business.industry ,Primary health care ,General Medicine ,Disease ,medicine.disease ,Nonprobability sampling ,Family medicine ,medicine ,Dementia ,Marital status ,Community survey ,business - Abstract
Background The Worldwide Hospice Palliative Care Alliance has recommended integration of palliative care into primary health care. Diminished capacity to provide palliative care is a barrier for integration. The purpose of this study was to screen for palliative care needs in the community. Methods A cross-sectional study was conducted in two rural communities of Udupi district. Supportive and Palliative Care Indicators Tool – 4ALL (SPICT-4ALL) was used to identify the palliative care needs. Purposive sampling was used to collect the individual information from the households for identifying the palliative care need. Conditions requiring palliative care and the sociodemographic factors associated with it were explored. Results Out of 2041 participants, 51.49% were female, and 19.65% were elderly. Less than a quarter of them (23.08%) had at least one chronic illness. Hypertension, diabetes, and ischemic heart disease were commonly found. 4.31% had satisfied the requisite SPICT criteria, which indicated a need for palliative care. Diseases of cardiovascular system followed by dementia and frailty were the most common conditions requiring palliative care. Univariate analysis showed that age, marital status, years of education, occupation, and the presence of morbidities were significantly associated with the need for palliative care. Being unemployed and having one or more morbidities were factors independently associated with requirement of palliative care. Conclusions The estimated palliative care need in the community survey exceeds the perceived need. Although palliative care is traditionally identified with cancer, the proportion of people with noncancer palliative care needs were significantly higher than cancer palliative care.
- Published
- 2023
33. Interhospital variability in health care–associated infections and payments after durable ventricular assist device implant among Medicare beneficiaries
- Author
-
Donald S. Likosky, Guangyu Yang, Min Zhang, Preeti N. Malani, Michael D. Fetters, Raymond J. Strobel, Carol E. Chenoweth, Hechuan Hou, Francis D. Pagani, Ashraf Shaaban Abdel Aziz Abou El Ela, Paul C. Tang, Michael P. Thompson, Keith Aaronson, Supriya Shore, Thomas Cascino, Katherine B. Salciccioli, Jeffrey S. McCullough, Michelle Hou, Allison M. Janda, Michael R. Mathis, Tessa M.F. Watt, Michael J. Pienta, Alexander Brescia, Austin Airhart, Daniel Liesman, and Khalil Nassar
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,medicine.medical_treatment ,media_common.quotation_subject ,Psychological intervention ,030204 cardiovascular system & hematology ,Medicare ,Health care associated ,Article ,Ventricular Function, Left ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,Registries ,Aged ,Retrospective Studies ,media_common ,Heart Failure ,Cross Infection ,business.industry ,Incidence (epidemiology) ,Medicare beneficiary ,Payment ,Patient Discharge ,United States ,Confidence interval ,Treatment Outcome ,030228 respiratory system ,Ventricular assist device ,Emergency medicine ,Surgery ,Heart-Assist Devices ,Implant ,Health Expenditures ,Cardiology and Cardiovascular Medicine ,business - Abstract
OBJECTIVE: The objective of this study was to investigate variations across hospitals in infection rates and associated costs, the latter reflected in 90-day Medicare payments. Despite high rates and expenditures of healthcare-associated infections associated with durable ventricular assist device implant, few studies have examined inter-hospital variation and associated costs. METHODS: Clinical data on 8688 patients who received primary durable ventricular assist devices from July 2008 to July 2017 from The Society of Thoracic Surgeons Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs) hospitals (n=120) were merged with post-implant 90-day Medicare claims. Terciles of hospital-specific, risk-adjusted infection rates per 100 patient-months were estimated using Intermacs and associated with Medicare payments (among 5440 Medicare beneficiaries). Primary outcomes included infections within 90 days of implant and Medicare payments. RESULTS: There were 3982 infections identified among 27.8% (2,417/8,688) of patients developing an infection. The median (25(th), 75(th) percentile) adjusted incidence of infections (per 100 patient-months) across hospitals was 14.3 (9.3, 19.5) and varied by hospital (range 0.0 – 35.6). Total Medicare payments from implant to 90-days were 9.0% (absolute difference: $13,652) greater in high versus low infection tercile hospitals, p
- Published
- 2022
34. Success in pediatric surgery: An updated survey of Program Directors 2020
- Author
-
L. Grier Arthur, Brian W. Gray, Barbara A. Gaines, Jordan E. Jackson, Benedict C. Nwomeh, Grace Z. Mak, Richard G. Weiss, Cynthia D. Downard, Aaron P. Garrison, Mackenzie L. Shindorf, Nicole M. Chandler, Shreya Gupta, Paul D. Danielson, Peter F. Ehrlich, Michel Lallier, Patrick J. Javid, and Edward Tagge
- Subjects
Canada ,Matriculation ,medicine.medical_specialty ,media_common.quotation_subject ,Specialties, Surgical ,Likert scale ,Phone ,Surveys and Questionnaires ,Pediatric surgery ,medicine ,Humans ,Quality (business) ,Fellowships and Scholarships ,Child ,Curriculum ,Retrospective Studies ,media_common ,Teamwork ,Medical education ,business.industry ,Internship and Residency ,General Medicine ,Ranking ,Pediatrics, Perinatology and Child Health ,Surgery ,business - Abstract
Background : One of the most competitive surgical sub-specialty fellowships remains Pediatric Surgery (PS), which requires candidates to develop a strong and research-oriented curriculum vitae. Although some objective factors of matriculation are known, factors for the interview selection and ranking per the program directors (PDs) have not been reviewed in over a decade. Methods : A web-based survey of US and Canadian PS program directors (PDs) (n=58) was used to evaluate a comprehensive list of factors in the selection criteria for PS fellowships. A mix of dichotomous, ranking, five-point Likert scale, and open-ended questions evaluated applicant characteristics, ABSITE scores, research productivity, interview day, and rank order criteria. Results : Fifty-five programs responded to the survey for a 95% participation rate. PDs desired an average of two years in dedicated research and weighted first authorship and total number of publications heavily. Only 38% of programs used an ABSITE score cutoff for offering interviews; however, the majority agreed that an overall upward trend was important. Quality letters of recommendation, especially from known colleagues, carried weight when deciding to offer interviews. Interview performance, being a team player, observed interpersonal interactions, perceived operative skills and patient care, and leadership were some of the notable factors when finalizing rank lists. Conclusions : A multitude of factors define a successful matriculant, including quality of letters of recommendation, quality and quantity of publications, supportive phone calls, observed interactions, interview performance, perceptions of being team player with leadership skills as well as perceptions of good operative skills and patient care.
- Published
- 2022
35. Umbilical access in laparoscopic surgery in infants less than 3 months: A single institution retrospective review
- Author
-
Pablo Aguayo, Rebecca M. Rentea, Kayla B. Briggs, Wendy Jo Svetanoff, David Juang, Shawn D. St. Peter, Tolulope A. Oyetunji, Richard J. Hendrickson, Charles L. Snyder, Jason D. Fraser, and James A. Fraser
- Subjects
Insufflation ,Laparoscopic surgery ,medicine.medical_specialty ,medicine.medical_treatment ,Population ,Hernia, Inguinal ,Postoperative Complications ,medicine ,Operative report ,Humans ,Child ,education ,Herniorrhaphy ,Retrospective Studies ,education.field_of_study ,business.industry ,Infant, Newborn ,Infant ,General Medicine ,Carbon Dioxide ,medicine.disease ,Surgery ,Umbilical hernia ,Inguinal hernia ,Embolism ,Pediatrics, Perinatology and Child Health ,Laparoscopy ,Complication ,business ,Hernia, Umbilical - Abstract
Introduction : Umbilical access in laparoscopic surgery has been cited as a factor for increased complications in low-birth-weight infants and those less than three months old. In a previous series, 10.6% of pediatric surgeons reported complications in this population associated with umbilical access, citing carbon dioxide (CO2) embolism as the most common complication. To further examine the safety of this technique, we report our outcomes with blunt transumbilical laparoscopic access at our institution over four years. Methods : A retrospective review was performed of patients less than three months of age who underwent laparoscopic pyloromyotomy or inguinal hernia repair from 2016-2019. Operative reports, anesthesia records, and postoperative documentation were reviewed for complications related to umbilical access. Complications included bowel injury, vascular injury, umbilical vein cannulation, CO2 embolism, umbilical surgical site infection (SSI), umbilical hernia requiring repair, and death. Results : Of 365 patients, 246 underwent laparoscopic pyloromyotomy, and 119 underwent laparoscopic inguinal hernia repairs. Median age at operation was 5.9 weeks [4.3,8.8], and median weight was 3.9 kg [3.4,4.6]. Nine complications (2.5%) occurred: 5 umbilical SSIs (1.4%), 1 bowel injury upon entry requiring laparoscopic repair (0.2%), 1 incisional hernia repair 22 days postoperatively (0.2%), and 2 cases of hypotension and bradycardia upon insufflation that resolved with desufflation (0.5%). There were no intraoperative mortalities or signs/symptoms of CO2 embolism. Conclusion : In this series, umbilical access for laparoscopic surgery in neonates less than three months of age was safe, with minimal complications. Although concern for umbilical vessel injury, cannulation, and CO2 embolism exists, these complications are not exclusively associated with umbilical access technique.
- Published
- 2022
36. Genotype-phenotype correlations in SCN8A-related disorders reveal prognostic and therapeutic implications
- Author
-
Roseline Caume, M Scott Perry, Massimo Mastrangelo, Margarete Koch-Hogrebe, Pasquale Striano, Karen Müller-Schlüter, Petra Laššuthová, Monisa D. Wagner, Ingo Helbig, Stephan Lauxmann, Emmanuel Scalais, Marie-Cécile Nassogne, Silvia Masnada, Henrike O. Heyne, Konrad Platzer, Frederic Bilan, Chloe A Stutterd, Sonja Walsh, Katrine M Johannesen, Damien Lederer, Ngoc Minh Le, Christina Fenger, Daniel Tibussek, Lukas Sonnenberg, Andrea Berger, Yuanyuan Liu, Mikhail Abramov, Karen E. Wain, Sergey Korostelev, P Y Billie Au, Elena L. Dadali, An-Sofie Schoonjans, Cornelia Betzler, Artem Borovikov, Johanna Krüger, Maert Rannap, Sebastian Lebon, Nils A Koch, Nancy Eisenhauer, Judith Kroell-Seger, Julian Schubert, Marije Meuwissen, Caroline Lund, Mark Fitzgerald, Federico Zara, Siddharth Srivastava, Claudia M Bonardi, Pia Zacher, Haim Bassan, Arve Vøllo, Katherine B. Howell, Francesca Darra, Guido Rubboli, Stephen W. Scherer, Bénédicte Gérard, Stefano Sartori, Annapurna Poduri, Helene Verhelst, Katalin Sterbova, Mathilde Nizon, Marketa Vlckova, Christina E. Hoei-Hansen, Renzo Guerrini, Ilya V. Kanivets, Juliann M. Savatt, Johannes Rebstock, Jakob Christensen, Cecilia Altuzarra, Dennis Lal, Judith S. Verhoeven, Agathe Roubertie, Constanze Heine, Dagmar Wieczorek, Ingo Borggraefe, Aster V. E. Harder, Anne Destrée, Wen-Hann Tan, Tobias Brünger, Shoji Ichikawa, Laura Canafoglia, Mahmoud Koko, Sergey Kutsev, Sabine Grønborg, Patrizia Accorsi, Heather E. Olson, Bert van der Zwaag, Cathrine E Gjerulfsen, Patrick May, A. A. Sharkov, M. Mahdi Motazacker, Manuela Pendziwiat, Richard J. Leventer, Anna Jansen, Lucio Giordano, Holger Lerche, Carla Marini, Karl Martin Klein, Eva H. Brilstra, Ahmed Eltokhi, Ethan M. Goldberg, Walid Fazeli, Rikke S. Møller, Dorota Hoffman-Zacharska, Michael Alber, Susanne Ruf, Jennifer L. Howe, Phillis Lakeman, Josua Kegele, Katherine L. Helbig, Marga Buzatu, Alice W Ho, Jan Benda, Ilona Krey, Marion Gérard, Sara Matricardi, Thomas U. Mayer, Philippe Gelisse, Jong M. Rho, Johannes R. Lemke, Pierangelo Veggiotti, Tobias Loddenkemper, Gaetan Lesca, Ulrike B. S. Hedrich, Silvana Franceschetti, Elena Gardella, Irina Mishina, María Vaccarezza, Timo Roser, Public Health Sciences, Mental Health and Wellbeing research group, Neurogenetics, Neuroprotection & Neuromodulation, Pediatrics, Human Genetics, ANS - Complex Trait Genetics, ARD - Amsterdam Reproduction and Development, Human genetics, and Amsterdam Reproduction & Development (AR&D)
- Subjects
medicine.medical_specialty ,SCN8A ,Gastroenterology ,Epilepsy ,Sodium channel blocker ,Neurodevelopmental disorder ,Seizures ,Intellectual Disability ,Internal medicine ,medicine ,Humans ,Missense mutation ,genetics ,Generalized epilepsy ,Genetic Association Studies ,Benign familial infantile epilepsy ,Generalized ,business.industry ,Infant ,personalized medicine ,Prognosis ,medicine.disease ,Phenotype ,Settore MED/39 - Neuropsichiatria Infantile ,NAV1.6 Voltage-Gated Sodium Channel ,Mutation ,epilepsy ,Original Article ,Epilepsy, Generalized ,Human medicine ,Neurology (clinical) ,Age of onset ,business ,Epileptic Syndromes ,Sodium Channel Blockers - Abstract
We report detailed functional analyses and genotype-phenotype correlations in 392 individuals carrying disease-causing variants in SCN8A, encoding the voltage-gated Na+ channel Nav1.6, with the aim of describing clinical phenotypes related to functional effects. Six different clinical subgroups were identified: Group 1, benign familial infantile epilepsy (n = 15, normal cognition, treatable seizures); Group 2, intermediate epilepsy (n = 33, mild intellectual disability, partially pharmaco-responsive); Group 3, developmental and epileptic encephalopathy (n = 177, severe intellectual disability, majority pharmaco-resistant); Group 4, generalized epilepsy (n = 20, mild to moderate intellectual disability, frequently with absence seizures); Group 5, unclassifiable epilepsy (n = 127); and Group 6, neurodevelopmental disorder without epilepsy (n = 20, mild to moderate intellectual disability). Those in Groups 1–3 presented with focal or multifocal seizures (median age of onset: 4 months) and focal epileptiform discharges, whereas the onset of seizures in patients with generalized epilepsy was later (median: 42 months) with generalized epileptiform discharges. We performed functional studies expressing missense variants in ND7/23 neuroblastoma cells and primary neuronal cultures using recombinant tetrodotoxin-insensitive human Nav1.6 channels and whole-cell patch-clamping. Two variants causing developmental and epileptic encephalopathy showed a strong gain-of-function (hyperpolarizing shift of steady-state activation, strongly increased neuronal firing rate) and one variant causing benign familial infantile epilepsy or intermediate epilepsy showed a mild gain-of-function (defective fast inactivation, less increased firing). In contrast, all three variants causing generalized epilepsy induced a loss-of-function (reduced current amplitudes, depolarizing shift of steady-state activation, reduced neuronal firing). Functional effects were known for 170 individuals. All 136 individuals carrying a functionally tested gain-of-function variant had either focal (n = 97, Groups 1–3) or unclassifiable (n = 39) epilepsy, whereas 34 individuals with a loss-of-function variant had either generalized (n = 14), no (n = 11) or unclassifiable (n = 6) epilepsy; only three had developmental and epileptic encephalopathy. Computational modelling in the gain-of-function group revealed a significant correlation between the severity of the electrophysiological and clinical phenotypes. Gain-of-function variant carriers responded significantly better to sodium channel blockers than to other anti-seizure medications, and the same applied for all individuals in Groups 1–3. In conclusion, our data reveal clear genotype-phenotype correlations between age at seizure onset, type of epilepsy and gain- or loss-of-function effects of SCN8A variants. Generalized epilepsy with absence seizures is the main epilepsy phenotype of loss-of-function variant carriers and the extent of the electrophysiological dysfunction of the gain-of-function variants is a main determinant of the severity of the clinical phenotype in focal epilepsies. Our pharmacological data indicate that sodium channel blockers present a treatment option in SCN8A-related focal epilepsy with onset in the first year of life.
- Published
- 2022
37. Structural MRI-Based Measures of Accelerated Brain Aging do not Moderate the Acute Antidepressant Response in Late-Life Depression
- Author
-
Brian D. Boyd, Bennett A. Landman, Claire Ryan, Seth Christman, Sarah M. Szymkowicz, Damian Elson, Warren D. Taylor, Camilo Bermudez, Ryan Ahmed, and Hakmook Kang
- Subjects
Oncology ,Aging ,medicine.medical_specialty ,Depression ,business.industry ,Brain ,Late life depression ,Magnetic Resonance Imaging ,Antidepressive Agents ,Psychiatry and Mental health ,Internal medicine ,Humans ,Medicine ,Antidepressant ,Geriatrics and Gerontology ,business ,Bupropion ,Brain aging - Abstract
Late-life depression (LLD) is characterized by accelerated biological aging. Accelerated brain aging, estimated from structural magnetic resonance imaging (sMRI) data by a machine learning algorithm, is associated with LLD diagnosis, poorer cognitive performance, and disability. We hypothesized that accelerated brain aging moderates the antidepressant response.Following MRI, participants entered an 8-week randomized, controlled trial of escitalopram. Nonremitting participants then entered an open-label 8-week trial of bupropion.Ninety-five individuals with LLD.A machine learning algorithm estimated each participant's brain age from sMRI data. This was used to calculate the brain-age gap (BAG), or how estimated age differed from chronological age. Secondary sMRI measures of aging pathology included white matter hyperintensity (WMH) volumes and hippocampal volumes. Mixed models examined the relationship between sMRI measures and change in depression severity. Initial analyses tested for a moderating effect of MRI measures on change in depression severity with escitalopram. Subsequent analyses tested for the effect of MRI measures on change in depression severity over time across trials.In the blinded initial phase, BAG was not significantly associated with a differential response to escitalopram over time. BAG was also not associated with a change in depression severity over time across both arms in the blinded phase or in the subsequent open-label bupropion phase. We similarly did not observe effects of WMH volume or hippocampal volume on change in depression severity over time.sMRI markers of accelerated brain aging were not associated with treatment response in this sequential antidepressant trial.
- Published
- 2022
38. The efficacy of suppressive antibiotic treatment in patients managed non-operatively for periprosthetic joint infection and a draining sinus
- Author
-
Lensen K. -J. D. F., Escudero-Sanchez R., Cobo J., Trebse R., Gubavu C., Tedeschi S., Lomas J. M., Arvieux C., Rodriguez-Pardo D., Fantoni M., Pais M. J. G., Jover F., Salles M. J. C., Sancho I., Sampedro M. F., Soriano A., Wouthuyzen-Bakker M., Roskar S., Praena J., Ribeiro T. C., Taccari T., Meheut A., Achermann Y., Andronic O., Asensi V., Moran-Castan C., Jover-Saenz A., Institut Català de la Salut, [Lensen KDF] Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. [Escudero-Sanchez R, Cobo J] Department of Infectious Diseases, Hospital Ramón y Cajal, IRYCIS, Madrid, Spain. [Trebše R] Service for Bone Infections, Valdoltra Orthopaedic Hospital, Ankaran, Slovenia. [Gubavu C] Department of Infectious and Tropical Diseases, CHR Orléans, Orléans, France. [Tedeschi S] Infectious Diseases Unit, Department of Medical and Surgical Sciences, University of Bologna Policlinico di Sant Orsola, Bologna, Italy. [Rodriguez-Pardo D] Servei de Malalties Infeccioses, Vall d'Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Lensen K.-J.D.F., Escudero-Sanchez R., Cobo J., Trebse R., Gubavu C., Tedeschi S., Lomas J.M., Arvieux C., Rodriguez-Pardo D., Fantoni M., Pais M.J.G., Jover F., Salles M.J.C., Sancho I., Sampedro M.F., Soriano A., Wouthuyzen-Bakker M., Roskar S., Praena J., Ribeiro T.C., Taccari T., Meheut A., Achermann Y., Andronic O., Asensi V., Moran-Castan C., and Jover-Saenz A.
- Subjects
prothetic joint infections, suppressive antibiotic therapy, draining sinus tract ,medicine.medical_specialty ,medicine.drug_class ,Original Full-Length Article ,Antibiotics ,Periprosthetic ,Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] ,Other subheadings::Other subheadings::/drug therapy [Other subheadings] ,medicine ,Bacterial Infections and Mycoses::Infection::Prosthesis-Related Infections [DISEASES] ,Orthopedics and Sports Medicine ,In patient ,Prospective cohort study ,Sinus (anatomy) ,Orthopedic surgery ,business.industry ,infecciones bacterianas y micosis::infección::infecciones relacionadas con prótesis [ENFERMEDADES] ,diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Articulacions artificials ,medicine.disease ,Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Surgery ,Infectious Diseases ,medicine.anatomical_structure ,Bacteremia ,Avaluació de resultats (Assistència sanitària) ,Infecció ,Implant ,business ,RD701-811 ,Cohort study - Abstract
Objectives: Patients with prosthetic joint infections (PJIs) not suitable for curative surgery may benefit from suppressive antibiotic therapy (SAT). However, the usefulness of SAT in cases with a draining sinus has never been investigated. Methods: A multicentre, retrospective observational cohort study was performed in which patients with a PJI and a sinus tract were eligible for inclusion if managed conservatively and if sufficient follow-up data were available (i.e. at least 2 years). SAT was defined as a period of > 6 months of oral antibiotic therapy. Results: SAT was initiated in 63 of 72 (87.5 %) included patients. Implant retention during follow-up was the same in patients receiving SAT vs. no SAT (79.4 % vs. 88.9 %; p=0.68). In total, 27 % of patients using SAT experienced side effects. In addition, the occurrence of prosthetic loosening in initially fixed implants, the need for surgical debridement, or the occurrence of bacteremia during follow-up could not be fully prevented with the use of SAT, which still occurred in 42 %, 6.3 %, and 3.2 % of cases, respectively. However, the sinus tract tended to close more often (42 % vs. 13 %; p=0.14), and a higher resolution of pain was observed (35 % vs. 14 %; p=0.22) in patients receiving SAT. Conclusions: SAT is not able to fully prevent complications in patients with a draining sinus. However, it may be beneficial in a subset of patients, particularly in those with pain or the hindrance of a draining sinus. A future prospective study, including a higher number of patients not receiving SAT, is needed.
- Published
- 2021
39. Social media use to improve communication on children and adolescent’s health: the role of the Italian Paediatric Society influencers
- Author
-
Bozzola E., Staiano A., Spina G., Zamperini N., Marino F., Roversi M., Corsello G., Villani A., Agostiniani R., Memo L., Peroni D., Banderali G., Turra R., Romeo N., Chiara A., Antonio D. V., Indinnimeo L., Ferrara P., Elena Bozzola, Anna Maria Staiano, Giulia Spina, Nicola Zamperini, Francesco Marino, Marco Roversi, Giovanni Corsello, and The Italian Paediatric Society Executive Board, Bozzola, E., Staiano, A., Spina, G., Zamperini, N., Marino, F., Roversi, M., Corsello, G., Villani, A., Agostiniani, R., Memo, L., Peroni, D., Banderali, G., Turra, R., Romeo, N., Chiara, A., Antonio, D. V., Indinnimeo, L., and Ferrara, P.
- Subjects
medicine.medical_specialty ,Adolescent ,Adolescent Health ,Context (language use) ,Pilot Projects ,Pediatrics ,RJ1-570 ,Social media ,Influencer ,medicine ,Humans ,Pilot Project ,Misinformation ,Child ,Children ,Societies, Medical ,Pediatric ,Consumer Health Information ,business.industry ,Public health ,Research ,Communication ,Child Health ,Health, Influencer ,Advertising ,Influencer marketing ,Health ,The Internet ,business ,Scientific communication ,Adolescent health ,Human - Abstract
Background Fake news on children’s and adolescent health are spreading. Internet availability and decreasing costs of media devices are contributing to an easy access to technology by families. Public health organizations are working to contrast misinformation and promote scientific communication. In this context, a new form of communication is emerging social media influencers. Aim of this study is to evaluate the role of paediatric influencers (PI) in communicating information about children and adolescents’ health. Materials and methods A group of PI was enrolled from December 2019 to January 2020 by a scientific commission nominated by the Italian Paediatric Society (SIP). PI were asked to share Facebook messages from the official page of the SIP to their own network. Social media tools have been evaluated across 12 months, from July 28, 2019, to July 11, 2020. For the purposes of clarity, we schematically divided the study period as follows: the period of PIs activity (January 6, 2020, to July 11, 2020) and the period when PIs were not yet active (July 28, 2019, to January 4, 2020). Information on Facebook page (lifetime total likes, daily new likes, daily page engaged, daily total reach) and on published post (lifetime post total reach, lifetime post organic reach, lifetime engaged users) were evaluated. Results A significant increase in Facebook daily new likes, page engagement and total reach, as well as in lifetime post total and organic reach was evidenced. As for PI, they reported a positive experience in most cases. Discussion In the digital era, communication strategies are becoming more important, so that the scientific community has to be actively involved in social media communication. Our pilot study demonstrated that the recruitment of paediatric influencers has increased communication and interaction of the SIP Facebook page. Conclusion Our study shows the potential role of influencers: spreading health messages via PI seems to be a successful strategy to promote correct communication about children’s and adolescents’ health.
- Published
- 2021
40. Long‐term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high‐frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study
- Author
-
Barbanti P., Aurilia C., Cevoli S., Egeo G., Fofi L., Messina R., Salerno A., Torelli P., Albanese M., Carnevale A., Bono F., D'Amico D., Filippi M., Altamura C., Vernieri F., Colombo B., Frediani F., Mercuri B., D'Onofrio F., Grazzi L., Aguggia M., Pierangeli G., Favoni V., Finocchi C., Di Fiore P., Costa C. M., Brunelli N., Fallacara A., Bertuzzo D., Zucco M., Di Clemente L., Trimboli M., Pascarella A., Manzo L., Barbanti P., Aurilia C., Cevoli S., Egeo G., Fofi L., Messina R., Salerno A., Torelli P., Albanese M., Carnevale A., Bono F., D'Amico D., Filippi M., Altamura C., Vernieri F., Colombo B., Frediani F., Mercuri B., D'Onofrio F., Grazzi L., Aguggia M., Pierangeli G., Favoni V., Finocchi C., Di Fiore P., Costa C.M., Brunelli N., Fallacara A., Bertuzzo D., Zucco M., Di Clemente L., Trimboli M., Pascarella A., Manzo L., Barbanti, Piero, Aurilia, Cinzia, Cevoli, Sabina, Egeo, Gabriella, Fofi, Luisa, Messina, Roberta, Salerno, Antonio, Torelli, Paola, Albanese, Maria, Carnevale, Antonio, Bono, Francesco, D'Amico, Domenico, Filippi, Massimo, Altamura, Claudia, and Vernieri, Fabrizio
- Subjects
Adult ,Male ,Calcitonin Gene-Related Peptide Receptor Antagonist ,medicine.medical_specialty ,Visual analogue scale ,Migraine Disorders ,Population ,Analgesic ,Longitudinal Studie ,Sex Factor ,Calcitonin gene-related peptide ,Antibodies, Monoclonal, Humanized ,calcitonin gene-related peptide ,Sex Factors ,Chronic Migraine ,Migraine Disorder ,Calcitonin Gene-Related Peptide Receptor Antagonists ,Interquartile range ,Internal medicine ,Outcome Assessment, Health Care ,sex ,Humans ,Medicine ,long-term treatment ,migraine ,Longitudinal Studies ,education ,allodynia ,education.field_of_study ,business.industry ,Middle Aged ,medicine.disease ,Italy ,Neurology ,Tolerability ,Migraine ,erenumab ,Hyperalgesia ,Chronic Disease ,Female ,Neurology (clinical) ,business ,Human - Abstract
Objective: To evaluate the long-term effectiveness, safety, and tolerability of erenumab in a real-world migraine population, looking for putative predictors of responsiveness. Background: Erenumab proved to be effective, safe, and well tolerated in the prevention of episodic migraine (EM) and chronic migraine (CM) in long-term extension studies of double-blind, placebo-controlled trials in patients with no more than two (EM) or three (CM) prior preventive treatment failures. Methods: A 48-week, multicenter, longitudinal cohort real-life study was conducted at 15headache centers across eight Italian regions between December 20, 2018 and July 31, 2020. We considered all consecutive patients with high-frequency episodic migraine (HFEM) or CM aged 18–65years. Each patient was treated with erenumab 70mg, administered monthly. The dose was switched to 140mg in nonresponders and in responders who had become nonresponders for at least 4weeks. Change in monthly migraine days (MMDs) or monthly headache days (MHDs) at Weeks 45–48 compared with baseline was the primary efficacy endpoint. Secondary endpoints encompassed variation in monthly analgesic intake, achievement of a ≥50%, ≥75%, or 100% reduction in migraine or headache days, and any change in the Visual Analogue Scale (VAS) and Headache Impact Test-6 scores (HIT-6) during the same time interval. Results: A total of 242 patients with migraine received at least one dose of erenumab 70mg and were considered for safety analysis, whereas 221 received a monthly erenumab dose for ≥48weeks and were included in the effectiveness and safety analysis set. All patients had previously been treated unsuccessfully with ≥3migraine-preventive medication classes. From baseline to Weeks 45–48, erenumab treatment reduced MMD by 4.3±5.3(mean±SD) in patients with HFEM, and MHD by 12.8±8.9 (mean±SD) in subjects with CM. VAS and HIT-6scores were decreased by 1.8±1.9 (mean±SD) and 12.3±11 (mean±SD) in HFEM, and by 3.0±2.2 (mean±SD) and 13.1±11.2 (mean±SD) in CM. Median monthly analgesic intake passed from 11.0 (interquartile range [IQR] 10.0–13.0) to 5 (IQR 2.0–8.0) in HFEM and from 20.0 (IQR 15.0–30.0) to 6.0 (IQR 3.8–10.0) in CM. The ≥50% responders were 56.1% (32/57) in HFEM and 75.6% (124/164) in CM; ≥75% responders were 31.6% (18/57) and 44.5% (73/164); and 100% responders were 8.8% (5/57) and 1.2% (2/164), respectively. At Week 48, 83.6% (137/164) of patients with CM had reverted to EM. Erenumab was safe and well tolerated. Responsiveness to erenumab was positively associated with cutaneous allodynia (OR: 5.44, 95% CI: 1.52–19.41; p=0.009) in HFEM. In patients with CM, ≥50% responsiveness was positively associated with male sex (OR: 2.99, 95% CI: 1.03–8.7; p=0.044) and baseline migraine frequency (OR: 1.12, 95% CI: 1.05–1.20; p=0.001) and negatively associated with psychiatric comorbidities (OR: 0.37, 95% CI: 0.15–0.87; p=0.023) and prior treatment failures (OR: 0.77, 95% CI: 0.64–0.92; p=0.004). Conclusions: Long-term (48-week) erenumab treatment provides sustained effectiveness, safety, and tolerability in real-life patients with HFEM or CM with ≥3 prior preventive treatment failures. The dose of 140mg was required in most patients along the study and should be taken into consideration as the starting dose. Allodynia (in HFEM), male sex, and baseline migraine frequency (in CM) might represent positive responsiveness predictors. Conversely, psychiatric comorbidities and multiple prior preventive treatment failures could be negative predictors in patients with CM.
- Published
- 2021
41. Esophageal stenting for benign and malignant disease
- Author
-
Daniel Blero, David Albers, Alessandro Repici, Manol Jovani, Simon Everett, Todd H. Baron, Jeanin E. van Hooft, Eduardo Rodrigues-Pinto, Lorenzo Fuccio, Angels Ginès, László Czakó, Ruben D. van der Bogt, Manon C.W. Spaander, Peter D. Siersema, Juan Carlos García-Pagán, Antonella De Ceglie, Massimo Conio, Spaander M.C.W., Van Der Bogt R.D., Baron T.H., Albers D., Blero D., De Ceglie A., Conio M., Czako L., Everett S., Garcia-Pagan J.-C., Gines A., Jovani M., Repici A., Rodrigues-Pinto E., Siersema P.D., Fuccio L., and Van Hooft J.E.
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,esophagu ,Brachytherapy ,Self Expandable Metallic Stents ,Medizin ,Esophageal and Gastric Varices ,Endoscopy, Gastrointestinal ,Malignant disease ,Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14] ,SDG 3 - Good Health and Well-being ,medicine ,cancer ,Humans ,endoscopy ,Adverse effect ,Feeding tube ,Gastrointestinal endoscopy ,business.industry ,General surgery ,Gastroenterology ,Stent ,Guideline ,Esophageal cancer ,medicine.disease ,benign disease ,stent ,Stents ,Gastrointestinal Hemorrhage ,business - Abstract
Main recommendations Malignant disease 1 ESGE recommends placement of partially or fully covered self-expandable metal stents (SEMSs) for palliation of malignant dysphagia over laser therapy, photodynamic therapy, and esophageal bypass.Strong recommendation, high quality evidence. 2 ESGE recommends brachytherapy as a valid alternative, alone or in addition to stenting, in esophageal cancer patients with malignant dysphagia and expected longer life expectancy.Strong recommendation, high quality evidence. 3 ESGE recommends esophageal SEMS placement for sealing malignant tracheoesophageal or bronchoesophageal fistulas. Strong recommendation, low quality evidence. 4 ESGE does not recommend SEMS placement as a bridge to surgery or before preoperative chemoradiotherapy because it is associated with a high incidence of adverse events. Other options such as feeding tube placement are preferable. Strong recommendation, low quality evidence. Benign disease 5 ESGE recommends against the use of SEMSs as first-line therapy for the management of benign esophageal strictures because of the potential for adverse events, the availability of alternative therapies, and their cost. Strong recommendation, low quality evidence. 6 ESGE suggests consideration of temporary placement of self-expandable stents for refractory benign esophageal strictures. Weak recommendation, moderate quality evidence. 7 ESGE suggests that fully covered SEMSs be preferred over partially covered SEMSs for the treatment of refractory benign esophageal strictures because of their very low risk of embedment and ease of removability. Weak recommendation, low quality evidence. 8 ESGE recommends the stent-in-stent technique to remove partially covered SEMSs that are embedded in the esophageal wall. Strong recommendation, low quality evidence. 9 ESGE recommends that temporary stent placement can be considered for the treatment of leaks, fistulas, and perforations. No specific type of stent can be recommended, and the duration of stenting should be individualized. Strong recommendation, low quality of evidence. 10 ESGE recommends considering placement of a fully covered large-diameter SEMS for the treatment of esophageal variceal bleeding refractory to medical, endoscopic, and/or radiological therapy, or as initial therapy for patients with massive bleeding. Strong recommendation, moderate quality evidence.
- Published
- 2021
42. Mortality from esophagectomy for esophageal cancer across low, middle, and high-income countries: An international cohort study
- Author
-
Kamarajah, Sk, Nepogodiev, D, Bekele, A, Cecconello, I, Evans, Rpt, Guner, A, Gossage, Ja, Harustiak, T, Hodson, J, Isik, A, Kidane, B, Leon-Takahashi, Am, Mahendran, Ha, Negoi, I, Okonta, Ke, Rosero, G, Sayyed, Rh, Singh, P, Takeda, Fr, van Hillegersberg, R, Vohra, Rs, White, Re, Griffiths, Ea, Alderson, D, Bundred, J, Gossage, J, Jefferies, B, Mckay, S, Mohamed, I, Siaw-Acheampong, K, Vohra, R, Wanigasooriya, K, Whitehouse, T, Gjata, A, Moreno, Ji, Guevara, Cr, Kechagias, A, Gockel, I, Kennedy, A, Da Roit, A, Bagajevas, A, Azagra, Js, Mejia-Fernandez, L, Wijnhoven, Bpl, El Kafsi, J, Sousa, M, Sampaio, As, Blanco, R, Wallner, B, Schneider, Pm, Hsu, Pk, Gananadha, S, Wills, V, Devadas, M, Duong, C, Talbot, M, Hii, Mw, Jacobs, R, Andreollo, Na, Johnston, B, Darling, G, Isaza-Restrepo, A, Arias-Amezquita, F, Raptis, D, Gaedcke, J, Reim, D, Izbicki, J, Egberts, Jh, Dikinis, S, Kjaer, Dw, Larsen, Mh, Achiam, Mp, Saarnio, J, Theodorou, D, Liakakos, T, Korkolis, Dp, Robb, Wb, Collins, C, Murphy, T, Reynolds, J, Tonini, V, Migliore, M, Bonavina, L, Valmasoni, M, Bardini, R, Weindelmayer, J, Terashima, M, Alghunaim, E, Elhadi, M, Medina-Franco, H, Lau, Pc, Heisterkamp, J, Rosman, C, Beban, G, Babor, R, Gordon, A, Rossaak, Ji, Pal, Kmi, Qureshi, Au, Naqi, Sa, Syed, Aa, Barbosa, J, Vicente, Cs, Leite, J, Freire, J, Casaca, R, Costa, Rct, Scurtu, Rr, Mogoanta, Ss, Bolca, C, Constantinoiu, S, Sekhniaidze, D, Bjelovic, M, Jby, So, Gacevski, G, Loureiro, C, Pera, M, Bianchi, A, Moreno, Gm, Fernandez, Jm, Carrera, Mst, Vallve-Bernal, M, Pascual, Mac, Elmahi, S, Halldestam, I, Hedberg, J, Monig, S, Gutknecht, S, Tez, M, Tirnaksiz, Mb, Colak, E, Sevinc, B, Hindmarsh, A, Khan, I, Khoo, D, Byrom, R, Gokhale, J, Wilkerson, P, Jain, P, Chan, D, Robertson, K, Iftikhar, S, Skipworth, R, Forshaw, M, Higgs, S, Nijjar, R, Viswanath, Yks, Turner, P, Dexter, S, Boddy, A, Allum, Wh, Oglesby, S, Cheong, E, Beardsmore, D, Maynard, N, Berrisford, R, Mercer, S, Puigt, S, Melhadot, R, Kelty, C, Underwood, T, Dawas, K, Lewis, W, Al-Bahrani, A, Bryce, G, Thomas, M, Arndt, At, Palazzo, F, Meguid, Ra, Fergusson, J, Beenen, E, Mosse, C, Salim, J, Cheah, S, Wright, T, Cerdeira, Mp, Mcquillan, P, Richardson, M, Liem, H, Spillane, J, Yacob, M, Albadawi, F, Thorpe, T, Dingle, A, Cabalag, C, Loi, K, Fisher, Om, Ward, S, Read, M, Johnson, M, Bassari, R, Bui, H, Sallum, Raa, da Rocha, Jrm, Lopes, Lr, Tercioti, V, Coelho, Jd, Ferrer, Jap, Buduhan, G, Tan, L, Srinathan, S, Shea, P, Yeung, J, Allison, F, Carroll, P, Vargas-Barato, F, Gonzalez, F, Ortega, J, Nino-Torres, L, Beltran-Garcia, Tc, Castilla, L, Pineda, M, Bastidas, A, Gomez-Mayorga, J, Cortes, N, Cetares, C, Caceres, S, Duarte, S, Pazdro, A, Snajdauf, M, Faltova, H, Sevcikova, M, Mortensen, Pb, Katballe, N, Ingemann, T, Morten, B, Kruhlikava, I, Ainswort, Ap, Stilling, Nm, Eckardt, J, Holm, J, Thorsteinsson, M, Siemsen, M, Brandt, B, Nega, B, Teferra, E, Tizazu, A, Kauppila, Jh, Koivukangas, V, Merilainen, S, Gruetzmann, R, Krautz, C, Weber, G, Golcher, H, Emons, G, Azizian, A, Ebeling, M, Niebisch, S, Kreuser, N, Albanese, G, Hesse, J, Volovnik, L, Boecher, U, Reeh, M, Triantafyllou, S, Schizas, D, Michalinos, A, Mpali, E, Mpoura, M, Charalabopoulos, A, Manatakis, Dk, Balalis, D, Bolger, J, Baban, C, Mastrosimone, A, Mcanena, O, Quinn, A, Suilleabhain, Cbo, Hennessy, Mm, Ivanovski, I, Khizer, H, Ravi, N, Donlon, N, Cervellera, M, Vaccari, S, Bianchini, S, Sartarelli, L, Asti, E, Bernardi, D, Merigliano, S, Provenzano, L, Scarpa, M, Saadeh, L, Salmaso, B, De Manzoni, G, Giacopuzzi, S, La Mendola, R, De Pasqual, Ca, Tsubosa, Y, Niihara, M, Irino, T, Makuuchi, R, Ishii, K, Mwachiro, M, Fekadu, A, Odera, A, Mwachiro, E, Alshehab, D, Ahmed, Ha, Shebani, Ao, Elhadi, A, Elnagar, Fa, Elnagar, Hf, Makkai-Popa, St, Wong, Lf, Tan, Yr, Thannimalai, S, Ca, Ho, Pang, Ws, Tan, Jh, Basave, Hnl, Cortes-Gonzalez, R, Lagarde, Sm, van Lanschot, Jjb, Cords, C, Jansen, Wa, Martijnse, I, Matthijsen, R, Bouwense, S, Klarenbeek, B, Verstegen, M, van Workum, F, Ruurda, Jp, van der Sluis, Pc, de Maat, M, Evenett, N, Johnston, P, Patel, R, Maccormick, A, Young, M, Smith, B, Ekwunife, C, Memon, Ah, Shaikh, K, Wajid, A, Khalil, N, Haris, M, Mirza, Zu, Qudus, Sba, Sarwar, Mz, Shehzadi, A, Raza, A, Jhanzaib, Mh, Farmanali, J, Zakir, Z, Shakeel, O, Nasir, I, Khattak, S, Baig, M, Noor, Ma, Ahmed, Hh, Naeem, A, Pinho, Ac, da Silva, R, Bernardes, A, Campos, Jc, Matos, H, Braga, T, Monteiro, C, Ramos, P, Cabral, F, Gomes, Mp, Martins, Pc, Correia, Am, Videira, Jf, Ciuce, C, Drasovean, R, Apostu, R, Paitici, S, Racu, Ae, Obleaga, Cv, Beuran, M, Stoica, B, Ciubotaru, C, Negoita, V, Cordos, I, Birla, Rd, Predescu, D, Hoara, Pa, Tomsa, R, Shneider, V, Agasiev, M, Ganjara, I, Gunjic, D, Veselinovic, M, Babic, T, Chin, Ts, Shabbir, A, Kim, G, Crnjac, A, Samo, H, Del Val, Id, Leturio, S, Ramon, Jm, Dal Cero, M, Rifa, S, Rico, M, Pomar, Ap, Corcoles, Jam, Miravalles, Jlr, Pais, Sa, Turienzo, Sa, Alvarezt, Ls, Alvarez, Ls, Campos, Pv, Rendo, Ag, Garcia, Ss, Santos, Epg, Martinez, Et, Fernandez, Dm, Magadan, Ac, Concepcion, Mv, Diaz, Lc, Rosat, Ra, Perez, Sle, Bailon, Cm, Tinoco, Cc, Bhojwani, Ec, Sanchez, Dp, Ahmed, Me, Dzhendov, T, Lindberg, F, Rutegard, M, Sundbom, M, Mickael, C, Colucci, N, Schnider, A, Er, S, Kurnaz, E, Turkyilmaz, S, Turkyilmaz, A, Yildirim, R, Baki, Be, Akkapulu, N, Karahan, O, Damburaci, N, Hardwickt, R, Safranek, P, Sujendran, V, Bennett, J, Afzal, Z, Shrotri, M, Chan, B, Exarchou, K, Gilbert, T, Amalesh, T, Mukherjee, D, Mukherjee, S, Wiggins, Th, Kennedy, R, Mccain, S, Harris, A, Dobson, G, Davies, N, Wilson, I, Mayo, D, Bennett, D, Young, R, Manby, P, Blencowe, N, Schiller, M, Byrne, B, Mitton, D, Wong, V, Elshaer, A, Cowen, M, Menon, V, Tan, Lc, Mclaughlin, E, Koshy, R, Sharp, C, Brewer, H, Das, N, Cox, M, Al Khyatt, W, Worku, D, Iqbal, R, Walls, L, Mcgregor, R, Fullarton, G, Macdonald, A, Mackay, C, Craig, C, Dwerryhouse, S, Hornby, S, Jaunoo, S, Wadley, M, Baker, C, Saad, M, Kelly, M, Davies, A, Di Maggio, F, Mistry, P, Singhal, R, Tucker, O, Kapoulas, S, Powell-Brett, S, Davis, P, Bromley, G, Watson, L, Verma, R, Ward, J, Shetty, V, Ball, C, Pursnani, K, Sarela, A, Sue, Lh, Mehta, S, Hayden, J, To, N, Palser, T, Hunter, D, Supramaniam, K, Butt, Z, Ahmed, A, Kumar, S, Chaudry, A, Moussa, O, Kordzadeh, A, Lorenzi, B, Wilson, M, Patil, P, Noaman, I, Willem, J, Bouras, G, Evans, R, Singh, M, Warrilow, H, Ahmad, A, Tewari, N, Yanni, F, Couch, J, Theophilidou, E, Reilly, Jj, van Boxel, G, Akbari, K, Zanotti, D, Sgromo, B, Sanders, G, Wheatley, T, Ariyarathenam, A, Reece-Smith, A, Humphreys, L, Choh, C, Carter, N, Knight, B, Pucher, P, Athanasiou, A, Tan, B, Abdulrahman, M, Vickers, J, Akhtar, K, Chaparala, R, Brown, R, Alasmar, Mma, Ackroyd, R, Patel, K, Tamhankar, A, Wyman, A, Walker, R, Grace, B, Abbassi, N, Slim, N, Ioannidi, L, Blackshaw, G, Havard, T, Escofet, X, Powell, A, Owera, A, Rashid, F, Jambulingam, P, Padickakudi, J, Ben-Younes, H, Mccormack, K, Makey, Ia, Karush, Mk, Seder, Cw, Liptay, Mj, Chmielewski, G, Rosato, El, Berger, Ac, Zheng, R, Okolo, E, Singh, A, Scott, Cd, Weyant, Mj, Mitchell, Jd, Moenig, Stefan Paul, Kamarajah S.K., Nepogodiev D., Bekele A., Cecconello I., Evans R.P.T., Guner A., Gossage J.A., Harustiak T., Hodson J., Isik A., Kidane B., Leon-Takahashi A.M., Mahendran H.A., Negoi I., Okonta K.E., Rosero G., Sayyed R.H., Singh P., Takeda F.R., van Hillegersberg R., Vohra R.S., White R.E., Griffiths E.A., Alderson D., Bundred J., Gossage J., Jefferies B., McKay S., Mohamed I., Siaw- Acheampong K., Vohra R., Wanigasooriya K., Whitehouse T., Gjata A., Moreno J.I., Guevara C.R., Kechagias A., Gockel I., Kennedy A., Da Roit A., Bagajevas A., Azagra J.S., Mejia-Fernandez L., Wijnhoven B.P.L., El Kafsi J., Sousa M., Sampaio A.S., Blanco R., Wallner B., Schneider P.M., Hsu P.K., Gananadha S., Wills V., Devadas M., Duong C., Talbot M., Hii M.W., Jacobs R., Andreollo N.A., Johnston B., Darling G., Isaza-Restrepo A., Arias- Amezquita F., Raptis D., Gaedcke J., Reim D., Izbicki J., Egberts J.H., Dikinis S., Kjaer D.W., Larsen M.H., Achiam M.P., Saarnio J., Theodorou D., Liakakos T., Korkolis D.P., Robb W.B., Collins C., Murphy T., Reynolds J., Tonini V., Migliore M., Bonavina L., Valmasoni M., Bardini R., Weindelmayer J., Terashima M., Alghunaim E., Elhadi M., Medina-Franco H., Lau P.C., Heisterkamp J., Rosman C., Beban G., Babor R., Gordon A., Rossaak J.I., Pal K.M.I., Qureshi A.U., Naqi S.A., Syed A.A., Barbosa J., Vicente C.S., Leite J., Freire J., Casaca R., Costa R.C.T., Scurtu R.R., Mogoanta S.S., Bolca C., Constantinoiu S., Sekhniaidze D., Bjelovic M., So J.B.Y., Gacevski G., Loureiro C., Pera M., Bianchi A., Moreno G.M., Martin Fernandez J., Trugeda Carrera M.S., Vallve-Bernal M., Citores Pascual M.A., Elmahi S., Halldestam I., Hedberg J., Monig S., Gutknecht S., Tez M., Tirnaksiz M.B., Colak E., Sevinc B., Hindmarsh A., Khan I., Khoo D., Byrom R., Gokhale J., Wilkerson P., Jain P., Chan D., Robertson K., Iftikhar S., Skipworth R., Forshaw M., Higgs S., Nijjar R., Viswanath Y.K.S., Turner P., Dexter S., Boddy A., Allum W.H., Oglesby S., Cheong E., Beardsmore D., Maynard N., Berrisford R., Mercer S., Puig S., Melhado R., Kelty C., Underwood T., Dawas K., Lewis W., Al-Bahrani A., Bryce G., Thomas M., Arndt A.T., Palazzo F., Meguid R.A., Fergusson J., Beenen E., Mosse C., Salim J., Cheah S., Wright T., Cerdeira M.P., McQuillan P., Richardson M., Liem H., Spillane J., Yacob M., Albadawi F., Thorpe T., Dingle A., Cabalag C., Loi K., Fisher O.M., Ward S., Read M., Johnson M., Bassari R., Bui H., Sallum R.A.A., da Rocha J.R.M., Lopes L.R., Tercioti V., Coelho J.D., Ferrer J.A.P., Buduhan G., Tan L., Srinathan S., Shea P., Yeung J., Allison F., Carroll P., Vargas-Barato F., Gonzalez F., Ortega J., Nino-Torres L., Beltran-Garcia T.C., Castilla L., Pineda M., Bastidas A., Gomez-Mayorga J., Cortes N., Cetares C., Caceres S., Duarte S., Pazdro A., Snajdauf M., Faltova H., Sevcikova M., Mortensen P.B., Katballe N., Ingemann T., Morten B., Kruhlikava I., Ainswort A.P., Stilling N.M., Eckardt J., Holm J., Thorsteinsson M., Siemsen M., Brandt B., Nega B., Teferra E., Tizazu A., Kauppila J.H., Koivukangas V., Merilainen S., Gruetzmann R., Krautz C., Weber G., Golcher H., Emons G., Azizian A., Ebeling M., Niebisch S., Kreuser N., Albanese G., Hesse J., Volovnik L., Boecher U., Reeh M., Triantafyllou S., Schizas D., Michalinos A., Mpali E., Mpoura M., Charalabopoulos A., Manatakis D.K., Balalis D., Bolger J., Baban C., Mastrosimone A., McAnena O., Quinn A., O Suilleabhain C.B., Hennessy M.M., Ivanovski I., Khizer H., Ravi N., Donlon N., Cervellera M., Vaccari S., Bianchini S., Sartarelli L., Asti E., Bernardi D., Merigliano S., Provenzano L., Scarpa M., Saadeh L., Salmaso B., De Manzoni G., Giacopuzzi S., La Mendola R., De Pasqual C.A., Tsubosa Y., Niihara M., Irino T., Makuuchi R., Ishii K., Mwachiro M., Fekadu A., Odera A., Mwachiro E., AlShehab D., Ahmed H.A., Shebani A.O., Elhadi A., Elnagar F.A., Elnagar H.F., Makkai-Popa S.T., Wong L.F., Tan Y.R., Thannimalai S., Ho C.A., Pang W.S., Tan J.H., Basave H.N.L., Cortes-Gonzalez R., Lagarde S.M., van Lanschot J.J.B., Cords C., Jansen W.A., Martijnse I., Matthijsen R., Bouwense S., Klarenbeek B., Verstegen M., van Workum F., Ruurda J.P., van der Sluis P.C., de Maat M., Evenett N., Johnston P., Patel R., MacCormick A., Young M., Smith B., Ekwunife C., Memon A.H., Shaikh K., Wajid A., Khalil N., Haris M., Mirza Z.U., Qudus S.B.A., Sarwar M.Z., Shehzadi A., Raza A., Jhanzaib M.H., Farmanali J., Zakir Z., Shakeel O., Nasir I., Khattak S., Baig M., Noor M.A., Ahmed H.H., Naeem A., Pinho A.C., da Silva R., Bernardes A., Campos J.C., Matos H., Braga T., Monteiro C., Ramos P., Cabral F., Gomes M.P., Martins P.C., Correia A.M., Videira J.F., Ciuce C., Drasovean R., Apostu R., Paitici S., Racu A.E., Obleaga C.V., Beuran M., Stoica B., Ciubotaru C., Negoita V., Cordos I., Birla R.D., Predescu D., Hoara P.A., Tomsa R., Shneider V., Agasiev M., Ganjara I., Gunjic D., Veselinovic M., Babic T., Chin T.S., Shabbir A., Kim G., Crnjac A., Samo H., Diez del Val I., Leturio S., Ramon J.M., Dal Cero M., Rifa S., Rico M., Pagan Pomar A., Martinez Corcoles J.A., Rodicio Miravalles J.L., Pais S.A., Turienzo S.A., Alvarez L.S., Campos P.V., Rendo A.G., Garcia S.S., Santos E.P.G., Martinez E.T., Fernandez D.M., Magadan A.C., Concepcion M.V., Diaz L.C., Rosat R.A., Perez S.L., Bailon C.M., Tinoco C.C., Choolani Bhojwani E., Sanchez D.P., Ahmed M.E., Dzhendov T., Lindberg F., Rutegard M., Sundbom M., Mickael C., Colucci N., Schnider A., Er S., Kurnaz E., Turkyilmaz S., Turkyilmaz A., Yildirim R., Baki B.E., Akkapulu N., Karahan O., Damburaci N., Hardwick R., Safranek P., Sujendran V., Bennett J., Afzal Z., Shrotri M., Chan B., Exarchou K., Gilbert T., Amalesh T., Mukherjee D., Mukherjee S., Wiggins T.H., Kennedy R., McCain S., Harris A., Dobson G., Davies N., Wilson I., Mayo D., Bennett D., Young R., Manby P., Blencowe N., Schiller M., Byrne B., Mitton D., Wong V., Elshaer A., Cowen M., Menon V., Tan L.C., McLaughlin E., Koshy R., Sharp C., Brewer H., Das N., Cox M., Al Khyatt W., Worku D., Iqbal R., Walls L., McGregor R., Fullarton G., Macdonald A., MacKay C., Craig C., Dwerryhouse S., Hornby S., Jaunoo S., Wadley M., Baker C., Saad M., Kelly M., Davies A., Di Maggio F., Mistry P., Singhal R., Tucker O., Kapoulas S., Powell-Brett S., Davis P., Bromley G., Watson L., Verma R., Ward J., Shetty V., Ball C., Pursnani K., Sarela A., Sue L.H., Mehta S., Hayden J., To N., Palser T., Hunter D., Supramaniam K., Butt Z., Ahmed A., Kumar S., Chaudry A., Moussa O., Kordzadeh A., Lorenzi B., Wilson M., Patil P., Noaman I., Willem J., Bouras G., Evans R., Singh M., Warrilow H., Ahmad A., Tewari N., Yanni F., Couch J., Theophilidou E., Reilly J.J., van Boxel G., Akbari K., Zanotti D., Sgromo B., Sanders G., Wheatley T., Ariyarathenam A., Reece-Smith A., Humphreys L., Choh C., Carter N., Knight B., Pucher P., Athanasiou A., Tan B., Abdulrahman M., Vickers J., Akhtar K., Chaparala R., Brown R., Alasmar M.M.A., Ackroyd R., Patel K., Tamhankar A., Wyman A., Walker R., Grace B., Abbassi N., Slim N., Ioannidi L., Blackshaw G., Havard T., Escofet X., Powell A., Owera A., Rashid F., Jambulingam P., Padickakudi J., Ben-Younes H., Mccormack K., Makey I.A., Karush M.K., Seder C.W., Liptay M.J., Chmielewski G., Rosato E.L., Berger A.C., Zheng R., Okolo E., Singh A., Scott C.D., Weyant M.J., Mitchell J.D., and Surgery
- Subjects
Male ,Esophageal Neoplasms ,SURGERY ,IMPACT ,medicine.medical_treatment ,Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14] ,0302 clinical medicine ,FAILURE ,Postoperative Period ,Prospective Studies ,030212 general & internal medicine ,Prospective cohort study ,Generalized estimating equation ,COMPLICATIONS ,ddc:617 ,Anastomosis, Surgical ,General Medicine ,Middle Aged ,Esophageal cancer ,Reconstructive and regenerative medicine Radboud Institute for Molecular Life Sciences [Radboudumc 10] ,HOSPITAL VOLUME ,Oncology ,Esophagectomy ,030220 oncology & carcinogenesis ,Anastomotic leak ,Global surgery ,Postoperative mortality ,Female ,Cohort study ,Adult ,medicine.medical_specialty ,Necrosis ,03 medical and health sciences ,All institutes and research themes of the Radboud University Medical Center ,Esophagus ,SDG 3 - Good Health and Well-being ,Internal medicine ,medicine ,Humans ,Developing Countries ,Aged ,business.industry ,Developed Countries ,Cancer ,Odds ratio ,GLOBAL BURDEN ,RESCUE ,medicine.disease ,Confidence interval ,Surgery ,business - Abstract
Background: No evidence currently exists characterising global outcomes following major cancer surgery, including esophageal cancer. Therefore, this study aimed to characterise impact of high income countries (HIC) versus low and middle income countries (LMIC) on the outcomes following esophagectomy for esophageal cancer.Method: This international multi-center prospective study across 137 hospitals in 41 countries included patients who underwent an esophagectomy for esophageal cancer, with 90-day follow-up. The main explanatory variable was country income, defined according to the World Bank Data classification. The primary outcome was 90-day postoperative mortality, and secondary outcomes were composite leaks (anastomotic leak or conduit necrosis) and major complications (Clavien-Dindo Grade III - V). Multivariable generalized estimating equation models were used to produce adjusted odds ratios (ORs) and 95% confidence intervals (CI95%).Results: Between April 2018 to December 2018, 2247 patients were included. Patients from HIC were more significantly older, with higher ASA grade, and more advanced tumors. Patients from LMIC had almost three-fold increase in 90-day mortality, compared to HIC (9.4% vs 3.7%, p < 0.001). On adjusted analysis, LMIC were independently associated with higher 90-day mortality (OR: 2.31, CI95%: 1.17-4.55, p = 0.015). However, LMIC were not independently associated with higher rates of anastomotic leaks (OR: 1.06, CI95%: 0.57-1.99, p = 0.9) or major complications (OR: 0.85, CI95%: 0.54-1.32, p = 0.5), compared to HIC.Conclusion: Resections in LMIC were independently associated with higher 90-day postoperative mortality, likely reflecting a failure to rescue of these patients following esophagectomy, despite similar composite anastomotic leaks and major complication rates to HIC. These findings warrant further research, to identify potential issues and solutions to improve global outcomes following esophagectomy for cancer.
- Published
- 2021
43. Association of polygenic score for major depression with response to lithium in patients with bipolar disorder
- Author
-
Amare, Azmeraw T., Schubert, Klaus Oliver, Hou, Liping, Clark, Scott R., Papiol, Sergi, Cearns, Micah, Heilbronner, Urs, Degenhardt, Franziska, Tekola-Ayele, Fasil, Hsu, Yi Hsiang, Shekhtman, Tatyana, Adli, Mazda, Akula, Nirmala, Akiyama, Kazufumi, Ardau, Raffaella, Arias, Bárbara, Aubry, Jean Michel, Backlund, Lena, Bhattacharjee, Abesh Kumar, Bellivier, Frank, Benabarre, Antonio, Bengesser, Susanne, Biernacka, Joanna M., Birner, Armin, Brichant-Petitjean, Clara, Cervantes, Pablo, Chen, Hsi Chung, Chillotti, Caterina, Cichon, Sven, Cruceanu, Cristiana, Czerski, Piotr M., Dalkner, Nina, Dayer, Alexandre, Del Zompo, Maria, DePaulo, J. Raymond, Étain, Bruno, Jamain, Stephane, Falkai, Peter, Forstner, Andreas J., Frisen, Louise, Frye, Mark A., Fullerton, Janice M., Gard, Sébastien, Garnham, Julie S., Goes, Fernando S., Grigoroiu-Serbanescu, Maria, Grof, Paul, Hashimoto, Ryota, Hauser, Joanna, Herms, Stefan, Hoffmann, Per, Hofmann, Andrea, Jiménez, Esther, Kahn, Jean Pierre, Kassem, Layla, Kuo, Po Hsiu, Kato, Tadafumi, Kelsoe, John R., Kittel-Schneider, Sarah, Kliwicki, Sebastian, König, Barbara, Kusumi, Ichiro, Laje, Gonzalo, Landén, Mikael, Lavebratt, Catharina, Leboyer, Marion, Leckband, Susan G., Tortorella, Alfonso, Manchia, Mirko, Martinsson, Lina, McCarthy, Michael J., McElroy, Susan L., Colom, Francesc, Mitjans, Marina, Mondimore, Francis M., Monteleone, Palmiero, Nievergelt, Caroline M., Nöthen, Markus M., Novák, Tomas, O’Donovan, Claire, Ozaki, Norio, Ösby, Urban, Pfennig, Andrea, Potash, James B., Reif, Andreas, Wray, Naomi R., Ripke, Stephan, Mattheisen, Manuel, Trzaskowski, Maciej, Byrne, Enda M., Abdellaoui, Abdel, Adams, Mark J., Agerbo, Esben, Air, Tracy M., Andlauer, Till F.M., Bacanu, Silviu Alin, Bækvad-Hansen, Marie, Beekman, Aartjan T.F., Bigdeli, Tim B., Binder, Elisabeth B., Blackwood, Douglas H.R., Bryois, Julien, Buttenschøn, Henriette N., Bybjerg-Grauholm, Jonas, Cai, Na, Castelao, Enrique, Christensen, Jane varregaard, Clarke, Toni Kim, Coleman, Jonathan R.I., Colodro-Conde, Lucía, Couvy-Duchesne, Baptiste, Craddock, Nick, Crawford, Gregory E., Davies, Gail, Deary, Ian J., Derks, Eske M., Direk, Nese, Dolan, Conor V., Dunn, Erin C., Eley, Thalia C., Escott-Price, Valentina, Kiadeh, Farnush Farhadi Hassan, Finucane, Hilary K., Frank, Josef, Gaspar, Héléna A., Gill, Michael, Gordon, Scott D., Grove, Jakob, Hall, Lynsey S., Hansen, Christine Søholm, Hansen, Thomas F., Hickie, Ian B., Homuth, Georg, Horn, Carsten, Hottenga, Jouke Jan, Hougaard, David M., Ising, Marcus, Jansen, Rick, Jorgenson, Eric, Knowles, James A., Kohane, Isaac S., Kraft, Julia, Kretzschmar, Warren W., Krogh, Jesper, Kutalik, Zoltán, Li, Yihan, Lind, Penelope A., MacIntyre, Donald J., MacKinnon, Dean F., Maier, Robert M., Maier, Wolfgang, Marchini, Jonathan, Mbarek, Hamdi, McGrath, Patrick, McGuffin, Peter, Medland, Sarah E., Mehta, Divya, Middeldorp, Christel M., Mihailov, Evelin, Milaneschi, Yuri, Milani, Lili, Montgomery, Grant W., Mostafavi, Sara, Mullins, Niamh, Nauck, Matthias, Ng, Bernard, Nivard, Michel G., Nyholt, Dale R., O’Reilly, Paul F., Oskarsson, Hogni, Owen, Michael J., Painter, Jodie N., Pedersen, Carsten Bøcker, Pedersen, Marianne Giørtz, Peterson, Roseann E., Pettersson, Erik, Peyrot, Wouter J., Pistis, Giorgio, Posthuma, Danielle, Quiroz, Jorge A., Qvist, Per, Rice, John P., Riley, Brien P., Rivera, Margarita, Mirza, Saira Saeed, Schoevers, Robert, Schulte, Eva C., Shen, Ling, Shi, Jianxin, Shyn, Stanley I., Sigurdsson, Engilbert, Sinnamon, Grant C.B., Smit, Johannes H., Smith, Daniel J., Stefansson, Hreinn, Steinberg, Stacy, Streit, Fabian, Strohmaier, Jana, Tansey, Katherine E., Teismann, Henning, Teumer, Alexander, Thompson, Wesley, Thomson, Pippa A., Thorgeirsson, Thorgeir E., Traylor, Matthew, Treutlein, Jens, Trubetskoy, Vassily, Uitterlinden, André G., Umbricht, Daniel, Van der Auwera, Sandra, van Hemert, Albert M., Viktorin, Alexander, Visscher, Peter M., Wang, Yunpeng, Webb, Bradley T., Weinsheimer, Shantel Marie, Wellmann, Jürgen, Willemsen, Gonneke, Witt, Stephanie H., Wu, Yang, Xi, Hualin S., Yang, Jian, Zhang, Futao, Arolt, Volker, Baune, Bernhard T., Berger, Klaus, Boomsma, Dorret I., Dannlowski, Udo, de Geus, E. J.C., Domenici, Enrico, Domschke, Katharina, Esko, Tõnu, Grabe, Hans J., Hamilton, Steven P., Hayward, Caroline, Heath, Andrew C., Kendler, Kenneth S., Kloiber, Stefan, Lewis, Glyn, Li, Qingqin S., Lucae, Susanne, Madden, Pamela A.F., Magnusson, Patrik K., Martin, Nicholas G., McIntosh, Andrew M., Metspalu, Andres, Mors, Ole, Mortensen, Preben Bo, Müller-Myhsok, Bertram, Nordentoft, Merete, O’Donovan, Michael C., Paciga, Sara A., Pedersen, Nancy L., Penninx, Brenda W.J.H., Perlis, Roy H., Porteous, David J., Preisig, Martin, Rietschel, Marcella, Schaefer, Catherine, Schulze, Thomas G., Smoller, Jordan W., Stefansson, Kari, Tiemeier, Henning, Uher, Rudolf, Völzke, Henry, Weissman, Myrna M., Werge, Thomas, Lewis, Cathryn M., Levinson, Douglas F., Breen, Gerome, Børglum, Anders D., Sullivan, Patrick F., Reininghaus, Eva, Rouleau, Guy A., Rybakowski, Janusz K., Schalling, Martin, Schofield, Peter R., Schweizer, Barbara W., Severino, Giovanni, Shilling, Paul D., Shimoda, Katzutaka, Simhandl, Christian, Slaney, Claire M., Squassina, Alessio, Stamm, Thomas, Stopkova, Pavla, Maj, Mario, Turecki, Gustavo, Vieta, Eduard, Veeh, Julia, Wright, Adam, Zandi, Peter P., Mitchell, Philip B., Bauer, Michael, Alda, Martin, McMahon, Francis J., APH - Mental Health, Amsterdam Neuroscience - Mood, Anxiety, Psychosis, Stress & Sleep, Psychiatry, Amsterdam Neuroscience - Complex Trait Genetics, Amsterdam Reproduction & Development (AR&D), Amsterdam Neuroscience - Compulsivity, Impulsivity & Attention, Amsterdam Neuroscience - Cellular & Molecular Mechanisms, Human genetics, APH - Digital Health, APH - Methodology, Biological Psychology, APH - Personalized Medicine, APH - Health Behaviors & Chronic Diseases, Complex Trait Genetics, Clinical Cognitive Neuropsychiatry Research Program (CCNP), Interdisciplinary Centre Psychopathology and Emotion regulation (ICPE), Jamain, Stéphane, University of Adelaide, South Australian Health and Medical Research Institute [ Adelaide] (SAHMRI), Mental Health Services [Adelaide, SA, Australia], National Institute of Mental Health (NIMH), Ludwig Maximilian University [Munich] (LMU), Georg-August-University = Georg-August-Universität Göttingen, Institut für Genetik - Universität Bonn / Institute of Genetics - University of Bonn, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Harvard Medical School [Boston] (HMS), Harvard School of Public Health, University of California [San Diego] (UC San Diego), University of California (UC), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Dokkyo Medical University, Università degli Studi di Cagliari = University of Cagliari (UniCa), Universitat Autònoma de Barcelona (UAB), Centro de Investigación Biomédica en Red de Salud Mental [Barcelona, Spain] (CIBERSAM), Hospital Sant Joan de Déu [Barcelona], Geneva University Hospital (HUG), Karolinska Institutet [Stockholm], Karolinska University Hospital [Stockholm], Optimisation thérapeutique en Neuropsychopharmacologie (OPTeN (UMR_S_1144 / U1144)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Karl-Franzens-Universität Graz, Mayo Clinic [Rochester], McGill University Health Center [Montreal] (MUHC), National Taiwan University [Taiwan] (NTU), University Hospital Basel [Basel], Poznan University of Medical Sciences [Poland] (PUMS), Johns Hopkins University (JHU), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Fondation FondaMental [Créteil], IMRB - 'Neuropsychiatrie translationnelle' [Créteil] (U955 Inserm - UPEC), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), University of Basel (Unibas), Neuroscience Research Australia [Sydney, NSW, Australia] (NRA), University of New South Wales [Sydney] (UNSW), Psychiatrie de l'enfant et de l'adolescent [CH C. Perrens, Bordeaux], SECOP - centre hospitalier Charles Perrens, Dalhousie University [Halifax], 'Prof. Dr. Alexandru Obregia' Clinical Hospital of Psychiatry [Bucharest, Romania], Mood Disorders Center of Ottawa (MDCO), University of Ottawa [Ottawa], Osaka University [Osaka], Graduate School of Medicine [Osaka], Centro de Investigación Biomédica en Red Salud Mental [Madrid] (CIBER-SAM), Psychiatrie et Psychologie Clinique de Liaison [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Psychothérapique de Nancy (CPN), National Institutes of Health [Bethesda] (NIH), Environmental Molecular Biology Laboratory (RIKEN), RIKEN - Institute of Physical and Chemical Research [Japon] (RIKEN), Goethe-University Frankfurt am Main, Landesklinikum Neunkirchen (LK Neunkirchen), Hokkaido University Graduate School of Medicine [Sapporo, Japan], Sahlgrenska Academy at University of Gothenburg [Göteborg], Research Service VA San Diego Healthcare System, Università degli Studi di Perugia = University of Perugia (UNIPG), University of Cincinnati (UC), IMIM-Hospital del Mar, Generalitat de Catalunya, Max Planck Institute of Experimental Medicine [Göttingen] (MPI), Max-Planck-Gesellschaft, University of Salerno (UNISA), University of the Study of Campania Luigi Vanvitelli, National Institute of Mental Health [Klecany, Czech Republic] (NIMH), Nagoya University Graduate School of Medicine [Japon], Technische Universität Dresden = Dresden University of Technology (TU Dresden), Medical University Graz, Montreal Neurological Institute and Hospital, McGill University = Université McGill [Montréal, Canada], Sigmund Freud University (SFU), Douglas Mental Health University Institute [Montréal], University of Heidelberg, Medical Faculty, Black Dog Institute [Sydney, Australia], Johns Hopkins Bloomberg School of Public Health [Baltimore], Westfälische Wilhelms-Universität Münster = University of Münster (WWU), Melbourne Medical School [Melbourne], Faculty of Medicine, Dentistry and Health Sciences [Melbourne], University of Melbourne-University of Melbourne, The Florey Institute of Neuroscience and Mental Health [Parkville, VIC, Australie], University of Melbourne, Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium: Naomi R Wray, Stephan Ripke, Manuel Mattheisen, Maciej Trzaskowski, Enda M Byrne, Abdel Abdellaoui, Mark J Adams, Esben Agerbo, Tracy M Air, Till F M Andlauer, Silviu-Alin Bacanu, Marie Bækvad-Hansen, Aartjan T F Beekman, Tim B Bigdeli, Elisabeth B Binder, Douglas H R Blackwood, Julien Bryois, Henriette N Buttenschøn, Jonas Bybjerg-Grauholm, Na Cai, Enrique Castelao, Jane Varregaard Christensen, Toni-Kim Clarke, Jonathan R I Coleman, Lucía Colodro-Conde, Baptiste Couvy-Duchesne, Nick Craddock, Gregory E Crawford, Gail Davies, Ian J Deary, Franziska Degenhardt, Eske M Derks, Nese Direk, Conor V Dolan, Erin C Dunn, Thalia C Eley, Valentina Escott-Price, Farnush Farhadi Hassan Kiadeh, Hilary K Finucane, Andreas J Forstner, Josef Frank, Héléna A Gaspar, Michael Gill, Fernando S Goes, Scott D Gordon, Jakob Grove, Lynsey S Hall, Christine Søholm Hansen, Thomas F Hansen, Stefan Herms, Ian B Hickie, Per Hoffmann, Georg Homuth, Carsten Horn, Jouke-Jan Hottenga, David M Hougaard, Marcus Ising, Rick Jansen, Eric Jorgenson, James A Knowles, Isaac S Kohane, Julia Kraft, Warren W Kretzschmar, Jesper Krogh, Zoltán Kutalik, Yihan Li, Penelope A Lind, Donald J MacIntyre, Dean F MacKinnon, Robert M Maier, Wolfgang Maier, Jonathan Marchini, Hamdi Mbarek, Patrick McGrath, Peter McGuffin, Sarah E Medland, Divya Mehta, Christel M Middeldorp, Evelin Mihailov, Yuri Milaneschi, Lili Milani, Francis M Mondimore, Grant W Montgomery, Sara Mostafavi, Niamh Mullins, Matthias Nauck, Bernard Ng, Michel G Nivard, Dale R Nyholt, Paul F O'Reilly, Hogni Oskarsson, Michael J Owen, Jodie N Painter, Carsten Bøcker Pedersen, Marianne Giørtz Pedersen, Roseann E Peterson, Erik Pettersson, Wouter J Peyrot, Giorgio Pistis, Danielle Posthuma, Jorge A Quiroz, Per Qvist, John P Rice, Brien P Riley, Margarita Rivera, Saira Saeed Mirza, Robert Schoevers, Eva C Schulte, Ling Shen, Jianxin Shi, Stanley I Shyn, Engilbert Sigurdsson, Grant C B Sinnamon, Johannes H Smit, Daniel J Smith, Hreinn Stefansson, Stacy Steinberg, Fabian Streit, Jana Strohmaier, Katherine E Tansey, Henning Teismann, Alexander Teumer, Wesley Thompson, Pippa A Thomson, Thorgeir E Thorgeirsson, Matthew Traylor, Jens Treutlein, Vassily Trubetskoy, André G Uitterlinden, Daniel Umbricht, Sandra Van der Auwera, Albert M van Hemert, Alexander Viktorin, Peter M Visscher, Yunpeng Wang, Bradley T Webb, Shantel Marie Weinsheimer, Jürgen Wellmann, Gonneke Willemsen, Stephanie H Witt, Yang Wu, Hualin S Xi, Jian Yang, Futao Zhang, Volker Arolt, Bernhard T Baune, Klaus Berger, Dorret I Boomsma, Sven Cichon, Udo Dannlowski, E J C de Geus, J Raymond DePaulo, Enrico Domenici, Katharina Domschke, Tõnu Esko, Hans J Grabe, Steven P Hamilton, Caroline Hayward, Andrew C Heath, Kenneth S Kendler, Stefan Kloiber, Glyn Lewis, Qingqin S Li, Susanne Lucae, Pamela A F Madden, Patrik K Magnusson, Nicholas G Martin, Andrew M McIntosh, Andres Metspalu, Ole Mors, Preben Bo Mortensen, Bertram Müller-Myhsok, Merete Nordentoft, Markus M Nöthen, Michael C O'Donovan, Sara A Paciga, Nancy L Pedersen, Brenda W J H Penninx, Roy H Perlis, David J Porteous, James B Potash, Martin Preisig, Marcella Rietschel, Catherine Schaefer, Thomas G Schulze, Jordan W Smoller, Kari Stefansson, Henning Tiemeier, Rudolf Uher, Henry Völzke, Myrna M Weissman, Thomas Werge, Cathryn M Lewis, Douglas F Levinson, Gerome Breen, Anders D Børglum, Patrick F Sullivan., Epidemiology, Internal Medicine, Child and Adolescent Psychiatry / Psychology, Georg-August-University [Göttingen], University of California, Universita degli Studi di Cagliari [Cagliari], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), University of Graz, Università degli Studi di Perugia (UNIPG), University of Münster, Karl-Franzens-Universität [Graz, Autriche], Amare, A. T., Schubert, K. O., Hou, L., Clark, S. R., Papiol, S., Cearns, M., Heilbronner, U., Degenhardt, F., Tekola-Ayele, F., Hsu, Y. -H., Shekhtman, T., Adli, M., Akula, N., Akiyama, K., Ardau, R., Arias, B., Aubry, J. -M., Backlund, L., Bhattacharjee, A. K., Bellivier, F., Benabarre, A., Bengesser, S., Biernacka, J. M., Birner, A., Brichant-Petitjean, C., Cervantes, P., Chen, H. -C., Chillotti, C., Cichon, S., Cruceanu, C., Czerski, P. M., Dalkner, N., Dayer, A., Del Zompo, M., Depaulo, J. R., Etain, B., Jamain, S., Falkai, P., Forstner, A. J., Frisen, L., Frye, M. A., Fullerton, J. M., Gard, S., Garnham, J. S., Goes, F. S., Grigoroiu-Serbanescu, M., Grof, P., Hashimoto, R., Hauser, J., Herms, S., Hoffmann, P., Hofmann, A., Jimenez, E., Kahn, J. -P., Kassem, L., Kuo, P. -H., Kato, T., Kelsoe, J. R., Kittel-Schneider, S., Kliwicki, S., Konig, B., Kusumi, I., Laje, G., Landen, M., Lavebratt, C., Leboyer, M., Leckband, S. G., Tortorella, A., Manchia, M., Martinsson, L., Mccarthy, M. J., Mcelroy, S. L., Colom, F., Mitjans, M., Mondimore, F. M., Monteleone, P., Nievergelt, C. M., Nothen, M. M., Novak, T., O'Donovan, C., Ozaki, N., Osby, U., Pfennig, A., Potash, J. B., Reif, A., Wray, N. R., Ripke, S., Mattheisen, M., Trzaskowski, M., Byrne, E. M., Abdellaoui, A., Adams, M. J., Agerbo, E., Air, T. M., Andlauer, T. F. M., Bacanu, S. -A., Baekvad-Hansen, M., Beekman, A. T. F., Bigdeli, T. B., Binder, E. B., Blackwood, D. H. R., Bryois, J., Buttenschon, H. N., Bybjerg-Grauholm, J., Cai, N., Castelao, E., Christensen, J., Clarke, T. -K., Coleman, J. R. I., Colodro-Conde, L., Couvy-Duchesne, B., Craddock, N., Crawford, G. E., Davies, G., Deary, I. J., Derks, E. M., Direk, N., Dolan, C. V., Dunn, E. C., Eley, T. C., Escott-Price, V., Kiadeh, F. F. H., Finucane, H. K., Frank, J., Gaspar, H. A., Gill, M., Gordon, S. D., Grove, J., Hall, L. S., Hansen, C. S., Hansen, T. F., Hickie, I. B., Homuth, G., Horn, C., Hottenga, J. -J., Hougaard, D. M., Ising, M., Jansen, R., Jorgenson, E., Knowles, J. A., Kohane, I. S., Kraft, J., Kretzschmar, W. W., Krogh, J., Kutalik, Z., Li, Y., Lind, P. A., Macintyre, D. J., Mackinnon, D. F., Maier, R. M., Maier, W., Marchini, J., Mbarek, H., Mcgrath, P., Mcguffin, P., Medland, S. E., Mehta, D., Middeldorp, C. M., Mihailov, E., Milaneschi, Y., Milani, L., Montgomery, G. W., Mostafavi, S., Mullins, N., Nauck, M., Ng, B., Nivard, M. G., Nyholt, D. R., O'Reilly, P. F., Oskarsson, H., Owen, M. J., Painter, J. N., Pedersen, C. B., Pedersen, M. G., Peterson, R. E., Pettersson, E., Peyrot, W. J., Pistis, G., Posthuma, D., Quiroz, J. A., Qvist, P., Rice, J. P., Riley, B. P., Rivera, M., Mirza, S. S., Schoevers, R., Schulte, E. C., Shen, L., Shi, J., Shyn, S. I., Sigurdsson, E., Sinnamon, G. C. B., Smit, J. H., Smith, D. J., Stefansson, H., Steinberg, S., Streit, F., Strohmaier, J., Tansey, K. E., Teismann, H., Teumer, A., Thompson, W., Thomson, P. A., Thorgeirsson, T. E., Traylor, M., Treutlein, J., Trubetskoy, V., Uitterlinden, A. G., Umbricht, D., Van der Auwera, S., van Hemert, A. M., Viktorin, A., Visscher, P. M., Wang, Y., Webb, B. T., Weinsheimer, S. M., Wellmann, J., Willemsen, G., Witt, S. H., Wu, Y., Xi, H. S., Yang, J., Zhang, F., Arolt, V., Baune, B. T., Berger, K., Boomsma, D. I., Dannlowski, U., de Geus, E. J. C., Domenici, E., Domschke, K., Esko, T., Grabe, H. J., Hamilton, S. P., Hayward, C., Heath, A. C., Kendler, K. S., Kloiber, S., Lewis, G., Li, Q. S., Lucae, S., Madden, P. A. F., Magnusson, P. K., Martin, N. G., Mcintosh, A. M., Metspalu, A., Mors, O., Mortensen, P. B., Muller-Myhsok, B., Nordentoft, M., O'Donovan, M. C., Paciga, S. A., Pedersen, N. L., Penninx, B. W. J. H., Perlis, R. H., Porteous, D. J., Preisig, M., Rietschel, M., Schaefer, C., Schulze, T. G., Smoller, J. W., Stefansson, K., Tiemeier, H., Uher, R., Volzke, H., Weissman, M. M., Werge, T., Lewis, C. M., Levinson, D. F., Breen, G., Borglum, A. D., Sullivan, P. F., Reininghaus, E., Rouleau, G. A., Rybakowski, J. K., Schalling, M., Schofield, P. R., Schweizer, B. W., Severino, G., Shilling, P. D., Shimoda, K., Simhandl, C., Slaney, C. M., Squassina, A., Stamm, T., Stopkova, P., Maj, M., Turecki, G., Vieta, E., Veeh, J., Wright, A., Zandi, P. P., Mitchell, P. B., Bauer, M., Alda, M., Mcmahon, F. J., and Adult Psychiatry
- Subjects
0301 basic medicine ,Netherlands Twin Register (NTR) ,Lithium (medication) ,[SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health ,Genome-wide association study ,Logistic regression ,THERAPY ,ddc:616.89 ,0302 clinical medicine ,Medicine ,Major depression ,PREDICTORS ,Depression (differential diagnoses) ,RISK ,Depression ,Psychiatry and Mental health ,Quartile ,Cohort ,AUGMENTATION ,medicine.drug ,POLARITY ,medicine.medical_specialty ,GENETICS ,Bipolar disorder ,[SDV.GEN.GH] Life Sciences [q-bio]/Genetics/Human genetics ,Lithium ,PROPHYLACTIC LITHIUM ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,SDG 3 - Good Health and Well-being ,Internal medicine ,Humans ,ddc:610 ,AGENTS ,Molecular Biology ,Genetic association ,Depressive Disorder, Major ,business.industry ,medicine.disease ,EFFICACY ,030104 developmental biology ,[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics ,[SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health ,PHARMACOLOGICAL-TREATMENTS ,business ,030217 neurology & neurosurgery ,Genome-Wide Association Study - Abstract
© 2020, The Author(s), under exclusive licence to Springer Nature Limited.Lithium is a first-line medication for bipolar disorder (BD), but only one in three patients respond optimally to the drug. Since evidence shows a strong clinical and genetic overlap between depression and bipolar disorder, we investigated whether a polygenic susceptibility to major depression is associated with response to lithium treatment in patients with BD. Weighted polygenic scores (PGSs) were computed for major depression (MD) at different GWAS p value thresholds using genetic data obtained from 2586 bipolar patients who received lithium treatment and took part in the Consortium on Lithium Genetics (ConLi+Gen) study. Summary statistics from genome-wide association studies in MD (135,458 cases and 344,901 controls) from the Psychiatric Genomics Consortium (PGC) were used for PGS weighting. Response to lithium treatment was defined by continuous scores and categorical outcome (responders versus non-responders) using measurements on the Alda scale. Associations between PGSs of MD and lithium treatment response were assessed using a linear and binary logistic regression modeling for the continuous and categorical outcomes, respectively. The analysis was performed for the entire cohort, and for European and Asian sub-samples. The PGSs for MD were significantly associated with lithium treatment response in multi-ethnic, European or Asian populations, at various p value thresholds. Bipolar patients with a low polygenic load for MD were more likely to respond well to lithium, compared to those patients with high polygenic load [lowest vs highest PGS quartiles, multi-ethnic sample: OR = 1.54 (95% CI: 1.18–2.01) and European sample: OR = 1.75 (95% CI: 1.30–2.36)]. While our analysis in the Asian sample found equivalent effect size in the same direction: OR = 1.71 (95% CI: 0.61–4.90), this was not statistically significant. Using PGS decile comparison, we found a similar trend of association between a high genetic loading for MD and lower response to lithium. Our findings underscore the genetic contribution to lithium response in BD and support the emerging concept of a lithium-responsive biotype in BD.
- Published
- 2021
44. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy
- Author
-
Chammartin, F., Lodi, S., Logan, R., Ryom, L., Mocroft, A., Kirk, O., D'Arminio Monforte, A., Reiss, P., Phillips, A., El-Sadr, W., Hatleberg, C. I., Pradier, C., Bonnet, F., Law, M., De Wit, S., Sabin, C., Lundgren, J. D., Bucher, H. C., Calvo, G., Dabis, F., Morfeldt, L., Weber, R., Lind-Thomsen, A., Salbol Brandt, R., Hillebreght, M., Zaheri, S., Wit, F. W. N. M., Scherrer, A., Schoni-Affolter, F., Rickenbach, M., Tavelli, A., Fanti, I., Leleux, O., Mourali, J., Le Marec, F., Boerg, E., Thulin, E., Sundstrom, A., Bartsch, G., Thompsen, G., Necsoi, C., Delforge, M., Fontas, E., Caissotti, C., Dollet, K., Mateu, S., Torres, F., Petoumenos, K., Blance, A., Huang, R., Puhr, R., Gronborg Laut, K., Kristensen, D., Kamara, D. A., Smith, C. J., Raben, D., Matthews, C., Bojesen, A., Grevsen, A. L., Powderly, B., Shortman, N., Moecklinghoff, C., Reilly, G., Smit, C., Ross, M., Fux, C. A., Morlat, P., Friis-Moller, N., Kowalska, J., Bohlius, J., Bower, M., Fatkenheuer, G., Grulich, A., Sjol, A., Meidahl, P., Iversen, J. S., Hillebregt, M., Prins, J. M., Kuijpers, T. W., Scherpbier, H. J., Van Der Meer, J. T. M., Godfried, M. H., Van Der Poll, T., Nellen, F. J. B., Geerlings, S. E., Van Vugt, M., Pajkrt, D., Bos, J. C., Wiersinga, W. J., Van Der Valk, M., Goorhuis, A., Hovius, J. W., Van Eden, J., Henderiks, A., Van Hes, A. M. H., Mutschelknauss, M., Nobel, H. E., Pijnappel, F. J. J., Jurriaans, S., Back, N. K. T., Zaaijer, H. L., Berkhout, B., Cornelissen, M. T. E., Schinkel, C. J., Thomas, X. V., Van Den Berge, M., Stegeman, A., Baas, S., Hage De Looff, L., Versteeg, D., Pronk, M. J. H., Ammerlaan, H. S. M., de Munnik, E. S., Jansz, A. R., Tjhie, J., Wegdam, M. C. A., Deiman, B., Scharnhorst, V., Van Der Plas, A., Weijsenfeld, A. M., Van Der Ende, M. E., de Vries-Sluijs, T. E. M. S., van Gorp, E. C. M., Schurink, C. A. M., Nouwen, J. L., Verbon, A., Rijnders, B. J. A., Bax, H. I., Van Der Feltz, M., Bassant, N., Van Beek, J. E. A., Vriesde, M., Van Zonneveld, L. M., De Oude-Lubbers, A., Van Den Berg-Cameron, H. J., Bruinsma-Broekman, F. B., de Groot, J., De Zeeuw-De Man, M., Boucher, C. A. B., Koopmans, M. P. G., van Kampen, J. J. A., Pas, S. D., Driessen, G. J. A., van Rossum, A. M. C., Van Der Knaap, L. C., Visser, E., Branger, J., Rijkeboer-Mes, A., Duijf-Van De Ven, C. J. H. M., Schippers, E. F., van Nieuwkoop, C., van IJperen, J. M., Geilings, J., van der Hut, G., Franck, P. F. H., Van Eeden, A., Brokking, W., Groot, M., Elsenburg, L. J. M., Damen, M., Kwa, I. S., Groeneveld, P. H. P., Bouwhuis, J. W., Van Den Berg, J. F., Van Hulzen, A. G. W., Van Der Bliek, G. L., Bor, P. C. J., Bloembergen, P., Wolfhagen, M. J. H. M., Ruijs, G. J. H. M., Kroon, F. P., De Boer, M. G. J., Bauer, M. P., Jolink, H., Vollaard, A. M., Dorama, W., Van Holten, N., Claas, E. C. J., Wessels, E., Den Hollander, J. G., Pogany, K., Roukens, A., Kastelijns, M., Smit, J. V., Smit, E., Struik-Kalkman, D., Tearno, C., Bezemer, M., van Niekerk, T., Pontesilli, O., Lowe, S. H., Oude Lashof, A. M. L., Posthouwer, D., Ackens, R. P., Schippers, J., Vergoossen, R., Weijenberg-Maes, B., van Loo, I. H. M., Havenith, T. R. A., Leyten, E. M. S., Gelinck, L. B. S., van Hartingsveld, A., Meerkerk, C., Wildenbeest, G. S., Mutsaers, J. A. E. M., Jansen, C. L., Mulder, J. W., Vrouenraets, S. M. E., Lauw, F. N., van Broekhuizen, M. C., Paap, H., Vlasblom, D. J., Smits, P. H. M., Weijer, S., El Moussaoui, R., Bosma, A. S., van Vonderen, M. G. A., van Houte, D. P. F., Kampschreur, L. M., Dijkstra, K., Faber, S., Weel, J., Kootstra, G. J., Delsing, C. E., van der Burg-Van de Plas, M., Heins, H., Lucas, E., Kortmann, W., van Twillert, G., Cohen Stuart, J. W. T., Diederen, B. M. W., van Truijen-Oud, F. A., van der Reijden, W. A., Jansen, R., Brinkman, K., van den Berk, G. E. L., Blok, W. L., Frissen, P. H. J., Lettinga, K. D., Schouten, W. E. M., Veenstra, J., Brouwer, J. C., Geerders, F. G., Hoeksema, K., Kleene, J. M., van der Meche, B. I., Spelbrink, M., Sulman, H., Toonen, A. J. M., Wijnands, S., Kwa, D., Witte, E., Koopmans, P. P., Keuter, M., van der Ven, A. J. A. M., ter Hofstede, H. J. M., Dofferhoff, A. S. M., van Crevel, R., Albers, M., Bosch, M. E. W., Grintjes-Huisman, K. J. T., Zomer, J. B., Stelma, F. F., Rahamat-Langendoen, J., Burger, D., Richter, C., Gisolf, H. E., Hassing, J. R., ter Beest, G., van Bentum, P. H. M., Langebeek, N., Tiemessen, R., Swanink, C. M. A., van Lelyveld, S. F. L., Soetekouw, R., Hulshoff, N., van der Prijt, L. M. M., van der Swaluw, J., Bermon, N., Herpers, B. L., Veenendaal, D., Verhagen, W. D. M., van Wijk, M., van Kasteren, M. E. E., Brouwer, E. A., de Kruijf-Van de Wiel, B. A. F. M., Kuipers, M., Santegoets, R. M. W. J., van der Ven, B., Marcelis, H. J., Buiting, A. G. M., Kabel, J. P., Bierman, W. F. W., Scholvinck, H., Wilting, R. K., Stienstra, Y., de Groot-De Jonge, H., van der Meulen, A. P., de Weerd, A. D., Ludwig-Roukema, J., Niesters, H. G. M., Riezebos-Brilman, A., van Leer-Buter, C. C., Knoester, M., Hoepelman, A. I. M., Mudrikova, T., Ellerbroek, M. P., Oosterheert, J. J., Arends, E. J., Barth, E. R., Wassenberg, M. W. M., Schadd, M. E., van Elst-Laurijssen, D. H. M., van Oers-Hazelzet, B. E., Vervoort, S., van Berkel, M., Schuurman, R., Verduyn-Lunel, F., Wensing, A. M. J., Peters, E. J. G., van Agtmael, A. M., Bomers, M., de Vocht, J., Heitmuller, M., Laan, M. L., Pettersson, M. A., Vandenbroucke-Grauls, C. M. J. E., Ang, W. C., Geelen, S. P. M., Wolfs, T. F. W., Bont, J. L., Nauta, N., Bezemer, O. D., van Sighem, I. A., Boender, S. T., de Jong, A., Bergsma, D., Hoekstra, P., de Lang, A., Grivell, S., Jansen, A., Rademaker, J. M., Raethke, M., Meijering, R., Schnorr, S., de Groot, L., van den Akker, M., Bakker, Y., Claessen, E., El Berkaoui, A., Koops, J., Kruijne, E., Lodewijk, C., Munjishvili, L., Peeck, B., Ree, C., Regtop, R., Ruijs, Y., Rutkens, T., van de Sande, L., Schoorl, M., Timmerman, A., Tuijn, E., Veenenberg, L., van der Vliet, S., Wisse, A., Woudstra, T., Tuk, B., Dupon, M., Gaborieau, V., Lacoste, D., Malvy, D., Mercie, P., Neau, D., Pellegrin, L. J., Tchamgoue, S., Lazaro, E., Cazanave, C., Vandenhende, M., Vareil, O. M., Gerard, Y., Blanco, P., Bouchet, S., Breilh, D., Fleury, H., Pellegrin, I., Chene, G., Thiebaut, R., Wittkop, L., Lawson-Ayayi, S., Gimbert, A., Desjardin, S., Lacaze-Buzy, L., Petrov-Sanchez, V., Andre, N., Bernard, K., Caubet, O., Caunegre, L., Chossat, I., Courtault, C., Dauchy, A. F., Dondia, D., Duffau, P., Dutronc, H., Farbos, S., Faure, I., Ferrand, H., Greib, C., Hessamfar, M., Imbert, Y., Lataste, P., Marie, J., Mechain, M., Monlun, E., Ochoa, A., Pistone, T., Raymond, I., Receveur, C. M., Rispal, P., Sorin, L., Valette, C., Viallard, J. F., Wille, H., Wirth, G., Lafon, M., Trimoulet, P., Bellecave, P., Tumiotto, C., Haramburu, F., Miremeont-Salame, G., Blaizeau, J. M., Decoin, M., Hannapier, C., Lenaud, E., Pougetoux, A., Delveaux, S., D'Ivernois, C., Diarra, F., Uwamaliya-Nziyumvira, B., Palmer, G., Conte, V., Sapparrart, V., Moore, R., Edwards, S., Hoy, J., Watson, K., Roth, N., Lau, H., Bloch, M., Baker, D., Carr, A., Cooper, D., O'Sullivan, M., Nolan, D., Guelfi, G., Domingo, P., Sambeat, A. M., Gatell, J., Del Cacho, E., Cadafalch, J., Fuster, M., Codina, C., Sirera, G., Vaque, A., Clumeck, N., Gennotte, F. A., Gerard, M., Kabeya, K., Konopnicki, D., Libois, A., Martin, C., Payen, C. M., Semaille, P., Van Laethem, Y., Neaton, J., El-Sadr, M. W., Krum, E., Thompson, G., Wentworth, D., Luskin-Hawk, R., Telzak, E., Abrams, I. D., Cohn, D., Markowitz, N., Arduino, R., Mushatt, D., Friedland, G., Perez, G., Tedaldi, E., Fisher, E., Gordin, F., Crane, R. L., Sampson, J., Baxter, J., Gazzard, B., Horban, A., Karpov, I., Pedersen, C., Ristola, M., Rockstroh, J., Peters, L., Fischer, H. A., Larsen, F. J., Podlekareva, D., Cozzi-Lepri, A., Shepherd, L., Schultze, A., Amele, S., Losso, M., Kundro, M., Schmied, B., Zangerle, R., Vassilenko, A., Mitsura, M. V., Paduto, D., Florence, E., Vandekerckhove, L., Hadziosmanovic, V., Begovac, J., Machala, L., Jilich, D., Sedlacek, D., Kronborg, G., Benfield, T., Gerstoft, J., Katzenstein, T., Moller, F. N., Ostergaard, L., Wiese, L., Nielsen, N. L., Zilmer, K., Smidt, J., Aho, I., Viard, J. P., Girard, P. M., Duvivier, C., Schmidt, R., Degen, O., Stellbrink, J. H., Stefan, C., Bogner, J., Chkhartishvili, N., Gargalianos, P., Xylomenos, G., Armenis, K., Sambatakou, H., Szlavik, J., Gottfredsson, M., Mulcahy, F., Yust, I., Turner, D., Burke, M., Shahar, E., Hassoun, G., Elinav, H., Haouzi, M., Elbirt, D., Sthoeger, M. Z., Esposito, R., Mazeu, I., Mussini, C., Mazzotta, F., Gabbuti, A., Vullo, V., Lichtner, M., Zaccarelli, M., Antinori, A., Acinapura, R., Plazzi, M., Lazzarin, A., Castagna, A., Gianotti, N., Galli, M., Ridolfo, A., Rozentale, B., Uzdaviniene, V., Matulionyte, R., Staub, T., Hemmer, R., Ormaasen, V., Maeland, A., Bruun, J., Knysz, B., Gasiorowski, J., Inglot, M., Bakowska, E., Flisiak, R., Grzeszczuk, A., Parczewski, M., Maciejewska, K., Aksak-Was, B., Beniowski, M., Mularska, E., Smiatacz, T., Gensing, M., Jablonowska, E., Malolepsza, E., Wojcik, K., Mozer-Lisewska, I., Caldeira, L., Mansinho, K., Maltez, F., Radoi, R., Oprea, C., Panteleev, A., Panteleev, O., Yakovlev, A., Trofimora, T., Khromova, I., Kuzovatova, E., Borodulina, E., Vdoushkina, E., Jevtovic, D., Tomazic, J., Miro, M. J., Moreno, S., Rodriguez, J. M., Clotet, B., Jou, A., Paredes, R., Tural, C., Puig, J., Bravo, I., Gutierrez, M., Mateo, G., Laporte, M. J., Falconer, K., Thalme, A., Sonnerborg, A., Blaxhult, A., Flamholc, L., Cavassini, M., Calmy, A., Furrer, H., Battegay, M., Schmid, P., Kuznetsova, A., Kyselyova, G., Sluzhynska, M., Johnson, A. M., Simons, E., Orkin, C., Weber, J., Scullard, G., Clarke, A., Leen, C., Thulin, G., Akerlund, B., Koppel, K., Karlsson, A., Hakangard, C., Castelli, F., Cauda, R., Di Perri, G., Iardino, R., Ippolito, G., Marchetti, C. G., Perno, F. C., von Schloesser, F., Viale, P., Ceccherini-Silberstein, F., Girardi, E., Lo Caputo, S., Puoti, M., Andreoni, M., Ammassari, A., Balotta, C., Bandera, A., Bonfanti, P., Bonora, S., Borderi, M., Calcagno, A., Calza, L., Capobianchi, R. M., Cingolani, A., Cinque, P., De Luca, A., Di Biagio, A., Gori, A., Guaraldi, G., Lapadula, G., Madeddu, G., Maggiolo, F., Marcotullio, S., Monno, L., Nozza, S., Quiros Roldan, E., Rossotti, R., Rusconi, S., Santoro, M. M., Saracino, A., Galli, L., Lorenzini, P., Rodano, A., Shanyinde, M., Carletti, F., Carrara, S., Di Caro, A., Graziano, S., Petrone, F., Prota, G., Quartu, S., Truffa, S., Giacometti, A., Costantini, A., Barocci, V., Angarano, G., Santoro, C., Suardi, C., Donati, V., Verucchi, G., Minardi, C., Quirino, T., Abeli, C., Manconi, E. P., Piano, P., Cacopardo, B., Celesia, B., Vecchiet, J., Falasca, K., Pan, A., Lorenzotti, S., Sighinolfi, L., Segala, D., Vichi, F., Cassola, G., Viscoli, C., Alessandrini, A., Bobbio, N., Mazzarello, G., Mastroianni, C., Belvisi, V., Caramma, I., Chiodera, A., Milini, P., Rizzardini, G., Moioli, C. M., Piolini, R., Ridolfo, L. A., Salpietro, S., Tincati, C., Puzzolante, C., Abrescia, N., Chirianni, A., Borgia, G., Orlando, R., Bonadies, G., Di Martino, F., Gentile, I., Maddaloni, L., Cattelan, M. A., Marinello, S., Cascio, A., Colomba, C., Baldelli, F., Schiaroli, E., Parruti, G., Sozio, F., Magnani, G., Ursitti, A. M., Cristaudo, A., Baldin, G., Capozzi, M., Cicalini, S., Fontanelli Sulekova, L., Iaiani, G., Latini, A., Mastrorosa, I., Savinelli, S., Vergori, A., Cecchetto, M., Viviani, F., Bagella, P., Rossetti, B., Franco, A., Fontana Del Vecchio, R., Francisci, D., Di Giuli, C., Caramello, P., Orofino, C. G., Sciandra, M., Bassetti, M., Londero, A., Pellizzer, G., Manfrin, V., Starnini, G., Ialungo, A., Dellamonica, P., Bernard, E., Courjon, J., Cua, E., De Salvador-Guillouet, F., Durant, J., Etienne, C., Ferrando, S., Mondain-Miton, V., Naqvi, A., Perbost, I., Pillet, S., Prouvost-Keller, B., Pugliese, P., Rio, V., Risso, K., Roger, M. P., Aubert, V., Bernasconi, E., Ciuffi, A., Dollenmaier, G., Egger, M., Elzi, L., Fehr, J., Fellay, J., Gunthard, F. H., Haerry, D., Hasse, B., Hirsch, H. H., Hoffmann, M., Hosli, I., Kahlert, C., Kaiser, L., Keiser, O., Klimkait, T., Kouyos, D. R., Kovari, H., Ledergerber, B., Martinetti, G., Martinez de Tejada, B., Marzolini, C., Metzner, J. K., Muller, N., Nicca, D., Pantaleo, G., Paioni, P., Rauch, A., Rudin, C., Speck, R., Stockle, M., Tarr, P., Trkola, A., Vernazza, P., Wandeler, G., Yerly, S., Global Health, Infectious diseases, AII - Infectious diseases, APH - Aging & Later Life, Chammartin F., Lodi S., Logan R., Ryom L., Mocroft A., Kirk O., D'Arminio Monforte A., Reiss P., Phillips A., El-Sadr W., Hatleberg C.I., Pradier C., Bonnet F., Law M., De Wit S., Sabin C., Lundgren J.D., Bucher H.C., Calvo G., Dabis F., Morfeldt L., Weber R., Lind-Thomsen A., Salbol Brandt R., Hillebreght M., Zaheri S., Wit F.W.N.M., Scherrer A., Schoni-Affolter F., Rickenbach M., Tavelli A., Fanti I., Leleux O., Mourali J., Le Marec F., Boerg E., Thulin E., Sundstrom A., Bartsch G., Thompsen G., Necsoi C., Delforge M., Fontas E., Caissotti C., Dollet K., Mateu S., Torres F., Petoumenos K., Blance A., Huang R., Puhr R., Gronborg Laut K., Kristensen D., Kamara D.A., Smith C.J., Raben D., Matthews C., Bojesen A., Grevsen A.L., Powderly B., Shortman N., Moecklinghoff C., Reilly G., Smit C., Ross M., Fux C.A., Morlat P., Friis-Moller N., Kowalska J., Bohlius J., Bower M., Fatkenheuer G., Grulich A., Sjol A., Meidahl P., Iversen J.S., Hillebregt M., Prins J.M., Kuijpers T.W., Scherpbier H.J., Van Der Meer J.T.M., Godfried M.H., Van Der Poll T., Nellen F.J.B., Geerlings S.E., Van Vugt M., Pajkrt D., Bos J.C., Wiersinga W.J., Van Der Valk M., Goorhuis A., Hovius J.W., Van Eden J., Henderiks A., Van Hes A.M.H., Mutschelknauss M., Nobel H.E., Pijnappel F.J.J., Jurriaans S., Back N.K.T., Zaaijer H.L., Berkhout B., Cornelissen M.T.E., Schinkel C.J., Thomas X.V., Van Den Berge M., Stegeman A., Baas S., Hage De Looff L., Versteeg D., Pronk M.J.H., Ammerlaan H.S.M., de Munnik E.S., Jansz A.R., Tjhie J., Wegdam M.C.A., Deiman B., Scharnhorst V., Van Der Plas A., Weijsenfeld A.M., Van Der Ende M.E., de Vries-Sluijs T.E.M.S., van Gorp E.C.M., Schurink C.A.M., Nouwen J.L., Verbon A., Rijnders B.J.A., Bax H.I., Van Der Feltz M., Bassant N., Van Beek J.E.A., Vriesde M., Van Zonneveld L.M., De Oude-Lubbers A., Van Den Berg-Cameron H.J., Bruinsma-Broekman F.B., de Groot J., De Zeeuw-De Man M., Boucher C.A.B., Koopmans M.P.G., van Kampen J.J.A., Pas S.D., Driessen G.J.A., van Rossum A.M.C., Van Der Knaap L.C., Visser E., Branger J., Rijkeboer-Mes A., Duijf-Van De Ven C.J.H.M., Schippers E.F., van Nieuwkoop C., van IJperen J.M., Geilings J., van der Hut G., Franck P.F.H., Van Eeden A., Brokking W., Groot M., Elsenburg L.J.M., Damen M., Kwa I.S., Groeneveld P.H.P., Bouwhuis J.W., Van Den Berg J.F., Van Hulzen A.G.W., Van Der Bliek G.L., Bor P.C.J., Bloembergen P., Wolfhagen M.J.H.M., Ruijs G.J.H.M., Kroon F.P., De Boer M.G.J., Bauer M.P., Jolink H., Vollaard A.M., Dorama W., Van Holten N., Claas E.C.J., Wessels E., Den Hollander J.G., Pogany K., Roukens A., Kastelijns M., Smit J.V., Smit E., Struik-Kalkman D., Tearno C., Bezemer M., van Niekerk T., Pontesilli O., Lowe S.H., Oude Lashof A.M.L., Posthouwer D., Ackens R.P., Schippers J., Vergoossen R., Weijenberg-Maes B., van Loo I.H.M., Havenith T.R.A., Leyten E.M.S., Gelinck L.B.S., van Hartingsveld A., Meerkerk C., Wildenbeest G.S., Mutsaers J.A.E.M., Jansen C.L., Mulder J.W., Vrouenraets S.M.E., Lauw F.N., van Broekhuizen M.C., Paap H., Vlasblom D.J., Smits P.H.M., Weijer S., El Moussaoui R., Bosma A.S., van Vonderen M.G.A., van Houte D.P.F., Kampschreur L.M., Dijkstra K., Faber S., Weel J., Kootstra G.J., Delsing C.E., van der Burg-Van de Plas M., Heins H., Lucas E., Kortmann W., van Twillert G., Cohen Stuart J.W.T., Diederen B.M.W., van Truijen-Oud F.A., van der Reijden W.A., Jansen R., Brinkman K., van den Berk G.E.L., Blok W.L., Frissen P.H.J., Lettinga K.D., Schouten W.E.M., Veenstra J., Brouwer J.C., Geerders F.G., Hoeksema K., Kleene J.M., van der Meche B.I., Spelbrink M., Sulman H., Toonen A.J.M., Wijnands S., Kwa D., Witte E., Koopmans P.P., Keuter M., van der Ven A.J.A.M., ter Hofstede H.J.M., Dofferhoff A.S.M., van Crevel R., Albers M., Bosch M.E.W., Grintjes-Huisman K.J.T., Zomer J.B., Stelma F.F., Rahamat-Langendoen J., Burger D., Richter C., Gisolf H.E., Hassing J.R., ter Beest G., van Bentum P.H.M., Langebeek N., Tiemessen R., Swanink C.M.A., van Lelyveld S.F.L., Soetekouw R., Hulshoff N., van der Prijt L.M.M., van der Swaluw J., Bermon N., Herpers B.L., Veenendaal D., Verhagen W.D.M., van Wijk M., van Kasteren M.E.E., Brouwer E.A., de Kruijf-Van de Wiel B.A.F.M., Kuipers M., Santegoets R.M.W.J., van der Ven B., Marcelis H.J., Buiting A.G.M., Kabel J.P., Bierman W.F.W., Scholvinck H., Wilting R.K., Stienstra Y., de Groot-De Jonge H., van der Meulen A.P., de Weerd A.D., Ludwig-Roukema J., Niesters H.G.M., Riezebos-Brilman A., van Leer-Buter C.C., Knoester M., Hoepelman A.I.M., Mudrikova T., Ellerbroek M.P., Oosterheert J.J., Arends E.J., Barth E.R., Wassenberg M.W.M., Schadd M.E., van Elst-Laurijssen D.H.M., van Oers-Hazelzet B.E., Vervoort S., van Berkel M., Schuurman R., Verduyn-Lunel F., Wensing A.M.J., Peters E.J.G., van Agtmael A.M., Bomers M., de Vocht J., Heitmuller M., Laan M.L., Pettersson M.A., Vandenbroucke-Grauls C.M.J.E., Ang W.C., Geelen S.P.M., Wolfs T.F.W., Bont J.L., Nauta N., Bezemer O.D., van Sighem I.A., Boender S.T., de Jong A., Bergsma D., Hoekstra P., de Lang A., Grivell S., Jansen A., Rademaker J.M., Raethke M., Meijering R., Schnorr S., de Groot L., van den Akker M., Bakker Y., Claessen E., El Berkaoui A., Koops J., Kruijne E., Lodewijk C., Munjishvili L., Peeck B., Ree C., Regtop R., Ruijs Y., Rutkens T., van de Sande L., Schoorl M., Timmerman A., Tuijn E., Veenenberg L., van der Vliet S., Wisse A., Woudstra T., Tuk B., Dupon M., Gaborieau V., Lacoste D., Malvy D., Mercie P., Neau D., Pellegrin L.J., Tchamgoue S., Lazaro E., Cazanave C., Vandenhende M., Vareil O.M., Gerard Y., Blanco P., Bouchet S., Breilh D., Fleury H., Pellegrin I., Chene G., Thiebaut R., Wittkop L., Lawson-Ayayi S., Gimbert A., Desjardin S., Lacaze-Buzy L., Petrov-Sanchez V., Andre N., Bernard K., Caubet O., Caunegre L., Chossat I., Courtault C., Dauchy A.F., Dondia D., Duffau P., Dutronc H., Farbos S., Faure I., Ferrand H., Greib C., Hessamfar M., Imbert Y., Lataste P., Marie J., Mechain M., Monlun E., Ochoa A., Pistone T., Raymond I., Receveur C.M., Rispal P., Sorin L., Valette C., Viallard J.F., Wille H., Wirth G., Lafon M., Trimoulet P., Bellecave P., Tumiotto C., Haramburu F., Miremeont-Salame G., Blaizeau J.M., Decoin M., Hannapier C., Lenaud E., Pougetoux A., Delveaux S., D'Ivernois C., Diarra F., Uwamaliya-Nziyumvira B., Palmer G., Conte V., Sapparrart V., Moore R., Edwards S., Hoy J., Watson K., Roth N., Lau H., Bloch M., Baker D., Carr A., Cooper D., O'Sullivan M., Nolan D., Guelfi G., Domingo P., Sambeat A.M., Gatell J., Del Cacho E., Cadafalch J., Fuster M., Codina C., Sirera G., Vaque A., Clumeck N., Gennotte F.A., Gerard M., Kabeya K., Konopnicki D., Libois A., Martin C., Payen C.M., Semaille P., Van Laethem Y., Neaton J., El-Sadr M.W., Krum E., Thompson G., Wentworth D., Luskin-Hawk R., Telzak E., Abrams I.D., Cohn D., Markowitz N., Arduino R., Mushatt D., Friedland G., Perez G., Tedaldi E., Fisher E., Gordin F., Crane R.L., Sampson J., Baxter J., Gazzard B., Horban A., Karpov I., Pedersen C., Ristola M., Rockstroh J., Peters L., Fischer H.A., Larsen F.J., Podlekareva D., Cozzi-Lepri A., Shepherd L., Schultze A., Amele S., Losso M., Kundro M., Schmied B., Zangerle R., Vassilenko A., Mitsura M.V., Paduto D., Florence E., Vandekerckhove L., Hadziosmanovic V., Begovac J., Machala L., Jilich D., Sedlacek D., Kronborg G., Benfield T., Gerstoft J., Katzenstein T., Moller F.N., Ostergaard L., Wiese L., Nielsen N.L., Zilmer K., Smidt J., Aho I., Viard J.P., Girard P.M., Duvivier C., Schmidt R., Degen O., Stellbrink J.H., Stefan C., Bogner J., Chkhartishvili N., Gargalianos P., Xylomenos G., Armenis K., Sambatakou H., Szlavik J., Gottfredsson M., Mulcahy F., Yust I., Turner D., Burke M., Shahar E., Hassoun G., Elinav H., Haouzi M., Elbirt D., Sthoeger M.Z., Esposito R., Mazeu I., Mussini C., Mazzotta F., Gabbuti A., Vullo V., Lichtner M., Zaccarelli M., Antinori A., Acinapura R., Plazzi M., Lazzarin A., Castagna A., Gianotti N., Galli M., Ridolfo A., Rozentale B., Uzdaviniene V., Matulionyte R., Staub T., Hemmer R., Ormaasen V., Maeland A., Bruun J., Knysz B., Gasiorowski J., Inglot M., Bakowska E., Flisiak R., Grzeszczuk A., Parczewski M., Maciejewska K., Aksak-Was B., Beniowski M., Mularska E., Smiatacz T., Gensing M., Jablonowska E., Malolepsza E., Wojcik K., Mozer-Lisewska I., Caldeira L., Mansinho K., Maltez F., Radoi R., Oprea C., Panteleev A., Panteleev O., Yakovlev A., Trofimora T., Khromova I., Kuzovatova E., Borodulina E., Vdoushkina E., Jevtovic D., Tomazic J., Miro M.J., Moreno S., Rodriguez J.M., Clotet B., Jou A., Paredes R., Tural C., Puig J., Bravo I., Gutierrez M., Mateo G., Laporte M.J., Falconer K., Thalme A., Sonnerborg A., Blaxhult A., Flamholc L., Cavassini M., Calmy A., Furrer H., Battegay M., Schmid P., Kuznetsova A., Kyselyova G., Sluzhynska M., Johnson A.M., Simons E., Orkin C., Weber J., Scullard G., Clarke A., Leen C., Thulin G., Akerlund B., Koppel K., Karlsson A., Hakangard C., Castelli F., Cauda R., Di Perri G., Iardino R., Ippolito G., Marchetti C.G., Perno F.C., von Schloesser F., Viale P., Ceccherini-Silberstein F., Girardi E., Lo Caputo S., Puoti M., Andreoni M., Ammassari A., Balotta C., Bandera A., Bonfanti P., Bonora S., Borderi M., Calcagno A., Calza L., Capobianchi R.M., Cingolani A., Cinque P., De Luca A., Di Biagio A., Gori A., Guaraldi G., Lapadula G., Madeddu G., Maggiolo F., Marcotullio S., Monno L., Nozza S., Quiros Roldan E., Rossotti R., Rusconi S., Santoro M.M., Saracino A., Galli L., Lorenzini P., Rodano A., Shanyinde M., Carletti F., Carrara S., Di Caro A., Graziano S., Petrone F., Prota G., Quartu S., Truffa S., Giacometti A., Costantini A., Barocci V., Angarano G., Santoro C., Suardi C., Donati V., Verucchi G., Minardi C., Quirino T., Abeli C., Manconi E.P., Piano P., Cacopardo B., Celesia B., Vecchiet J., Falasca K., Pan A., Lorenzotti S., Sighinolfi L., Segala D., Vichi F., Cassola G., Viscoli C., Alessandrini A., Bobbio N., Mazzarello G., Mastroianni C., Belvisi V., Caramma I., Chiodera A., Milini P., Rizzardini G., Moioli C.M., Piolini R., Ridolfo L.A., Salpietro S., Tincati C., Puzzolante C., Abrescia N., Chirianni A., Borgia G., Orlando R., Bonadies G., Di Martino F., Gentile I., Maddaloni L., Cattelan M.A., Marinello S., Cascio A., Colomba C., Baldelli F., Schiaroli E., Parruti G., Sozio F., Magnani G., Ursitti A.M., Cristaudo A., Baldin G., Capozzi M., Cicalini S., Fontanelli Sulekova L., Iaiani G., Latini A., Mastrorosa I., Savinelli S., Vergori A., Cecchetto M., Viviani F., Bagella P., Rossetti B., Franco A., Fontana Del Vecchio R., Francisci D., Di Giuli C., Caramello P., Orofino C.G., Sciandra M., Bassetti M., Londero A., Pellizzer G., Manfrin V., Starnini G., Ialungo A., Dellamonica P., Bernard E., Courjon J., Cua E., De Salvador-Guillouet F., Durant J., Etienne C., Ferrando S., Mondain-Miton V., Naqvi A., Perbost I., Pillet S., Prouvost-Keller B., Pugliese P., Rio V., Risso K., Roger M.P., Aubert V., Bernasconi E., Ciuffi A., Dollenmaier G., Egger M., Elzi L., Fehr J., Fellay J., Gunthard F.H., Haerry D., Hasse B., Hirsch H.H., Hoffmann M., Hosli I., Kahlert C., Kaiser L., Keiser O., Klimkait T., Kouyos D.R., Kovari H., Ledergerber B., Martinetti G., Martinez de Tejada B., Marzolini C., Metzner J.K., Muller N., Nicca D., Pantaleo G., Paioni P., Rauch A., Rudin C., Speck R., Stockle M., Tarr P., Trkola A., Vernazza P., Wandeler G., Yerly S., Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Internal Medicine, Medical Microbiology & Infectious Diseases, Virology, Pediatric Surgery, Pediatrics, Chammartin, F, Lodi, S, Logan, R, Ryom, L, Mocroft, A, Kirk, O, D'Arminio Monforte, A, Reiss, P, Phillips, A, El-Sadr, W, Hatleberg, C, Pradier, C, Bonnet, F, Law, M, De Wit, S, Sabin, C, Lundgren, J, Bucher, H, Calvo, G, Dabis, F, Morfeldt, L, Weber, R, Lind-Thomsen, A, Salbol Brandt, R, Hillebreght, M, Zaheri, S, Wit, F, Scherrer, A, Schoni-Affolter, F, Rickenbach, M, Tavelli, A, Fanti, I, Leleux, O, Mourali, J, Le Marec, F, Boerg, E, Thulin, E, Sundstrom, A, Bartsch, G, Thompsen, G, Necsoi, C, Delforge, M, Fontas, E, Caissotti, C, Dollet, K, Mateu, S, Torres, F, Petoumenos, K, Blance, A, Huang, R, Puhr, R, Gronborg Laut, K, Kristensen, D, Kamara, D, Smith, C, Raben, D, Matthews, C, Bojesen, A, Grevsen, A, Powderly, B, Shortman, N, Moecklinghoff, C, Reilly, G, Smit, C, Ross, M, Fux, C, Morlat, P, Friis-Moller, N, Kowalska, J, Bohlius, J, Bower, M, Fatkenheuer, G, Grulich, A, Sjol, A, Meidahl, P, Iversen, J, Hillebregt, M, Prins, J, Kuijpers, T, Scherpbier, H, Van Der Meer, J, Godfried, M, Van Der Poll, T, Nellen, F, Geerlings, S, Van Vugt, M, Pajkrt, D, Bos, J, Wiersinga, W, Van Der Valk, M, Goorhuis, A, Hovius, J, Van Eden, J, Henderiks, A, Van Hes, A, Mutschelknauss, M, Nobel, H, Pijnappel, F, Jurriaans, S, Back, N, Zaaijer, H, Berkhout, B, Cornelissen, M, Schinkel, C, Thomas, X, Van Den Berge, M, Stegeman, A, Baas, S, Hage De Looff, L, Versteeg, D, Pronk, M, Ammerlaan, H, de Munnik, E, Jansz, A, Tjhie, J, Wegdam, M, Deiman, B, Scharnhorst, V, Van Der Plas, A, Weijsenfeld, A, Van Der Ende, M, de Vries-Sluijs, T, van Gorp, E, Schurink, C, Nouwen, J, Verbon, A, Rijnders, B, Bax, H, Van Der Feltz, M, Bassant, N, Van Beek, J, Vriesde, M, Van Zonneveld, L, De Oude-Lubbers, A, Van Den Berg-Cameron, H, Bruinsma-Broekman, F, de Groot, J, De Zeeuw-De Man, M, Boucher, C, Koopmans, M, van Kampen, J, Pas, S, Driessen, G, van Rossum, A, Van Der Knaap, L, Visser, E, Branger, J, Rijkeboer-Mes, A, Duijf-Van De Ven, C, Schippers, E, van Nieuwkoop, C, van IJperen, J, Geilings, J, van der Hut, G, Franck, P, Van Eeden, A, Brokking, W, Groot, M, Elsenburg, L, Damen, M, Kwa, I, Groeneveld, P, Bouwhuis, J, Van Den Berg, J, Van Hulzen, A, Van Der Bliek, G, Bor, P, Bloembergen, P, Wolfhagen, M, Ruijs, G, Kroon, F, De Boer, M, Bauer, M, Jolink, H, Vollaard, A, Dorama, W, Van Holten, N, Claas, E, Wessels, E, Den Hollander, J, Pogany, K, Roukens, A, Kastelijns, M, Smit, J, Smit, E, Struik-Kalkman, D, Tearno, C, Bezemer, M, van Niekerk, T, Pontesilli, O, Lowe, S, Oude Lashof, A, Posthouwer, D, Ackens, R, Schippers, J, Vergoossen, R, Weijenberg-Maes, B, van Loo, I, Havenith, T, Leyten, E, Gelinck, L, van Hartingsveld, A, Meerkerk, C, Wildenbeest, G, Mutsaers, J, Jansen, C, Mulder, J, Vrouenraets, S, Lauw, F, van Broekhuizen, M, Paap, H, Vlasblom, D, Smits, P, Weijer, S, El Moussaoui, R, Bosma, A, van Vonderen, M, van Houte, D, Kampschreur, L, Dijkstra, K, Faber, S, Weel, J, Kootstra, G, Delsing, C, van der Burg-Van de Plas, M, Heins, H, Lucas, E, Kortmann, W, van Twillert, G, Cohen Stuart, J, Diederen, B, van Truijen-Oud, F, van der Reijden, W, Jansen, R, Brinkman, K, van den Berk, G, Blok, W, Frissen, P, Lettinga, K, Schouten, W, Veenstra, J, Brouwer, J, Geerders, F, Hoeksema, K, Kleene, J, van der Meche, B, Spelbrink, M, Sulman, H, Toonen, A, Wijnands, S, Kwa, D, Witte, E, Koopmans, P, Keuter, M, van der Ven, A, ter Hofstede, H, Dofferhoff, A, van Crevel, R, Albers, M, Bosch, M, Grintjes-Huisman, K, Zomer, J, Stelma, F, Rahamat-Langendoen, J, Burger, D, Richter, C, Gisolf, H, Hassing, J, ter Beest, G, van Bentum, P, Langebeek, N, Tiemessen, R, Swanink, C, van Lelyveld, S, Soetekouw, R, Hulshoff, N, van der Prijt, L, van der Swaluw, J, Bermon, N, Herpers, B, Veenendaal, D, Verhagen, W, van Wijk, M, van Kasteren, M, Brouwer, E, de Kruijf-Van de Wiel, B, Kuipers, M, Santegoets, R, van der Ven, B, Marcelis, H, Buiting, A, Kabel, J, Bierman, W, Scholvinck, H, Wilting, R, Stienstra, Y, de Groot-De Jonge, H, van der Meulen, A, de Weerd, A, Ludwig-Roukema, J, Niesters, H, Riezebos-Brilman, A, van Leer-Buter, C, Knoester, M, Hoepelman, A, Mudrikova, T, Ellerbroek, M, Oosterheert, J, Arends, E, Barth, E, Wassenberg, M, Schadd, M, van Elst-Laurijssen, D, van Oers-Hazelzet, B, Vervoort, S, van Berkel, M, Schuurman, R, Verduyn-Lunel, F, Wensing, A, Peters, E, van Agtmael, A, Bomers, M, de Vocht, J, Heitmuller, M, Laan, M, Pettersson, M, Vandenbroucke-Grauls, C, Ang, W, Geelen, S, Wolfs, T, Bont, J, Nauta, N, Bezemer, O, van Sighem, I, Boender, S, de Jong, A, Bergsma, D, Hoekstra, P, de Lang, A, Grivell, S, Jansen, A, Rademaker, J, Raethke, M, Meijering, R, Schnorr, S, de Groot, L, van den Akker, M, Bakker, Y, Claessen, E, El Berkaoui, A, Koops, J, Kruijne, E, Lodewijk, C, Munjishvili, L, Peeck, B, Ree, C, Regtop, R, Ruijs, Y, Rutkens, T, van de Sande, L, Schoorl, M, Timmerman, A, Tuijn, E, Veenenberg, L, van der Vliet, S, Wisse, A, Woudstra, T, Tuk, B, Dupon, M, Gaborieau, V, Lacoste, D, Malvy, D, Mercie, P, Neau, D, Pellegrin, L, Tchamgoue, S, Lazaro, E, Cazanave, C, Vandenhende, M, Vareil, O, Gerard, Y, Blanco, P, Bouchet, S, Breilh, D, Fleury, H, Pellegrin, I, Chene, G, Thiebaut, R, Wittkop, L, Lawson-Ayayi, S, Gimbert, A, Desjardin, S, Lacaze-Buzy, L, Petrov-Sanchez, V, Andre, N, Bernard, K, Caubet, O, Caunegre, L, Chossat, I, Courtault, C, Dauchy, A, Dondia, D, Duffau, P, Dutronc, H, Farbos, S, Faure, I, Ferrand, H, Greib, C, Hessamfar, M, Imbert, Y, Lataste, P, Marie, J, Mechain, M, Monlun, E, Ochoa, A, Pistone, T, Raymond, I, Receveur, C, Rispal, P, Sorin, L, Valette, C, Viallard, J, Wille, H, Wirth, G, Lafon, M, Trimoulet, P, Bellecave, P, Tumiotto, C, Haramburu, F, Miremeont-Salame, G, Blaizeau, J, Decoin, M, Hannapier, C, Lenaud, E, Pougetoux, A, Delveaux, S, D'Ivernois, C, Diarra, F, Uwamaliya-Nziyumvira, B, Palmer, G, Conte, V, Sapparrart, V, Moore, R, Edwards, S, Hoy, J, Watson, K, Roth, N, Lau, H, Bloch, M, Baker, D, Carr, A, Cooper, D, O'Sullivan, M, Nolan, D, Guelfi, G, Domingo, P, Sambeat, A, Gatell, J, Del Cacho, E, Cadafalch, J, Fuster, M, Codina, C, Sirera, G, Vaque, A, Clumeck, N, Gennotte, F, Gerard, M, Kabeya, K, Konopnicki, D, Libois, A, Martin, C, Payen, C, Semaille, P, Van Laethem, Y, Neaton, J, El-Sadr, M, Krum, E, Thompson, G, Wentworth, D, Luskin-Hawk, R, Telzak, E, Abrams, I, Cohn, D, Markowitz, N, Arduino, R, Mushatt, D, Friedland, G, Perez, G, Tedaldi, E, Fisher, E, Gordin, F, Crane, R, Sampson, J, Baxter, J, Gazzard, B, Horban, A, Karpov, I, Pedersen, C, Ristola, M, Rockstroh, J, Peters, L, Fischer, H, Larsen, F, Podlekareva, D, Cozzi-Lepri, A, Shepherd, L, Schultze, A, Amele, S, Losso, M, Kundro, M, Schmied, B, Zangerle, R, Vassilenko, A, Mitsura, M, Paduto, D, Florence, E, Vandekerckhove, L, Hadziosmanovic, V, Begovac, J, Machala, L, Jilich, D, Sedlacek, D, Kronborg, G, Benfield, T, Gerstoft, J, Katzenstein, T, Moller, F, Ostergaard, L, Wiese, L, Nielsen, N, Zilmer, K, Smidt, J, Aho, I, Viard, J, Girard, P, Duvivier, C, Schmidt, R, Degen, O, Stellbrink, J, Stefan, C, Bogner, J, Chkhartishvili, N, Gargalianos, P, Xylomenos, G, Armenis, K, Sambatakou, H, Szlavik, J, Gottfredsson, M, Mulcahy, F, Yust, I, Turner, D, Burke, M, Shahar, E, Hassoun, G, Elinav, H, Haouzi, M, Elbirt, D, Sthoeger, M, Esposito, R, Mazeu, I, Mussini, C, Mazzotta, F, Gabbuti, A, Vullo, V, Lichtner, M, Zaccarelli, M, Antinori, A, Acinapura, R, Plazzi, M, Lazzarin, A, Castagna, A, Gianotti, N, Galli, M, Ridolfo, A, Rozentale, B, Uzdaviniene, V, Matulionyte, R, Staub, T, Hemmer, R, Ormaasen, V, Maeland, A, Bruun, J, Knysz, B, Gasiorowski, J, Inglot, M, Bakowska, E, Flisiak, R, Grzeszczuk, A, Parczewski, M, Maciejewska, K, Aksak-Was, B, Beniowski, M, Mularska, E, Smiatacz, T, Gensing, M, Jablonowska, E, Malolepsza, E, Wojcik, K, Mozer-Lisewska, I, Caldeira, L, Mansinho, K, Maltez, F, Radoi, R, Oprea, C, Panteleev, A, Panteleev, O, Yakovlev, A, Trofimora, T, Khromova, I, Kuzovatova, E, Borodulina, E, Vdoushkina, E, Jevtovic, D, Tomazic, J, Miro, M, Moreno, S, Rodriguez, J, Clotet, B, Jou, A, Paredes, R, Tural, C, Puig, J, Bravo, I, Gutierrez, M, Mateo, G, Laporte, M, Falconer, K, Thalme, A, Sonnerborg, A, Blaxhult, A, Flamholc, L, Cavassini, M, Calmy, A, Furrer, H, Battegay, M, Schmid, P, Kuznetsova, A, Kyselyova, G, Sluzhynska, M, Johnson, A, Simons, E, Orkin, C, Weber, J, Scullard, G, Clarke, A, Leen, C, Thulin, G, Akerlund, B, Koppel, K, Karlsson, A, Hakangard, C, Castelli, F, Cauda, R, Di Perri, G, Iardino, R, Ippolito, G, Marchetti, C, Perno, F, von Schloesser, F, Viale, P, Ceccherini-Silberstein, F, Girardi, E, Lo Caputo, S, Puoti, M, Andreoni, M, Ammassari, A, Balotta, C, Bandera, A, Bonfanti, P, Bonora, S, Borderi, M, Calcagno, A, Calza, L, Capobianchi, R, Cingolani, A, Cinque, P, De Luca, A, Di Biagio, A, Gori, A, Guaraldi, G, Lapadula, G, Madeddu, G, Maggiolo, F, Marcotullio, S, Monno, L, Nozza, S, Quiros Roldan, E, Rossotti, R, Rusconi, S, Santoro, M, Saracino, A, Galli, L, Lorenzini, P, Rodano, A, Shanyinde, M, Carletti, F, Carrara, S, Di Caro, A, Graziano, S, Petrone, F, Prota, G, Quartu, S, Truffa, S, Giacometti, A, Costantini, A, Barocci, V, Angarano, G, Santoro, C, Suardi, C, Donati, V, Verucchi, G, Minardi, C, Quirino, T, Abeli, C, Manconi, E, Piano, P, Cacopardo, B, Celesia, B, Vecchiet, J, Falasca, K, Pan, A, Lorenzotti, S, Sighinolfi, L, Segala, D, Vichi, F, Cassola, G, Viscoli, C, Alessandrini, A, Bobbio, N, Mazzarello, G, Mastroianni, C, Belvisi, V, Caramma, I, Chiodera, A, Milini, P, Rizzardini, G, Moioli, C, Piolini, R, Ridolfo, L, Salpietro, S, Tincati, C, Puzzolante, C, Abrescia, N, Chirianni, A, Borgia, G, Orlando, R, Bonadies, G, Di Martino, F, Gentile, I, Maddaloni, L, Cattelan, M, Marinello, S, Cascio, A, Colomba, C, Baldelli, F, Schiaroli, E, Parruti, G, Sozio, F, Magnani, G, Ursitti, A, Cristaudo, A, Baldin, G, Capozzi, M, Cicalini, S, Fontanelli Sulekova, L, Iaiani, G, Latini, A, Mastrorosa, I, Savinelli, S, Vergori, A, Cecchetto, M, Viviani, F, Bagella, P, Rossetti, B, Franco, A, Fontana Del Vecchio, R, Francisci, D, Di Giuli, C, Caramello, P, Orofino, C, Sciandra, M, Bassetti, M, Londero, A, Pellizzer, G, Manfrin, V, Starnini, G, Ialungo, A, Dellamonica, P, Bernard, E, Courjon, J, Cua, E, De Salvador-Guillouet, F, Durant, J, Etienne, C, Ferrando, S, Mondain-Miton, V, Naqvi, A, Perbost, I, Pillet, S, Prouvost-Keller, B, Pugliese, P, Rio, V, Risso, K, Roger, M, Aubert, V, Bernasconi, E, Ciuffi, A, Dollenmaier, G, Egger, M, Elzi, L, Fehr, J, Fellay, J, Gunthard, F, Haerry, D, Hasse, B, Hirsch, H, Hoffmann, M, Hosli, I, Kahlert, C, Kaiser, L, Keiser, O, Klimkait, T, Kouyos, D, Kovari, H, Ledergerber, B, Martinetti, G, Martinez de Tejada, B, Marzolini, C, Metzner, J, Muller, N, Nicca, D, Pantaleo, G, Paioni, P, Rauch, A, Rudin, C, Speck, R, Stockle, M, Tarr, P, Trkola, A, Vernazza, P, Wandeler, G, Yerly, S, Internal medicine, Pediatric surgery, Medical Microbiology and Infection Prevention, Amsterdam Gastroenterology Endocrinology Metabolism, Faculteit Medische Wetenschappen/UMCG, Microbes in Health and Disease (MHD), and Molecular Pharmacology
- Subjects
Male ,HIV AIDS ,HIV Infections ,0302 clinical medicine ,Interquartile range ,Risk Factors ,Neoplasms ,Medicine ,030212 general & internal medicine ,Prospective Studies ,Prospective cohort study ,0303 health sciences ,Incidence ,Absolute risk reduction ,Drugs ,General Medicine ,Middle Aged ,Viral Load ,Antiretroviral therapy ,3. Good health ,AIDS ,Cancer treatment ,Prevention policy and public health ,Cohort ,Infectious diseases ,Cohort studies ,Female ,Viral load ,Adult ,medicine.medical_specialty ,Anti-HIV Agents ,HIV Infections/drug therapy ,Socio-culturale ,Time-to-Treatment ,03 medical and health sciences ,Acquired immunodeficiency syndrome (AIDS) ,SDG 3 - Good Health and Well-being ,Internal medicine ,Internal Medicine ,Humans ,Adverse effect ,030306 microbiology ,business.industry ,HIV ,Cancer ,medicine.disease ,CD4 Lymphocyte Count ,Anti-HIV Agents/therapeutic use ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,business ,Neoplasms/epidemiology - Abstract
BACKGROUND: Immediate initiation of antiretroviral therapy (ART) regardless of CD4 cell count reduces risk for AIDS and non-AIDS-related events in asymptomatic, HIV-positive persons and is the standard of care. However, most HIV-positive persons initiate ART when their CD4 count decreases below 500 × 10 9 cells/L. Consequences of delayed ART on risk for non-AIDS-defining and AIDS-defining cancer, one of the most common reasons for death in HIV, are unclear. OBJECTIVE: To estimate the long-term risk difference for cancer with the immediate ART strategy.DESIGN: Multinational prospective cohort study.SETTING: The D:A:D (Data collection on Adverse events of anti-HIV Drugs) study, which included HIV-positive persons from Europe, Australia, and the United States.PARTICIPANTS: 8318 HIV-positive persons with at least 1 measurement each of CD4 cell count and viral load while ART-naive (study period, 2006 to 2016).MEASUREMENTS: The parametric g-formula was used, with adjustment for baseline and time-dependent confounders (CD4 cell count and viral load), to assess the 10-year risk for non-AIDS-defining and AIDS-defining cancer of immediate versus deferred (at CD4 counts RESULTS: During 64 021 person-years of follow-up, 231 cases of non-AIDS-defining cancer and 272 of AIDS-defining cancer occurred among HIV-positive persons with a median age of 36 years (interquartile range, 29 to 43 years). With immediate ART, the 10-year risk for non-AIDS-defining cancer was 2.97% (95% CI, 2.37% to 3.50%) and that for AIDS-defining cancer was 2.50% (CI, 2.37% to 3.38%). Compared with immediate ART initiation, the 10-year absolute risk differences when deferring ART to CD4 counts less than 500 × 10 9 cells/L and less than 350 × 10 9 cells/L were 0.12 percentage point (CI, -0.01 to 0.26 percentage point) and 0.29 percentage point (CI, -0.03 to 0.73 percentage point), respectively, for non-AIDS-defining cancer and 0.32 percentage point (CI, 0.21 to 0.44 percentage point) and 1.00 percentage point (CI, 0.67 to 1.44 percentage points), respectively, for AIDS-defining cancer. LIMITATION: Potential residual confounding due to observational study design.CONCLUSION: In this young cohort, effects of immediate ART on 10-year risk for cancer were small, and further supportive data are needed for non-AIDS-defining cancer.PRIMARY FUNDING SOURCE: Highly Active Antiretroviral Therapy Oversight Committee.
- Published
- 2021
45. Predictors of Successful Early Discharge for Total Hip and Knee Arthroplasty in Octogenarians
- Author
-
Fabio Orozco, Danielle Y. Ponzio, Courtney D. Bell, Zachary D. Post, Andrew B. Kay, Andres F. Duque, and Alvin Ong
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,medicine ,Total hip replacement ,Orthopedics and Sports Medicine ,Surgery ,business ,Arthroplasty ,Early discharge - Abstract
Background: Decreased length of stay after total joint arthroplasty (TJA) is becoming a more common way to contain healthcare costs and increase patient satisfaction. There is little evidence to support “early” discharge in elderly patients. Purpose: We sought to identify preoperative factors that correlated with early discharge (by postoperative day [POD] 1) in comparison to late discharge (after POD2) in octogenarians after TJA. Methods: In a retrospective cohort study from a single institution, we identified 482 patients ages 80 to 89 who underwent primary TJA from January 2014 to December 2017; 319 had total knee arthroplasty (TKA) and 163 had total hip arthroplasty (THA). Data collected included preoperative knee range of motion (ROM), demographics, and comorbidities; 90-day readmission and mortality rates were also evaluated. P values for continuous data were calculated using student’s t test and for categorical data using χ2 testing. Results: Of octogenarian patients, 30.9% were discharged by POD1. Early discharge was associated with being male, married, and nonsmoking, as well as having an American Society of Anesthesiologists (ASA) score of 2, independent preoperative ambulation, and a postoperative caregiver. Type of procedure (TKA vs THA), body mass index, laterality, preoperative range of motion (ROM) for TKA, and single vs multilevel home did not affect the probability of early discharge. Discharge on POD1 was not associated with increased 90-day readmission rates. There were no deaths. Conclusion: Early discharge for octogenarians can be successfully implemented in a select subset of patients without increasing 90-day readmission or death rates. There are multiple factors that predict successful early discharge.
- Published
- 2023
46. Sustained reduction in catheter-associated urinary tract infections using multi-faceted strategies led by champions: A quality improvement initiative
- Author
-
Nicholas A Turner, Sarah S. Lewis, Rebekah Wrenn, Chris D Sova, Becky Smith, Staci S. Reynolds, and Sonali D Advani
- Subjects
Microbiology (medical) ,medicine.medical_specialty ,Cross Infection ,Quality management ,Catheters ,Epidemiology ,business.industry ,Urinary system ,Urine ,Quality Improvement ,Article ,Catheter ,Intensive Care Units ,Infectious Diseases ,Intensive care ,Internal medicine ,Catheter-Related Infections ,Urinary Tract Infections ,Medicine ,Humans ,business ,Urinary Catheterization - Abstract
We reviewed the sustainability of a multifaceted intervention on catheter-associated urinary tract infection (CAUTI) in 3 intensive care units. During the 4-year postintervention period, we observed reductions in urine culture rates (from 80.9 to 47.5 per 1,000 patient days; P < .01), catheter utilization (from 0.68 to 0.58; P < .01), and CAUTI incidence rates (from 1.7 to 0.8 per 1,000 patient days; P = .16).
- Published
- 2023
47. A modified Camel and Cactus Test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort
- Author
-
Moore, Katrina, Convery, Rhian, Bocchetta, Martina, Neason, Mollie, Cash, David M., Greaves, Caroline, Russell, Lucy L., Clarke, Mica T. M., Peakman, Georgia, van Swieten, John, Jiskoot, Lize, Moreno, Fermin, Barandiaran, Myriam, Sanchez-Valle, Raquel, Borroni, Barbara, Laforce, Robert, Dore, Marie-Claire, Masellis, Mario, Tartaglia, Maria Carmela, Graff, Caroline, Galimberti, Daniela, Rowe, James B., Finger, Elizabeth, Synofzik, Matthis, Karnath, Hans-Otto, Vandenberghe, Rik, de Mendonca, Alexandre, Maruta, Carolina, Tagliavini, Fabrizio, Santana, Isabel, Ducharme, Simon, Butler, Chris, Gerhard, Alex, Levin, Johannes, Danek, Adrian, Otto, Markus, Warren, Jason D., Rohrer, Jonathan D., Rossor, Martin N., Fox, Nick C., Woollacott, Ione O. C., Shafei, Rachelle, Heller, Carolin, Guerreiro, Rita, Bras, Jose, Thomas, David L., Nicholas, Jennifer, Mead, Simon, Meeter, Lieke, Panman, Jessica, Papma, Janne, van Minkelen, Rick, Pijnenburg, Yolande, Indakoetxea, Begona, Gabilondo, Alazne, Tainta, Mikel, de Arriba, Maria, Gorostidi, Ana, Zulaica, Miren, Villanua, Jorge, Diaz, Zigor, Borrego-Ecija, Sergi, Olives, Jaume, Llado, Albert, Balasa, Mircea, Antonell, Anna, Bargallo, Nuria, Premi, Enrico, Cosseddu, Maura, Gazzina, Stefano, Padovani, Alessandro, Gasparotti, Roberto, Archetti, Silvana, Black, Sandra, Mitchell, Sara, Rogaeva, Ekaterina, Freedman, Morris, Keren, Ron, Tang-Wa, David, Oijerstedt, Linn, Andersson, Christin, Jelic, Vesna, Thonberg, Hakan, Arighi, Andrea, Fenoglio, Chiara, Scarpini, Elio, Fumagalli, Giorgio, Cope, Thomas, Timberlake, Carolyn, Rittman, Timothy, Shoesmith, Christen, Bartha, Robart, Rademakers, Rosa, Wilke, Carlo, Bender, Benjamin, Bruffaerts, Rose, Van Damme, Philip, Vandenbulcke, Mathieu, Ferreira, Catarina B., Miltenberger, Gabriel, Verdelho, Ana, Afonso, Sonia, Taipa, Ricardo, Caroppo, Paola, Di Fede, Giuseppe, Giaccone, Giorgio, Prioni, Sara, Redaelli, Veronica, Rossi, Giacomina, Tiraboschi, Pietro, Duro, Diana, Almeida, Maria Rosario, Castelo-Branco, Miguel, Leitao, Maria Joao, Tabuas-Pereira, Miguel, Santiago, Beatriz, Gauthier, Serge, Rosa-Neto, Pedro, Veldsman, Michele, Flanagan, Toby, Prix, Catharina, Hoegen, Tobias, Wlasich, Elisabeth, Loosli, Sandra, Schonecker, Sonja, Semler, Elisa, Anderl-Straub, Sarah, Neurology, Clinical Psychology, Clinical Genetics, Moore, Katrina [0000-0002-4458-8390], Convery, Rhian [0000-0002-9477-1812], Bocchetta, Martina [0000-0003-1814-5024], Neason, Mollie [0000-0001-9419-7171], Greaves, Caroline [0000-0002-6446-1960], Russell, Lucy L [0000-0001-5023-5893], Clarke, Mica TM [0000-0003-0570-4296], Peakman, Georgia [0000-0002-3319-138X], Galimberti, Daniela [0000-0002-9284-5953], Otto, Markus [0000-0003-4273-4267], Rohrer, Jonathan D [0000-0002-6155-8417], and Apollo - University of Cambridge Repository
- Subjects
Oncology ,Cactaceae ,medicine.medical_specialty ,Camelus ,Semantic dementia ,Temporal lobe ,Atrophy ,Progranulins ,ddc:150 ,complications [Frontotemporal Dementia] ,C9orf72 ,Internal medicine ,Developmental and Educational Psychology ,medicine ,MAPT ,progranulin ,Semantic memory ,Animals ,Humans ,genetics ,genetics [Frontotemporal Dementia] ,semantic knowledge ,C9orf72 Protein ,Cognition ,medicine.disease ,Semantics ,Neuropsychology and Physiological Psychology ,Frontal lobe ,Frontotemporal Dementia ,Psychology ,Frontotemporal dementia - Abstract
Impaired semantic knowledge is a characteristic feature of some forms of frontotemporal dementia (FTD), particularly the sporadic disorder semantic dementia. Less is known about semantic cognition in the genetic forms of FTD caused by mutations in the genes MAPT, C9orf72, and GRN. We developed a modified version of the Camel and Cactus Test (mCCT) to investigate the presence of semantic difficulties in a large genetic FTD cohort from the Genetic FTD Initiative (GENFI) study. Six-hundred-forty-four participants were tested with the mCCT including 67 MAPT mutation carriers (15 symptomatic, and 52 in the presymptomatic period), 165 GRN mutation carriers (33 symptomatic, 132 presymptomatic), and 164 C9orf72 mutation carriers (56 symptomatic, 108 presymptomatic) and 248 mutation-negative members of FTD families who acted as a control group. The presymptomatic mutation carriers were further split into those early and late in the presymptomatic period (more than vs. within 10 years of expected symptom onset). Groups were compared using a linear regression model, adjusting for age and education, with bootstrapping. Performance on the mCCT had a weak negative correlation with age (rho = −0.20) and a weak positive correlation with education (rho = 0.13), with an overall abnormal score (below the 5th percentile of the control population) being below 27 out of a total of 32. All three of the symptomatic mutation groups scored significantly lower than controls: MAPT mean 22.3 (standard deviation 8.0), GRN 24.4 (7.2), C9orf72 23.6 (6.5) and controls 30.2 (1.6). However, in the presymptomatic groups, only the late MAPT and late C9orf72 mutation groups scored lower than controls (28.8 (2.2) and 28.9 (2.5) respectively). Performance on the mCCT correlated strongly with temporal lobe volume in the symptomatic MAPT mutation group (rho > 0.80). In the C9orf72 group, mCCT score correlated with both bilateral temporal lobe volume (rho > 0.31) and bilateral frontal lobe volume (rho > 0.29), whilst in the GRN group mCCT score correlated only with left frontal lobe volume (rho = 0.48). This study provides evidence for presymptomatic impaired semantic knowledge in genetic FTD. The different neuroanatomical associations of the mCCT score may represent distinct cognitive processes causing deficits in different groups: loss of core semantic knowledge associated with temporal lobe atrophy (particularly in the MAPT group), and impaired executive control of semantic information associated with frontal lobe atrophy. Further studies will be helpful to address the longitudinal change in mCCT performance and the exact time at which presymptomatic impairment occurs.
- Published
- 2022
48. Long-term stoma-related reinterventions after anterior resection for rectal cancer with or without anastomosis: population data from the Dutch snapshot study
- Author
-
Hazen, S. J. A., Vogel, I., Borstlap, W. A. A., Dekker, J. W. T., Tuynman, J. B., Tanis, P. J., Kusters, M., Deijen, C. L., den Dulk, M., Bonjer, H. J., van de Velde, C. J., Aalbers, A. G. J., Acherman, Y., Algie, G. D., von Geusau, B. Alting, Amelung, F., Aukema, T. S., Bakker, I. S., Bartels, S. A., Basha, S., Bastiaansen, A. J. N. M., Belgers, E., Bleeker, W., Blok, J., Bosker, R. J. I., Bosmans, J. W., Boute, M. C., Bouvy, N. D., Bouwman, H., Brandt-Kerkhof, A., Brinkman, D. J., Bruin, S., Bruns, E. R. J., Burbach, J. P. M., Burger, J. W. A., Buskens, C. J., de Mik, S. M. L., van Duijvendijk, P., Gooszen, J. A. H., Hoogland, P., Lamme, B., Marres, C. C., Musters, G. D., van Rossem, C. C., Schreuder, A. M., Swank, H. A., van beek, S. C., van Westreenen, H. L., Westerduin, E., Surgery, CCA - Imaging and biomarkers, CCA - Cancer Treatment and quality of life, Amsterdam Gastroenterology Endocrinology Metabolism, APH - Global Health, APH - Quality of Care, CCA - Cancer biology and immunology, Anatomy and neurosciences, General practice, Obstetrics and gynaecology, VU University medical center, Amsterdam Reproduction & Development (AR&D), Graduate School, CCA - Cancer Treatment and Quality of Life, and AGEM - Amsterdam Gastroenterology Endocrinology Metabolism
- Subjects
medicine.medical_specialty ,Colorectal cancer ,Anastomosis ,medicine.medical_treatment ,digestive system ,Stoma ,Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14] ,medicine ,Rectal cancer ,business.industry ,Gastroenterology ,Colostomy ,Permanent stoma ,Anterior resection ,medicine.disease ,digestive system diseases ,Colorectal surgery ,Surgery ,medicine.anatomical_structure ,surgical procedures, operative ,Sphincter ,Hartmann’s procedure ,business ,Cohort study ,Abdominal surgery - Abstract
Item does not contain fulltext BACKGROUND: The aim of this study was to analyze the stoma-related reinterventions, complications and readmissions after an anterior resection for rectal cancer, based on a cross-sectional nationwide cohort study with 3-year follow-up. METHODS: Rectal cancer patients who underwent a resection with either a functional anastomosis, a defunctioned anastomosis, or Hartmann's procedure (HP) with an end colostomy in 2011 in 71 Dutch hospitals were included. The primary outcome was number of stoma-related reinterventions. RESULTS: Of the 2095 patients with rectal cancer, 1400 patients received an anterior resection and were included in this study; 257 received an initially functional anastomosis, 741 a defunctioned anastomosis, and 402 patients a HP. Of the 1400 included patients, 62% were males, 38% were females and the mean age was 67 years (SD 11.1). Following a primary functional anastomosis, 48 (19%) patients received a secondary stoma. Stoma-related complications occurred in six (2%) patients, requiring reintervention in one (0.4%) case. In the defunctioned anastomosis group, stoma-related complications were present in 92 (12%) patients, and required reintervention in 23 (3%) patients, in 10 (1%) of these more than 1 year after initial resection. Stoma-related complications occurred in 92 (23%) patients after a HP, and required reintervention in 39 (10%) patients in 17 (4%) of cases more than 1 year after initial resection. The permanent stoma rate was 11% and 20%, in the functional anastomosis and the defuctioned anastomosis group, respectively. The end colostomy in the HP group was reversed in 4% of cases. CONCLUSIONS: Construction of a stoma after resection for rectal cancer with preservation of the sphincter is accompanied with long-term stoma-related morbidity. Stoma complications are more frequent after a HP. Even after 1 year, a significant number of reinterventions are required.
- Published
- 2022
49. Cognitive composites for genetic frontotemporal dementia: GENFI-Cog
- Author
-
Poos, Jackie M, Moore, Katrina M, Seelaar, Harro, Vandamme, Philip, Vandenbulcke, Mathieu, Ferreira, Catarina B, Miltenberger, Gabriel, Maruta, Carolina, Verdelho, Ana, Afonso, Sónia, Taipa, Ricardo, Caroppo, Paola, Di Fede, Giuseppe, Pijnenburg, Yolande A L, Giaccone, Giorgio, Prioni, Sara, Redaelli, Veronica, Rossi, Giacomina, Duro, Diana, Almeida, Maria Rosario, Castelo-Branco, Miguel, Leitão, Maria João, Tabuas-Pereira, Miguel, Santiago, Beatriz, Moreno, Fermin, Gauthier, Serge, Rosa-Neto, Pedro, Veldsman, Michele, Thompson, Paul, Langheinrich, Tobias, Prix, Catharina, Hoegen, Tobias, Wlasich, Elisabeth, Loosli, Sandra, Schonecker, Sonja, Sanchez-Valle, Raquel, Anderl-Straub, Sarah, Lombardi, Jolina, Bargalló, Nuria, Benussi, Alberto, Cantoni, Valentina, Bertoux, Maxime, Bertrand, Anne, Brice, Alexis, Camuzat, Agnès, Colliot, Olivier, Borroni, Barbara, Sayah, Sabrina, Funkiewiez, Aurélie, Rinaldi, Daisy, Lombardi, Gemma, Nacmias, Benedetta, Saracino, Dario, Bessi, Valentina, Ferrari, Camilla, Cañada, Marta, Deramecourt, Vincent, Laforce, Robert, Kuchcinski, Gregory, Lebouvier, Thibaud, Ourselin, Sebastien, Polito, Cristina, Rollin, Adeline, Masellis, Mario, Tartaglia, Carmela, Graff, Caroline, Galimberti, Daniela, Nicholas, Jennifer, Rowe, James B, Finger, Elizabeth, Synofzik, Matthis, Vandenberghe, Rik, de Mendonça, Alexandre, Tiraboschi, Pietro, Santana, Isabel, Ducharme, Simon, Butler, Chris, Gerhard, Alexander, Russell, Lucy L, Levin, Johannes, Danek, Adrian, Otto, Markus, Le Ber, Isabel, Pasquier, Florence, van Swieten, John C, Rohrer, Jonathan D, Initiative, Genetic FTD, Bouzigues, Arabella, Rossor, Martin N, Peakman, Georgia, Fox, Nick C, Warren, Jason D, Bocchetta, Martina, Swift, Imogen J, Shafei, Rachelle, Heller, Carolin, Todd, Emily, Cash, David, Woollacott, Ione, Zetterberg, Henrik, Convery, Rhian S, Nelson, Annabel, Guerreiro, Rita, Bras, Jose, Thomas, David L, Mead, Simon, Meeter, Lieke, Panman, Jessica, van Minkelen, Rick, Barandiaran, Myriam, Indakoetxea, Begoña, Jiskoot, Lize C, Gabilondo, Alazne, Tainta, Mikel, Gorostidi, Ana, Zulaica, Miren, Díez, Alina, Villanua, Jorge, Borrego-Ecija, Sergi, Olives, Jaume, Lladó, Albert, Balasa, Mircea, van der Ende, Emma, Antonell, Anna, Bargallo, Nuria, Premi, Enrico, Gazzina, Stefano, Gasparotti, Roberto, Archetti, Silvana, Black, Sandra, Mitchell, Sara, Rogaeva, Ekaterina, Freedman, Morris, van den Berg, Esther, Keren, Ron, Tang-Wai, David, Thonberg, Hakan, Öijerstedt, Linn, Andersson, Christin, Jelic, Vesna, Arighi, Andrea, Fenoglio, Chiara, Scarpini, Elio, Fumagalli, Giorgio, Papma, Janne M, Cope, Thomas, Timberlake, Carolyn, Rittman, Timothy, Shoesmith, Christen, Bartha, Robart, Rademakers, Rosa, Wilke, Carlo, Karnarth, Hans-Otto, Bender, Benjamin, Bruffaerts, Rose, Neurology, Amsterdam Neuroscience - Neurodegeneration, Medical Research Council, Clinical Genetics, Rowe, James [0000-0001-7216-8679], Rohrer, Jonathan D [0000-0002-6155-8417], and Apollo - University of Cambridge Repository
- Subjects
PROGRESSION ,Neuropsychological Tests ,Composite score ,Genetic FTD Initiative (GENFI) ,diagnosis [Frontotemporal Dementia] ,Cognition ,CRITERIA ,Attention ,genetics [Frontotemporal Dementia] ,11 Medical and Health Sciences ,Language ,Executive function ,Frontotemporal dementia ,Memory ,Neuropsychology ,Social cognition ,Humans ,Mutation ,Prodromal Symptoms ,Sample Size ,tau Proteins ,Frontotemporal Dementia ,CARRIERS ,Neurology ,Psychology ,Life Sciences & Biomedicine ,CLINICAL-TRIALS ,RC321-571 ,medicine.medical_specialty ,Cognitive Neuroscience ,Clinical Neurology ,genetics [Mutation] ,Neurosciences. Biological psychiatry. Neuropsychiatry ,Physical medicine and rehabilitation ,Cog ,mental disorders ,medicine ,ddc:610 ,RC346-429 ,Science & Technology ,Research ,Neurosciences ,medicine.disease ,genetics [tau Proteins] ,Neurosciences & Neurology ,Neurology (clinical) ,Neurology. Diseases of the nervous system - Abstract
Funder: Alzheimer's Research UK, Funder: Alzheimer's Society, Funder: Brain Research UK, Funder: the Wolfson Foundation, Funder: NIHR UCL/H Biomedical Research Centre, Funder: Leonard Wolfson Experimental Neurology Centre Clinical Research Facility, Funder: UK Dementia Research Institute, Funder: UK Medical Research Council, Funder: Bluefield project, Funder: the Association for Frontotemporal Dementias Research Grant 2009, BACKGROUND: Clinical endpoints for upcoming therapeutic trials in frontotemporal dementia (FTD) are increasingly urgent. Cognitive composite scores are often used as endpoints but are lacking in genetic FTD. We aimed to create cognitive composite scores for genetic frontotemporal dementia (FTD) as well as recommendations for recruitment and duration in clinical trial design. METHODS: A standardized neuropsychological test battery covering six cognitive domains was completed by 69 C9orf72, 41 GRN, and 28 MAPT mutation carriers with CDR�� plus NACC-FTLD ��� 0.5 and 275 controls. Logistic regression was used to identify the combination of tests that distinguished best between each mutation carrier group and controls. The composite scores were calculated from the weighted averages of test scores in the models based on the regression coefficients. Sample size estimates were calculated for individual cognitive tests and composites in a theoretical trial aimed at preventing progression from a prodromal stage (CDR�� plus NACC-FTLD 0.5) to a fully symptomatic stage (CDR�� plus NACC-FTLD ��� 1). Time-to-event analysis was performed to determine how quickly mutation carriers progressed from CDR�� plus NACC-FTLD = 0.5 to ��� 1 (and therefore how long a trial would need to be). RESULTS: The results from the logistic regression analyses resulted in different composite scores for each mutation carrier group (i.e. C9orf72, GRN, and MAPT). The estimated sample size to detect a treatment effect was lower for composite scores than for most individual tests. A Kaplan-Meier curve showed that after 3 years, ~ 50% of individuals had converted from CDR�� plus NACC-FTLD 0.5 to ��� 1, which means that the estimated effect size needs to be halved in sample size calculations as only half of the mutation carriers would be expected to progress from CDR�� plus NACC FTLD 0.5 to ��� 1 without treatment over that time period. DISCUSSION: We created gene-specific cognitive composite scores for C9orf72, GRN, and MAPT mutation carriers, which resulted in substantially lower estimated sample sizes to detect a treatment effect than the individual cognitive tests. The GENFI-Cog composites have potential as cognitive endpoints for upcoming clinical trials. The results from this study provide recommendations for estimating sample size and trial duration.
- Published
- 2022
50. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial
- Author
-
Sheela Sitaraman, Richard Roxburgh, Kristina Gutschmidt, Ela Stefanescu, Drago Bratkovic, Thomas Burrow, Kornblum Cornelia, Kristl Claeys, Miriam Freimer, Ozlem Goker-Alpan, Srilakshmi Kuchipudi, Alan Pestronk, Wolfgang Löscher, Francoise Bouhour, Maria Judit Molnar, Ans T. van der Ploeg, Halina Bartosik-Psujek, Mitchell Goldman, Robert D. Henderson, Stephanie Dearmey, Colin Quinn, Paula R. Clemens, Priya S. Kishnani, Jennifer B Avelar, Nicola Longo, Shahram Attarian, Robert Hopkin, Tomo Sawada, Blaž Koritnik, George Konstantinos Papadimas, Hideaki Shiraishi, Christopher Lindberg, Jin-Hong Shin, Ivaylo Tarnev, Tahseen Mozaffar, Heather Lau, Michel Tchan, Jozsef Janszky, Tobias Ruck, Sabrina Sacconi, Benedikt Schoser, Hashiguchi Akihiro, Patrick Deegan, Ernest Butler, Nuria Vidal-Fernandez, Antonio Toscano, Tarekegn Hiwot, Gee Kim, Emmanuelle Salort-Campana, Jeff Castelli, Pascal Laforet, Céline Tard, Crystal Eldridge, Aneal Khan, Stephan Wenninger, Simona Fecarotta, Jordi Díaz-Manera, Jorge Alonso-Pérez, Yin-Hsiu Chien, Mark Tarnopolsky, Olimpia Musumeci, Hiroshi Kobayashi, Helio Pedro, Jonathan Cauci, Agnes Sebok, Cynthia Bodkin, Hai Jiang, Julie Berthy, Vescei Laszlo, Derralynn Hughes, David Reyes-Leiva, Aleksandra Dominovic-Kovacevic, Mazen M. Dimachkie, Hernan Amartino, Hani Kushlaf, Barry J. Byrne, Giancarlo Parenti, Henning Andersen, Mark Roberts, Marie Wencel, Jaime Vengoechea, Schoser, B., Roberts, M., Byrne, B. J., Sitaraman, S., Jiang, H., Laforet, P., Toscano, A., Castelli, J., Diaz-Manera, J., Goldman, M., van der Ploeg, A. T., Bratkovic, D., Kuchipudi, S., Mozaffar, T., Kishnani, P. S., Sebok, A., Pestronk, A., Dominovic-Kovacevic, A., Khan, A., Koritnik, B., Tard, C., Lindberg, C., Quinn, C., Eldridge, C., Bodkin, C., Reyes-Leiva, D., Hughes, D., Stefanescu, E., SALORT-CAMPANA, E., Butler, E., Bouhour, F., Kim, G., Konstantinos Papadimas, G., Parenti, G., Bartosik-Psujek, H., Kushlaf, H., Akihiro, H., Lau, H., Pedro, H., Andersen, H., Amartino, H., Shiraishi, H., Kobayashi, H., Tarnev, I., Vengoechea, J., Avelar, J., Shin, J. -H., Cauci, J., Alonso-Perez, J., Janszky, J., Berthy, J., Cornelia, K., Gutschmidt, K., Claeys, K., Judit Molnar, M., Wencel, M., Tarnopolsky, M., Dimachkie, M., Tchan, M., Freimer, M., Longo, N., Vidal-Fernandez, N., Musumeci, O., Goker-Alpan, O., Deegan, P., Clemens, P. R., Roxburgh, R., Henderson, R., Hopkin, R., Sacconi, S., Fecarotta, S., Attarian, S., Wenninger, S., Dearmey, S., Hiwot, T., Burrow, T., Ruck, T., Sawada, T., Laszlo, V., Loscher, W., Chien, Y. -H., and Pediatrics
- Subjects
education.field_of_study ,medicine.medical_specialty ,1-Deoxynojirimycin ,Adolescent ,Glycogen Storage Disease Type II ,business.industry ,Population ,alpha-Glucosidases ,Enzyme replacement therapy ,Placebo ,Treatment Outcome ,Double-Blind Method ,SDG 3 - Good Health and Well-being ,Internal medicine ,Miglustat ,medicine ,Clinical endpoint ,Humans ,Respiratory function ,Neurology (clinical) ,Adverse effect ,education ,business ,Alglucosidase alfa ,medicine.drug - Abstract
Summary Background Pompe disease is a rare disorder characterised by progressive loss of muscle and respiratory function due to acid α-glucosidase deficiency. Enzyme replacement therapy with recombinant human acid α-glucosidase, alglucosidase alfa, is the first approved treatment for the disease, but some patients do not respond, and many do not show a sustained benefit. We aimed to assess the safety and efficacy of an investigational two-component therapy (cipaglucosidase alfa, a novel recombinant human acid α-glucosidase, plus miglustat, an enzyme stabiliser) for late-onset Pompe disease. Methods We did a randomised, double-blind, parallel-group, phase 3 trial at 62 neuromuscular and metabolic medical centres in 24 countries in the Americas, Asia-Pacific, and Europe. Eligible participants were aged 18 years or older with late-onset Pompe disease, and had either been receiving alglucosidase alfa for at least 2 years or were enzyme replacement therapy-naive. Participants were randomly assigned (2:1) using interactive response technology software, stratified by 6-min walk distance and previous enzyme replacement therapy status, to intravenous cipaglucosidase alfa (20 mg/kg) plus oral miglustat or to intravenous alglucosidase alfa (20 mg/kg) plus oral placebo once every 2 weeks for 52 weeks. Patients, investigators, and outcome assessors were masked to treatment assignment. The primary endpoint was change from baseline to week 52 in 6-min walk distance, assessed using a mixed-effect model for repeated measures analysis for comparison of superiority in the intention-to-treat population (all patients who received at least one dose of study drug). This study is now complete and is registered with ClinicalTrials.gov , NCT03729362 . Findings Between Dec 3, 2018, and Nov 26, 2019, 130 patients were screened for eligibility and 125 were enrolled and randomly assigned to receive cipaglucosidase alfa plus miglustat (n=85) or alglucosidase alfa plus placebo (n=40). Two patients in the alglucosidase alfa plus placebo group did not receive any dose due to absence of genotype confirmation of late-onset Pompe disease and were excluded from analysis. Six patients discontinued (one in the alglucosidase alfa plus placebo group, five in the cipaglucosidase alfa plus miglustat group), and 117 completed the study. At week 52, mean change from baseline in 6-min walk distance was 20·8 m (SE 4·6) in the cipaglucosidase alfa plus miglustat group versus 7·2 m (6·6) in the alglucosidase alfa plus placebo group using last observation carried forward (between-group difference 13·6 m [95% CI −2·8 to 29·9]). 118 (96%) of 123 patients experienced at least one treatment-emergent adverse event during the study; the incidence was similar between the cipaglucosidase alfa plus miglustat group (n=81 [95%]) and the alglucosidase alfa plus placebo group (n=37 [97%]). The most frequently reported treatment-emergent adverse events were fall (25 [29%] patients in the cipaglucosidase alfa plus miglustat group vs 15 [39%] in the alglucosidase alfa plus placebo group), headache (20 [24%] vs 9 [24%]), nasopharyngitis (19 [22%] vs 3 [8%]), myalgia (14 [16%] vs 5 [13%]), and arthralgia (13 [15%]) vs 5 [13%]). 12 serious adverse events occurred in eight patients in the cipaglucosidase alfa plus miglustat group; only one event (anaphylaxis) was deemed related to study drug. One serious adverse event (stroke) occurred in the alglucosidase alfa plus placebo group, which was deemed unrelated to study drug. There were no deaths. Interpretation Cipaglucosidase alfa plus miglustat did not achieve statistical superiority to alglucosidase alfa plus placebo for improving 6-min walk distance in our overall population of patients with late-onset Pompe disease. Further studies should investigate the longer-term safety and efficacy of cipaglucosidase alfa plus miglustat and whether this investigational two-component therapy might provide benefits, particularly in respiratory function and in patients who have been receiving enzyme replacement therapy for more than 2 years, as suggested by our secondary and subgroup analyses. Funding Amicus Therapeutics.
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.